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A role for cyclooxygenase enzymes and prostaglandins (such as prostaglandin E2)
has been observed in benign endometrial pathologies (endometriosis, excessive
blood loss and dysmenorrhoea) and in adenocarcinoma. Cyclooxygenase and
prostaglandin E synthase enzymes catalyse the conversion of arachidonic acid to
prostaglandin E2. Once synthesised, prostaglandin E2 mediates its effects via four G
protein coupled receptors namely EP1, EP2, EP3 and EP4. These receptors signal via
alternate and sometimes opposing pathways. The initial aim of the research presented
in this thesis was to investigate the temporal expression and signalling of the
prostaglandin E2 pathway in the normal human endometrium across the menstrual
cycle. Prostaglandin E synthase and prostaglandin E2 were localised to glandular
epithelial and endothelial cells. Similarly, expression of the prostaglandin E2
receptors, namely EP2 and EP4, was temporally up regulated and co-localised to the
glandular and vascular compartments. This was associated with enhanced cAMP
turnover in response to exogenous prostaglandin E2. In order to investigate further
the role of cyclooxygenase-2 and prostaglandin E2 in glandular epithelial cells we
generated a stably transfected endometrial epithelial cell line (Ishikawa)
overexpressing cyclooxygenase-2 in either the sense or antisense directions. Using
these cell lines we observed enhanced secretion of prostaglandins E2 and F2tt into the
culture media of the cyclooxygenase-2 sense cells compared with the
cyclooxygenase-2 antisense and wild type cells in response to exogenous arachidonic
acid. Co-incubation of the cells with NS398 (specific cyclooxygenase-2 inhibitor)
abolished the increase in prostaglandin synthesis. Overexpression of
XIV
cyclooxygenase-2 was accompanied with significantly elevated EP2/EP3 receptor
expression. No differences were detected for EP1, EP4 and FP receptors. These
results indicate a possible autocrine/paracrine action of cyclooxygenase-2 enzyme
products on expression of prostanoid receptors such as EP2/EP3. During the course
of my PhD, numerous reports were published implicating cyclooxygenase-2 and its
products in angiogenesis through the expression of angiogenic factors such as
vascular endothelial growth factor, basic fibroblast growth factor and angiopoietins.
To investigate the potential role of cyclooxygenase-2 in regulation of endometrial
angiogenesis, cDNA array technology was employed to identify differentially
expressed genes that may be involved in vascular function. Using this technique, a
total of 81 genes were differentially regulated including cathepsin D. Cathepsin D
mRNA and protein expression were elevated in the cyclooxygenase-2 antisense cells
compared with the sense and wild type cells. Cathepsin D is known to proteolytically
cleave plasminogen to the antiangiogenic factor angiostatin. Hence, we investigated
the generation of angiostatin from plasminogen in conditioned media collected from
cyclooxygenase-2 sense, cyclooxygenase-2 antisense and wild type cells. The
cleavage of angiostatin from plasminogen was markedly enhanced in conditioned
media from cyclooxygenase-2 antisense cells compared with cyclooxygenase-2 sense
and wild type cells. Co-incubation of plasminogen with pepstatin A, a selective
cathepsin D inhibitor, markedly reduced the cleavage of angiostatin from
plasminogen thus further implicating cathepsin D in the differential angiostatin
production by the cyclooxygenase-2 sense and antisense cell lines.
In conclusion data presented in this thesis outline the temporal regulation of
prostaglandin E2 receptor expression and signalling in the human endometrium.
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Moreover, we report a novel role for cyclooxygenase-2 in promoting angiogenesis
through suppression of production of antiangiogenic factors such as angiostatin. The
elevated expression of cyclooxgenase-2 observed in numerous endometrial
pathologies may therefore play a crucial role in regulation of angiogenesis through
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Chapter 1 General Introduction
1.1 Introduction
Menorrhagia; excessive blood loss in menstruation, dysmenorrhoea; associated with
painful menstruation and endometriosis; where uterine tissue is found in sites outside
of the uterus, are common benign gynaecological conditions (1). The underlying
mechanisms of common gynaecological pathologies are poorly understood. A role
for cyclooxygenase-2 (COX-2) and its products, the prostaglandins, in the pathology
of these conditions has been proposed by a number of studies (2-7). The focus of this
thesis is on the role of COX-2 and its products the prostaglandins in endometrial
function. This introduction will give a brief overview of the structure, histology and
normal function of the endometrium, the roles of COX-2 and prostaglandins in
physiological and pathological states including normal endometrial function and the
association with endometrial pathologies.
1.2 Uterus / Endometrial Histology
The uterus is the inverted pear shaped organ situated in the pelvic cavity.
Developmentally, the uterus is a muscular expansion of the Miillerian duct. There are
three distinct structural regions of the uterus namely the uterine fundus, the uterine
corpus and the uterine isthmus. The uterine fundus and corpus have a three layered
wall. The wall consist of the perimetrium; a thin membrane, the myometrium; a layer
of smooth muscle and the endometrium; a glandular lining. The endometrium is
composed of the stratum basalis and the stratum functionalis (see figure 1.1). The
superficial functionalis layer consists of a lining epithelium and uterine glands with a
1
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stroma embedded with a vascular tree. The functionalis layer is shed monthly during
menstruation, conversely, the basalis layer is not shed during menstruation; and, it
gives rise to the new functionalis layer post menstruation. The primary roles of the
endometrium are to provide an implantation window, regeneration in the absence of
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Figure 1.1 Histology of the human uterus A proliferative phase, B secretory phase. (Haemotoxylin-
and Eosin stained. Reproduced from http://asb.aecom.yu.edu)
1.3 Steroidal Control and The Menstrual Cycle
In humans, the normal menstrual cycle lasts between 25 and 35 days (10). The
menstrual cycle is ultimately under the control of the ovarian steroidal cycle. The
cycle is divided into three phases: the proliferative or follicular phase, the secretory
phase and in the absence of implantation, the menstrual phase; during which the
functionalis layer of the endometrium is shed (see figure 1.2). The proliferative phase
is post menstruation from day five of the cycle until ovulation which occurs on day
14, the predominant hormone is estradiol. The secretory or luteal phase occurs days
14-28 of a 28 day cycle and the predominant hormone is progesterone. In the absence
of implantation, the fall in progesterone and estrogen as a result of the demise of the
2
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corpus luteum initiate menstruation (11). The role of progesterone withdrawal in the
induction of menstruation is highlighted by the observation that artificial
maintenance of high progesterone levels results in the absence of menstruation. In
contrast, administration of the progesterone receptor antagonist initiates uterine
bleeding (12, 13). Interestingly, all mammals display withdrawal of progesterone and
estrogen concurrent with corpus luteal regression. However, only humans, old-world
primates and some bats menstruate (14).
1.3.1 Proliferative and Secretory Phases
Dating the endometrium according to histology and stage of the menstrual cycle was
characterised by Noyes et al in the 1950s, the criteria are still used today (15). The
initial repair of the endometrial surface occurs two days after the beginning of
menstruation and is complete possibly within 48 hours (16). The early proliferative
phase days 5-7 of the menstrual cycle, is typified with short narrow glands and a thin
regenerating surface epithelium especially between the glands (15). An increased
mitotic index is seen at day 5 of the menstrual cycle which remains high until the
early secretory phase. (17). As proliferation continues, the endometrium thickens and
reaches full thickness of 3 - 4mm by the time of ovulation. The mid proliferative
glands begin to extend and curve with columnar surface epithelium. By late
proliferative phase, the endometrium displays an undulant surface (15). After
ovulation and early in the secretory phase, the lumina of the glands begin to fill with
glycogen-rich secretions. The glands enlarge and become more tortuous. This is
accompanied with a reduced mitotic activity in the epithelial cells (18, 19). The
3
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stromal cells differentiate and decidualisation occurs. This process is marked by
prolactin secretion (20). Decidualisation is crucial for the initiation and establishment
of pregnancy (21). The process of decidualisation is thought to be partly mediated by
progesterone and also by increased intracellular cAMP levels (21). In the peri
implantation period, there is an influx of uterine specific natural killer cells (uNK)
which are important in the regulation of the permissive invasion of cytotrophoblast
cells (22).
1.3.2 Menstruation
In the absence of implantation and a decline in progesterone levels, menstruation is
initiated. Menstruation is now thought to be a two staged process involving an
inflammatory response and cells of the immune system (9, 11, 12). The initial phase
of menstruation is progesterone dependent and probably reversible. Conversely, the
second phase associated with the hypoxia and the activation of lytic systems is
thought to be progesterone independent and irreversible (9). Withdrawal of
progesterone is characterised by the upregulation of cytokines such as interleukin-8
(IL-8) and monocyte chemoatactic peptide-1 (MCP-1). Recently, gene array
technology was employed to identify those chemokines important for leukocyte
recruitment to the endometrium (22). The chemokine expression depended on the
stage of the menstrual cycle. Chemokines that recruit marcrophage, NK and T cell
population were upregulated in the periimplantation phase and early pregnancy.
Upregulation of chemokines including IL-8 were observed in the pre menstrual phase
and are thought to be responsible for recruiting leucocytes associated with
4
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menstruation (22). Additionally, progesterone withdrawal results in enhanced COX-2
expression; and ultimately prostaglandin levels such as PGF2a, along with a reduced
prostaglandin dehydrogenase (PGDH) expression (21, 23). The infiltrated leucocytes
offer a further source of cytokines which in turn leads to the further recruitment of
leucocytes (21). Within the uterus, matrix metalloptroteinases (MMPs) expression
are upregulated post progesterone withdrawal. The MMPs are in part synthesised by
stromal cells of the endometrium and also released by the infiltrated leucocytes (9).
The increase in endometrial MMPs is concomitant with a significant elevation in
gelatinase and collagenase activity at menstruation compared with other stages of the
menstrual cycle. Moreover, inhibition ofMMP activity in an endometrial explant in
vitro model prevents its breakdown in a reversible manner (24). These observations








Figure 1.2 A Schematic diagram representing hormonal control and growth across the menstrual
cycle in the human endometrium. (Adapted from Essential Reproduction (26)
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1.4 Angiogensis in The Endometrium
Angiogenesis is the growth of new blood vessels from existing blood vessels.
Physiological angiogenesis is most common in fetal growth and development. The
endometrium is an unusual tissue in that it undergoes regular physiological
angiogenesis which except for wound healing and in the corpus luteum is rare in
normal adult tissues (27). The mechanism of angiogenesis in the endometrium
appears to be different to that seen in other systems. Classically, angiogenesis has
demonstrated a sprouting mechanism. Within the endometrium, the lack of staining
for intergrin ovft; which is associated with sprouting angiogenesis, suggested an
alternative mechanism. Intussucsceptive angiogenesis is now thought to be the main
mechanism of angiogenesis within the endometrium with an elongation process in
the functionalis layer (18, 27, 28). The process of intussucsceptive angiogenesis
involves the lumen of a vessel dividing internally into two as endothelial cells
proliferate and migrate inwards (27). Angiogenesis in the endometrium varies
spatially and temporally across the menstrual cycle. During and post menstruation,
repair occurs in the basalis layer, in the functionalis layer, spiral arterioles develop
and coil during both the proliferative and secretory phases of the menstrual cycle. A
capillary plexus forms just below the luminal epithelial surface and maximal blood
flow is observed during the early and mid secretory phase. The capillary plexus
forms in preparation for the implanting embryo (27). Endometrial angiogenesis is
thought to partly be under the direct control of reproductive steroids and indirect
control by angiogenic factors expressed by multiple cell types of the endometrium.
Many growth factors have been identified in the endometrium (29). Potential
6
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angiogenic regulators include vascular endothelial growth factor- A,(VEGF-A),
VEGF-B, VEGF-C, angiopoietin-1 (Ang-1) and Ang-2. The contribution by
individual growth factors and their cellular origin may be cycle dependent. It has
been suggested that growth factors derived from endometrial NK cells may be
important for angiogenesis during the secretory phase (30). Additionally, intra¬
vascular neutrophil derived VEGF-A may promote functionalis layer angiogenesis
during the proliferative phase (29). Supernatants collected from cultured
endometrium contain soluble factors such as VEGF-A that regulate angiogenesis.
Moreover, those from the proliferative phase of the menstrual cycle promote a
greater enhancement of pro angiogenic endothelial cell transcriptome change relative
to the secretory phase (31). Abberant vascular function is thought to be involved in a
number of endometrial pathologies such as menorrhagia as discussed in section
1.6.1. The expression of the angiopoietins-1 and 2 (Ang-1 and Ang-2) has been
shown in the human endometrium. An altered ratio of Ang-1: Ang-2 has been
demonstrated in menorrhagic endometrium with an overall shift to Ang-2 (32).
Further research in endometrial angiogenesis may help to elucidate the underlying
mechanisms of these pathologies (18).
1.5 Apoptosis in The Endometrium
Apoptosis is programmed cell death and is thought to be an important mechanism in
maintaining homeostasis within the endometrium (33). Studies have detected
apoptosis in the glandular epithelium in the late secretory and menstrual phases of
the cycle, in contrast with the proliferative phase where little apoptosis has been
7
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described (33). bcl-2 is a well studied apoptosis related protein and inhibits
apoptosis; conversely, BAX a member of the bcl-2 family is pro apoptotic (33). The
ratio of bcl-2 and BAX may play a role in controlling the susceptibility of a cell to
apoptose (34). In the endometrium, it has been hypothesised that BAX and bcl-2 may
be under the control of ovarian hormones with a negative correlation of apoptosis
and estradiol in the proliferative phase (35). bcl-2 is expressed in endometrial
glandular and stromal cells with maximal expression in the late proliferative phase.
Conversely, BAX expression is low in the proliferative phase and rises in the
secretory phase. Apoptosis may play a role in the pathophysiology of; the benign
gynaecological condition, endometriosis (see section 1.6.1). Enhanced expression of
anti apoptotic bcl-2 protein has been demonstrated in ectopic endometrial tissue
compared with paired eutopic endometrium (36). An elevation in bcl-2 has also been
reported in proliferative eutopic endometrium from women with endometriosis
relative to endometrium from women with normal menstruation (37). It is still not
known if alterations in apoptosis are important in the initiation of endometriosis or a
secondary effect following the establishment of the disease (33). However altered
apoptosis is likely to contribute to the pathology of endometriosis.
1.6 Endometrial Pathologies
1.6.1 Benign Endometrial Pathologies
Menorrhagia; dysmenorrhoea and endometriosis are common benign gynaecological
conditions. Menorrhagia in the absence of identified uterine pathology is defined as
8
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blood loss greater than 80ml lost per menstrual cycle. Up to 30% of women of
reproductive age and 50% of perimenopausal women suffer from menorrhagia. In the
developed world, menorrhagia is the most common cause of anaemia. Menorrhagia
is the most frequent indicator for hysterectomy and accounts for at least 70% of 7000
hysterectomies performed annually in the UK (38-40).
Dysmenorrhoea associated with painful menstruation in the absence of pelvic
pathology is very common effecting between 30% and 50% ofmenstruating women.
In women with dysmenorrhoea, uterine hypercontractility has been observed
resulting in reduced uterine blood flow and ischaemia. A correlation between
minimal blood flow and maximal pain has been identified. (5)
Endometriosis is where endometrial glands and stroma are found in sites outside of
the uterus including the pelvic peritoneum. This disease is of unknown aetiology and
affects between 2 - 10% of women of reproductive age and 40% of women seeking
infertility evaluation (41). Retrograde menstruation; which is the reflux of menses
through the fallopian tube to the peritoneal cavity was first proposed by Sampson in
1927 and is the most widely accepted mechanism underlying endometriosis (41, 42).
Whilst between 70-90% of menstruating women, display retrograde menstruation,
the aberrant mechanisms resulting in endometriosis remain to be elucidated. It has
been postulated that outflow obstruction of the menstrual flow may result in
excessive retrograde menstruation leading to endometriosis. Moreover, both
endometriosis and dysmenorrhoea may be manifestations of aberrant menstrual flow
(41).
9
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Of all gynaecologist referrals by GPs one third are due to menstrual disorders. In
England and Wales, 25 000 procedures a year are performed for the treatment of
menstrual problems. These benign gynaecological pathologies are a considerable
health issue for women and place a financial burden on the health services (43).
1.6.2 Endometrial Carcinomas
Within the developed world, endometrial cancers are the most common female
reproductive tract gynaecological malignancies and are associated with post
menopausal women. Owing to symptoms such as abnormal vaginal bleeding, the
disease is often caught early and this is reflected in the 86% five year survival rate.
Approximately 80% of all endometrial cancers are endometrial carcinomas (44).
There are two recognised forms of endometrial carcinoma. Type I and Type II (45).
Type I endometroid carcinomas are generally low-grade, low-stage and associated
with an unopposed estrogen state. The tumours are of normal endometrial histology
with the resemblance of proliferative endometrial glands (44). Type II serous
carcinomas are poorly differentiated, associated within the setting of atrophy and are
not linked with unopposed estrogen (44). These carcinomas are aggressive in nature
and associated with a poor prognosis (46). The risk factors for type II endometrial
carcinomas is advanced age and previous pelvic irradiation (47). The aetiology of
endometrial cancer is poorly understood. For type I endometrial carcinomas,
mutations primarily in exons 3,4,5,7 and 8 in the PTEN (Phosphatase and Tensin
10
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Homolog) tumour suppressor gene are observed in up to 50% of the tumours.
Interestingly, these mutations were not observed in either ovarian or cervical
carcinomas suggesting the mutations are particularly significant in the pathogenesis
of endometroid carcinomas (48). PTEN mutations have been demonstrated in 20% of
hyperplastic lesions indicating these mutations may be an early event in the
tumorigenesis of endometrial carcinoma (44). Microsatellite instability (MI)
accompanied with hypermethylation of hMLHl (Mut L Homolog 1) promoter; the
DNA mismatch repair protein, is also observed in Type I endometrial carcinomas,
especially in subjects with hereditary non polyposis colorectal cancer (44). Mutation
of the K-ras oncogene has been idenfitifed in some endometrial carcinoma samples
and is associated with positive expression of the progesterone receptor (49).
Conversely, type II carcinomas rarely exhibit MI and PTEN mutations (48, 50).
Mutations in p53 have been reported in endometroid carcinoma but are most
commonly associated with type II serous carcinomas (46). Up to 90% of uterine
serous carcinomas have been shown to display mutations in the p53 gene with a high
percentage of p53 mutations also observed in intraepithelial carcinomas a putative
precursor to uterine serous carcinomas (44, 46). This observation has led to the
suggestion that p53 mutations are an early event in the pathogenesis of uterine serous
carcinomas and may in part contribute to the aggressiveness of this disease (46).
1.6.2.2 Endometrial Cell Lines
A number of established cell lines of endometrial origin are available for in-vitro
studies. These include HES and Ishikawa cells; both of which are used for studies
described in later chapters of this thesis, and MFE-296 cells. The Ishikawa and MFE-
11
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296 cell lines are derived respectively from well and moderately well differentiated
human endometrial carcinomas (51, 52). Conversely, HES cells transformed
spontaneously from a benign proliferative endometrial specimen (53). Positive
cytokeratin expression by the cell lines indicates an epithelial origin (52, 53).
Ishikawa cells have been demonstrated to express estrogen and progesterone
receptors and grow in a monolayer on plastic. Culture of Ishikawa cells in the
presence of physiological concentrations of estradiol is associated with enhanced
proliferation, increased specific progesterone binding and increased alkaline
phosphatase activity (52). Interestingly, MFE-296 cells express androgen receptors
with low progesterone receptor expression (51).
1.7 Cyclooxygenase Enzymes and Prostanoids in Endometrial
Pathology
The aetiology and underlying molecular mechanisms of the endometrial pathologies
discussed above in sections 1.6 have yet to be fully established. A role for the
cyclooxygenase enzymes and their products the prostanoids has been identified in
both benign and neoplastic endometrial pathologies (40).
Women with menorrhagia display elevated synthesis of PGE2 and expression of
PGE2 binding sites in the uterus compared with those with normal menstruation (2-4,
54). Moreover, there is an altered ratio in the profile of prostaglandins synthesised.
PGE2 relative to PGF2a and PGI2 relative to thromboxane A2 synthesis are increased.
A positive correlation with PGE2 and menstrual blood loss has been observed. Nitric
12
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Oxide is also elevated in menstrual flow from women with menorrhagia (54). It is
suggested that an increase in vasodilatory agents may be contributing to the degree or
duration of menstrual blood loss in women with menorrhagia (40). The profile of
prostaglandins synthesised in women with primary dysmenorrhoea is altered with an
elevation in both PGE2 and PGF2a in the menstrual blood flow (55). Endometrial
explant studies have shown an increased capacity to synthesise PGF2a in response to
AA in explants from women with dysmenorrhoea compared with explants from
women with pain free menstruation (56). This observation has suggested either an
elevation in COX enzyme expression or activity or increased prostaglandin synthase
expression (40). Furthermore, PGE2 and PGF2a have both been implicated in
hyperalgesia in inflammatory models of nociception (57, 58). A role for COX and
the prostaglandins in endometriosis has been suggested. Immunohistochemical
studies have demonstrated an upregulation of COX-2 in endometriotic endometrium.
An elevation in prostaglandins in the peritoneal fluid of infertile women with
endometriosis has also been described (6, 7).
Numerous studies have implicated COX enzymes in tumorigenesis and the
development of neoplastic pathologies (see section 1.13). COX-2 expression, is
elevated in endometrial, cervical and ovarian carcinomas (59-63). Although, there
have been conflicting reports on the upregulation of COX-2 in ovarian cancers (1).
Elevated COX-1 expression has been reported in ovarian and cervical cancers but not
endometrial (61, 64, 65).
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These studies have led to the suggestion that inhibition of COX or the signalling
pathway of prostanoids may be therapeutically useful in the treatment of endometrial
carcinomas as suggested for other carcinomas such as colon (66, 67). The association
of COX and prostaglandins with benign endometrial pathologies has led to the
administration of inhibitors of COX such as mefanamic acid and ibruprofen as a first
line treatment (39) The use of inhibitors of COX for menorrhagia and
dysmenorrhoea results in both an analgesic effect and a reduction of 25% in
menstrual blood loss (68). Inhibition of COX enzymes is discussed more fully in
section 1.11.
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1.8 Arachidonic Acid Metabolism
Prostanoid biosynthesis is dependent on the release of, the C-20 unsaturated fatty
acid, arachidonic acid (AA) from the membrane phospholipids by phospholipase A2
(PLA2). The dietry precursor ofAA is linoleic acid and AA is stored esterified to the









Figure 1.3. Schematic diagram of the prostanoid biosynthetic pathway
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Numerous isoforms of PLA2 have been identified; these include secretory PLA2,
7+
cytosolic PLA2 and Ca independent PLA2. Of those, the cytosolic PLA2 (cPLA2) is
considered the key isoform in eicosanoid formation (69, 70). It has been suggested
that CPLA2 may play an important role in pathological states (70). CPLA2 has
recently been demonstrated to be overexpressed in human colorectal adenocarcinoma
stromal cells, upregulate COX-2 mRNA expression and may play an important role
in COX-2 mediated angiogenesis (71, 72). The translocation of cPLA2 to the
perinuclear membranes occurs following an elevation in cytoplasmic calcium levels
and the activation of the MAPK intracellular signalling pathway (70). PLA2 then
catalyses the hydrolysis of the esterified form of AA and this cleaves AA from the
cell membrane.
AA is metabolised by one of three pathways. Metabolism of AA by Cytochrome
P450, COX enzymes and lipoxygenase (LOX) enzymes ultimately gives rise to
prostaglandin epoxides, prostanoids and leukotrienes respectively. Collectively,
prostaglandin epoxides, prostanoids and leukotrienes are known as eicosanoids (70).
This thesis focuses on COX and prostaglandin mediated effects.
1.9 Cyclooxygenase Enzymes (COX)
The COX enzymes metabolise AA in a two stage process (see figure 1.3). Initially
the cyclooxygenase activity oxygenates free AA to the unstable prostaglandin
intermediate; PGG2. The hydroperoxidase action of the COX enzymes then converts
PGG2 to the prostanoid precursor PGH2 (73). Differences in the metabolism of AA
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by the COX isoforms have been observed with COX-2 requiring less AA than COX-
1 to be functional (74). NSAIDs including aspirin act to inhibit COX activity and
subsequent prostaglandin release.
1.9.1 COX Structure
There are three isoforms of the COX enzymes namely, COX-1, COX-2 and COX-3
(70). COX-1 and COX-2 are derived from distinct genes. COX-1 is a 68 kDa protein
and derived from a gene located on chromosome 9. The COX-1 gene is 25 kb in size
with 11 exons and is transcribed to a 2.8 kb mRNA (70). The gene encoding COX-2
spans 8 kb and is located on chromosome 1 with 10 exons. The transcribed mRNA is
4.1 - 4.5 kb and gives rise to a protein of 72 kDa (70). The COX enzymes have been
characterised in a number of species. Between species, COX-1 and COX-2 display
around 80% - 90% homology. Furthermore, COX-1 and COX-2 from the same
species share 60% - 65% sequence homology based on the amino acid composition
(67). The COX-3 isoform has been most recently cloned. COX-3 mRNA is derived
from the COX-1 gene and retains intron 1. In humans COX-3 is expressed as a 5.2
kb transcript (75).
COX enzymes are glycosylated integral membrane proteins (76). Post translational
processing gives rise to either homodimers or heterodimers of COX-2 of 72 kDa and
72 kDa / 74 kDa respectively. However, post translational processing of COX-1
gives rise to a homodimer of 72 kDa. COX enzymes exist as dimers both structurally
and functionally with superimposable crystal structures (77). Dimerisation is
required for the catalytic activity and glycosylation for the cyclooxygenase and
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peroxidase activities. Alternative sites of glycosylation of COX-2 gives rise to the 72
kDa and 74 kDa subunits. There are three structural domains namely, an N-terminal
epidermal growth factor (EGF) like domain, a membrane binding domain and a
globular catalytic domain with the heme-binding site (70). The COX enzymes bind
one mole of high-spin ferric heme per mole monomer (76). One of the major
structural differences between COX-1 and COX-2 is that COX-2 has a truncated
signal peptide and an insertion of 18 amino acids at the C terminal. Although the
functional significance of the insertion of 18 amino acids at the C terminal is
unknown, it has been suggested it may be important for targeting COX-2 to the
nuclear membrane (76, 78).
1.9.2 COX Biosynthetic Signalling Pathways
Mice knockout studies where either the COX-1 or COX-2 genes have been disrupted
and pharmacological inhibition of COX enzymes demonstrate divergent effects (79-
81). These observations suggest the individual COX enzymes may have distinct
physiological roles. The COX enzymes share similar catalytic mechanisms and
kinetics. However, the COX-2 active site is approximately 20% bigger than the
COX-1 site (82). The difference in the size of the active site has been exploited in the
generation ofCOX-2 selective inhibitors. COX-1 exhibits negative allosterism at low
AA concentrations. Prostaglandin synthesis can be stimulated with 1 pM AA in cells
expressing COX-2, however, COX-1 generated prostaglandins require AA in
concentrations of at least lOpM (83). It has been suggested that this may allow COX-
2 to compete more effectively for AA in systems where both enzymes are expressed.
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The COX enzymes are found in the endoplasmic reticulum, and the nuclear
membrane (84). There is some evidence that COX-2 is more associated with the
nucleur membrane compared with COX-1 (84). This has given rise to the suggestion
that COX-2 products may be involved in gene transcription or regulation at the
nuclear level possibly via nuclear peroxisome proliferator-activated receptors
(PPARs) (84, 85). Thus, indicating an intracrine role for PGs arising from COX-2
(84). In addition, COX-1 and COX-2 products also signal via GPCRs on the cell
surface. There is evidence that COX-1 and COX-2 preferentially metabolise AA to
specific prostaglandins with COX-2 shifting the balance to the production of PGE2
and PGI2 (86). This observation may in part due to the localised expression of the
prostaglandin synthases. PGI synthase and mPGE synthase both associate with the
perinuclear membrane where COX-2 is more concentrated (70, 74). The cellular
location of synthases can depend on the mode of stimulation. In HEK293 cells,
stimulation with A23187 results in haematopoietic-type Prostaglandin D2 Synthase
(HPGD) synthase translocating to the endoplasmic reticulum and preferentially
coupling with COX-1. Conversely, stimulation with IL-1/3, HPGD synthase is
translocated to the perinuclear envelope and results in preferential coupling with
COX-2 (74). Moreover, the differences in the metabolism of AA and the cellular
locations ofCOX-1, COX-2 and the terminal prostaglandin synthases may contribute
to divergence of the apparently similar biosynthetic systems for COX-1 and COX-2
(70).
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1.10 Regulation of COX Enzymes
1.10.1 COX-1
COX-1 was originally purified in 1976, later being cloned in 1988. COX-1 is
constitutively expressed in many cell types and is classically associated with
physiological and housekeeping functions. Constitutive expression of COX-1 in
endothelium, monocytes, platelets, renal collecting tubes and seminal vesicles has
been demonstrated at high levels (87). An elevation in the expression of COX-1 in
differentiating cells has been observed suggesting COX-1 is developmentally
regulated (88). Interestingly, recent studies have shown COX-1 to be inducible in
certain cancers (64, 65, 89-92). The COX-1 promoter does not contain a TATA or
CAAT box. The possible transcriptional regulatory elements identified in the COX-1
promoter include Spl, AP-2, NF-IL-6 and GATA (70, 87). Two Spl cis-regulatory
elements in the COX-1 promoter have been recognised and are thought to contribute
to constitutive expression of COX-1. The Spl sites bind the trans-activating Spl
protein. Deletion of one of the Spl sites results in a 50% reduction in transcription
increasing to 75% reduction where both Spl cis-regulatory elements are deleted (93).
1.10.2 COX-2
Unlike COX-1, COX-2 is an immediate gene and is rapidly induced by growth
factors, cytokines and phorbal esters and is generally associated with pathological
conditions (73, 79, 94, 95). The stimulus to induce COX-2 is dependent upon cell
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type and related to the relevant physiological processes. For instance in the kidney,
COX-2 expression is upregulated in response to increase salt concentration, however,
in granulosa cells, FSH and LH induce COX-2 expresison (96-98). Under
physiological conditions, COX-2 is normally expressed at almost undetectable levels,
however, COX-2 is constitutively expressed in the brain, kidney, ovary and uterus
(99-102). Further evidence for a role ofCOX-2 in homeostasis comes from studies in
COX-2 knockout mice which display systemic abnormalities as discussed in section
1.12 (103). The COX-2 gene promoter region contains a number of identified
transcription elements namely, NF-IL-6, AP-2, Spl, two NF-kjS, CRE and E-box
(70).
The MAPK and NF-k/3 signalling pathways are important in the control of COX-2
expression. The MAPK signalling cascade is divided into three pathways: ERK1/2,
JNK/SAPK and p38 MAPK. Activators of the MAPK signalling pathways include
growth factors, inflammatory mediators such as lipopolysaccharide (LPS) and tumor
necrosis factor alpha (TNFo:) (77). Inhibition of ERK 1/2 MAPK in monocytes
stimulated with LPS inhibits COX-2 expression. LPS stimulated monocytes treated
with the p38 MAPK inhibitor results in the destabilisation of COX-2 (77). These
studies indicate that in LPS stimulated monocytes, COX-2 expression and post
translational regulation is dependent on the ERK 1/2 and p38 MAPK pathways. The
JNK/SAPK and p38 signalling pathways have been demonstrated in different cellular
models to mediate the upregulation in COX-2 expression by IL-1. In HeLa cells
(cervical adenocarcinoma cells) inhibition of the p38 pathway attenuated COX-2
induction by IL-1 (95). Interestingly, the prostaglandin PGE2 has been demonstrated
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to stabilise COX-2 mRNA resulting in elevated COX-2 protein expression via the
p38 MAPK pathway (104). Stabilisation of COX-2 mRNA by p38 MAPK is thought
to be as a result of inhibition of deadenylation. Moreover, inhibition of p38 MAPK
rapidly destabilises COX-2 mRNA.(104-106).
COX-2 induction by a variety of agents and conditions including IL-1/3 in
osteoblastic cells and hypoxia has been shown to be mediated via the NF-k/3 pathway
(77). Glucocorticoids inhibit COX-2 induction via AP-1 and NF-k/3 dependent
transcription. Within the human endometrium, it is thought the negative regulation of
COX-2 expression by progesterone is partly mediated via the NF-k/3 pathway (107,
108). Further evidence for the role of the NF-k/3 pathway in COX-2 expression is
demonstrated by mutations in the NF-k/3 cis-regulatory region resulting in reduced
COX-2 induction by TNFo: stimulation (77).
1.10.3 COX-3
COX-3 displays a different pharmacological response compared with COX-1 and
COX-2 and appears to be most sensitive to drugs with low anti inflammatory
properties (75). The role and regulation of COX-3 in human physiology and
pathological conditions has still to be elucidated.
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1.11 Pharmacological Inhibiton of COX Enzymes
The NSAIDs block the synthesis of COX derived prostaglandins by inhibiting COX
activity. There are essentially two groups ofNSAIDS, non selective that block both
COX-1 and COX-2 activity such as aspirin and ibuprofen and the COX-2 selective
inhibitors which include celecoxib and NS398 (77). Whilst the non selective
NSAIDs block the activities of both COX-1 and COX-2, there is evidence that they
bind more tightly to COX-1 than COX-2 (109). The NSAIDs compete with AA to
bind to the COX active site. NSAIDs block COX activity by one of three
mechanisms. Ibuprofen like drugs act by rapid, reversible binding; time dependent,
high affinity, slowly reversible binding is shown by drugs such as flurbiprofen or
acetylation of Ser530 ofwhich aspirin is the only drug that acts in this way (69, 77).
Acetylation of Ser530 irreversibly prevents AA from binding to the substrate binding
site thus requiring new protein synthesis. Other COX inhibitors demonstrate
competitive binding and upon disassociation, COX levels return to basal (77). At
higher concentrations, NSAIDs mediate their effects via alternative actions such as
inhibition of IkB kinase-/? preventing the activation of genes by NFk (3 (110)
NSAIDs are used as anti-inflammatory, antipyretic and analgesic agents (111).
Mefenamic acid an NSAID is the first line treatment for common gynaecological
conditions such as menhorragia (39). Furthermore, use of NSAIDs has been shown
to reduce the risk of colorectal cancer and reduce the size and number of colorectal
polyps in patients with FAP. The use of NSAIDs has been linked with a 40-50%
reduction in deaths from colorectal cancer (112). This has led to the suggestion that
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NSAIDs are therapeutically useful in the treatment of carcinomas in a variety of
tissues including the endometrium (66, 113).
Non selective NSAIDs have been associated with side effects including ulceration of
the gastrointestinal tract and renal failure in patients with severely compromised
renal function (114). The adverse side effects associated with non selective COX
inhibition are thought to be due to the inhibition of the normal physiological actions
of COX-1. These observations prompted the development of COX-2 selective
inhibitors. COX-2 selective inhibitors are generally better tolerated than the non
selective NSAIDs and display inhibition of the production of prostaglandins
associated with COX-2 activity (115, 116). As previously mentioned the active
binding site in COX-2 is approximately 20% bigger than in COX-1 and consists of
an extra side pocket. It is this feature that allows COX-2 to accept a wider range of
substrates than COX-1 and is exploited by COX-2 inhibitors. This is confirmed by
restricting the size of the binding site, by substituting the Val523 to an isoleucine,
COX-2 no longer shows affinity for the COX-2 selective inhibitors (18).
Recently concerns were raised about the safety of COX-2 selective inhibitors. Most
noteworthy was the withdrawal of rofecoxib owing to its link with increased risk of
myocardial infarction and strokes (117). The safety of other COX-2 selective
NSAIDs has also been questioned. There is evidence that this class of drugs is
heterogeneous in its actions (118). Rofecoxib is highly targeted to COX-2 and also
displays one of the longest half lives (117). Celecoxib has been shown to inhibit
proliferation and apoptosis in human vascular endothelial cells, whilst, rofecoxib
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displayed neither of these effects (118, 119). Whilst more studies will be needed to
confirm the safety of other COX-2 inhibitors, the differences shown in the actions
mediated between the COX-2 selective inhibitors suggest they may still offer a
useful therapy (117).
1.12 COX Knockout Studies and Effects on Reproduction
Further insights into the roles of the COX enzymes have come from COX knockout
studies. COX-1 as mentioned in 1.10.1 is considered a housekeeping gene and
associated with maintaining homeostasis. Despite this, disruption of the COX-1 gene
in mice is coupled with surprisingly few deleterious effects (120). COX-1 is
considered important in maintaining gastric integrity, kidney function and platelet
aggregation. Surprisingly, COX-1 (-/-) mice displayed no gastric or intestinal
ulceration or renal dysfunction. Moreover, treatment of the COX-1 (-/-) mice with
the non selective COX inhibitor indomethacin was associated with reduced gastric
ulceration compared with wild type mice (120). COX-1 (-/-) mice do display an
altered inflammatory response to AA and reduced platelet aggregation. Furthermore,
in mice, COX-1 and prostaglandin activity is crucial for parturition and pup survival.
COX-1 (-/-) demonstrate delayed parturition and neonatal death (121). Whilst not
demonstrated by Langenbach et al (122), other studies involving COX disruption
report a compensatory action by the remaining COX activity (120, 121, 123). COX-2
as outlined in 1.10.2 is generally considered to be involved in pathological conditions
with limited housekeeping functions. Flowever, in contrast with COX-1, disruption
of the COX-2 gene is not coupled with an impaired inflammatory response but is
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linked with severe renal abnormalities and multiple reproductive failures (80, 103).
Whilst male COX-2 (-/-) mice showed normal fertility, ovulation, fertilisation,
blastocycst implantation and decidulisation are all compromised in female COX-2 (-
/-) mice (80, 103). PGE2 receptors expressed in the COX-2 null mouse uterus are
comparative with wild type. Moreover, infused PGE2 failed to induce decidulisation,
thus suggesting other COX-2 products may be important in successful decidulisation.
As previously mentioned, COX-2 is more associated with the nuclear membrane than
COX-1 (85). Failure of PGs to restore COX-2 functions in a cell model has prompted
the suggestion that nuclear prostanoid receptors play an important role in conferring
COX-2 actions (80). Pharmacological selective inhibition ofCOX-2 showed reduced
ovulation, fertilisation and implantation although these effects were not as dramatic
as those seen in the COX-2 knockout mice. Simultaneous inhibition of COX-1 and
COX-2 with NSAID treatment augmented the negative effect on implantation and
decidulisation suggesting a compensatory action of COX-1 (81). In humans, there is
some evidence that use of COX-2 selective inhibitors can impair fertility, cessation
of the use of these drugs restores fertility (124). These studies demonstrate that
COX-2 plays an important physiological role in renal and reproductive systems. The
COX knockout mouse models highlight the oversimplification in categorising COX-
1 exclusively as a housekeeping gene and COX-2 solely being involved in
pathological states.
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1.13 COX Enzymes in Cancer and Relevance of 15-PGDH
Over recent years, there has been mounting evidence for a role of the COX enzymes
in carcinogenesis and the progression of the disease. Initial circumstantial evidence
of a role for COX enzymes in cancers came from experiments in the 1980s.
Prostaglandin synthesis was demonstrated to be elevated in human breast carcinomas
and correlated with neoplastic cell density and tumour invasion (125).
Epidemiological studies reported a 40-50% reduction in the risk of contracting
colorectal disease in subjects with long term aspirin use (126). Further studies have
shown a similar negative correlation between NSAID use and reduced death rates
from cancers of the esophagus, stomach, breast, lung, prostate, urinary bladder and
ovary (78). Familial Adenomatous Polyposis (FAP), an autosomal dominant disorder
is characterized by the formation of hundreds of colorectal adenomas that progress to
colorectal cancer. Patients with FAP treated with NSAIDs show a marked reduction
in the number of colorectal polyps (127-129). Moreover numerous studies have now
demonstrated an upregulation of COX-2 expression in carcinomas including
colorectal, head and neck, oesophagus, pancreas, lung, prostate, bladder, and female
reproductive cancers; endometrial, cervical and ovarian (61, 92, 130-133). An in-
vivo model has demonstrated the growth of tumours in COX-2 null mice injected
with lewis lung carcinoma cells is attenuated when compared with wild type cells
(134). Furthermore, a significant reduction in VEGF production was also reported in
the COX-2 null mouse fibroblasts. These effects in the COX-2 null mice were
inducible in wild type mice treated with a COX-2 selective inhibitor (134).
Interestingly, overexpression of COX-2 in a mouse skin tumour model resulted in a
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suppression of tumour development. This observation suggests an alternative
involvement for COX-2 in skin tumorgenesis (135).
It is now well accepted that delivery of nutrients and consequently tumour growth is
dependant on angiogenesis and ultimately a vascular supply to the tumour (136).
Putative mechanisms by which COX-2 influences tumour growth came from
experiments in rat intestinal cells stably transfected with the COX-2 cDNA.
Overexpression of COX-2 was associated with an elevation in the synthesis of
prostaglandins. The increased generation of prostaglandins was accompanied with a
decrease in apoptosis, enhanced cellular proliferation and an upregulated expression
of angiogenic factors (137-139). Once synthesised, the angiogenic factors act in a
paracrine manner to promote endothelial cell migration and microvascular tube
formation (138). Moreover, treatment with NSAIDs in the overexpressing COX-2
models resulted in restoration of the basal apoptotic rate and an inhibition in
angiogenic factor production thus supporting the notion that the protective effects of
NSAIDs are mediated via their actions on the COX enzymes and reduced
prostaglandin synthesis (137).
Until recently, the elevated expression of the COX products the prostaglandins in
cancer models was thought to be due to the overexpression of COX-2 (140).
However, catabolism of prostaglandins is dependent on the rate limiting enzyme, 15
- Hydroxyprostaglandin dehydrogenase (15-PGDH). The local accumulation of
PGE2 is most likely to depend on a balance between COX expression and 15-PGDH
(140, 141). The expression of 15-PGDH has been shown to be markedly reduced in
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colon cancer samples relative to normal colon giving rise to the suggestion that an
upregulation ofCOX-2 in concert with a down regulation of 15-PGDH is required in
colon cancer development (140, 142). The underlying molecular mechanisms have
yet to be fully elucidated. However, TGF-/3 a known colon tumour suppressor
induces 15-PGDH expression and this action may contribute to its tumour
suppression action (141). Conversely, EGF has been demonstrated to down regulate
15-PGDH. A feed forward mechanism has been suggested for accumulating PGE2
whereby COX-2 derived PGE2 transactivates the EGFR. In turn this results in
decreased 15-PGDH and an increased local PGE2 concentration.
Whilst there is a wealth of evidence supporting a role for COX-2 in tumorigenesis,
there is now evidence that COX-1 is also upregulated in certain carcinomas.
Inhibition of COX-1 in a mouse FAP model is associated with a reduction in the
number of intestinal polyps (79). Moreover, selective inhibition of COX-1 shows
protective effects against colon cancer (78). These studies demonstrate that both
COX isoforms play a role in tumorigenesis. Futher studies are required to establish
the contribution of each isoform to tumour promotion (78).
1.14 Prostaglandins
Early experiments by Ulf von Euler led to the discovery of prostaglandins in the
1930s (73). Prostaglandins belong to the prostanoid group of the eicosanoids.
Prostanoids comprise of the prostaglandins which contain a cyclopentane ring and
thromboxanes with an oxane ring and are derived from C-20 fatty acids such as AA
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by the cyclooxygenase enzymes. All the prostanoids contain a trans- double bond at
C13-C14 and a hydroxyl group at C15 (143). Modifications of the cyclopentane ring
gives rise to the different prostaglandin types e.g. PGE and PGF series (144). The
prostaglandins include PGD2, PGE2, PGF2tt and PGI2. Once AA is metabolised as
described above to PGH2, PGH2 acts as the substrate for prostanoid synthesis. PGH2
is acted on by synthases specific to each prostanoid for instance PGE synthase
(PGES) catalyses the conversion of PGH2 to PGE2. Most cells of the body synthesise
prostaglandins (73). The specific prostaglandins synthesised depends on the
prostaglandin synthases present in the cell or tissue with the profile of prostaglandin
synthases present thought to be cell specific (77). Once synthesised, prostaglandins
acting in an autocrine / paracrine manner are transported out of the cell by facilitated
transport by the prostaglandin transporter (145, 146). Prostaglandins have a relatively
short half life and act local to the site of synthesis (69).
Prostaglandins are important in a wide range of physiological and pathological
processes (77). In a physiological setting, prostaglandins are involved in maintaining
cardiac function, renal function, mediation of pain and reproduction. The
prostaglandins have been implicated in the pathogenesis of cancer, rheumatoid
arthritis, Creutzfeldt-Jakob Disease (CJD) and Alzheimer's disease (77, 147, 148).
The roles of prostaglandins and the signalling pathways that mediate their effects are
discussed in the following sections.
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1.15 Prostaglandin Receptors
Prostanoids mediate their effects via G protein coupled receptors on the cell surface
(149).The first PG receptor to be cloned was the TXA2; TP receptor. In humans, a
total of 9 prostanoid receptors encoded by separate genes have been described (143).
Three groups of receptors have been described, the first IP, EP2, EP4 and DP are
relaxant receptors and couple with Gs to stimulate cAMP turnover. The second group
comprises of TP, EP1 and FP receptors and are considered the contractile receptors
and couple with Gq to increase intracellular Ca2+ levels. Lastly EP3 and CRTH2
couples with Gi and inhibits adenylate cyclase and cAMP turnover (143, 149). These
groups however, do contain exceptions where receptors can couple to multiple G-
proteins (143). The prostaglandin receptors display only a 20% - 30% homology
between them. Even when comparing EP1, EP2, EP3 and EP4, the homology is still
very low. Studies have shown that the prostanoid receptors signalling via the same
pathways demonstrate higher homology than when comparing those sharing the
same ligands (144). With the exception of the recently discovered DP2 receptor, the
receptors are G protein coupled with seven transmembrane domains and members of
the rhodopsin-type receptor superfamily (149). The prostanoid GPCRs show
selective ligand binding specificity. PGE2, PGI2, PGF2<*, PGD2 and TXA2 act on the
EP1-4, IP, FP, DPI and TP receptors respectively (see figure 1.4). The DP2 receptor;
or chemoattractant receptor homologous molecule expressed on Th2 cells (CRTH2),
lacks homology with the prostaglandin receptors and is more closely related to the
chemoattractant GPCRs than other prostaglandin receptors (148, 150, 151) The EP3
and more recently the FP receptors have been demonstrated to have alternative splice
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variants (149, 152, 153). The receptors signal via multiple pathways. Co-expression
of prostanoid receptors signalling via opposing pathways is often present. This has
been suggested to act as means to maintain homeostatic control and in part explain
the diverse and complex actions elicited by prostaglandins (154).
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Figure 1.4 Schematic representation of the cyclooxygenase and prostanoid biosynthetic and signalling
pathway. (Reproduced from Jabbour and Sales 2004 (155))
Recently the nuclear located peroxisome proliferator-activated receptors (PPARs)
have been identified (156). PGJ2 and PGI2 are known ligands of these receptors (85,
156, 157).
1.15.1 EP Receptors
PGE2 elicits its effects via the EP receptors. There are 4 recognised EP receptors
termed EP1, EP2, EP3 and EP4 (149). EP3 displays at least eight alternative splice
variants (158). These receptors act via different signalling and sometimes opposing
pathways even within the same tissue (154, 159). PGE2 mediated actions via EP
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receptors expressed on the cell surface has been widely described. PGE2 is known to
have diverse physiological functions including an involvement in maintaining gastric
integrity, preserving renal function and has a role in controlling blood pressure (149).
The presence of functional EP receptors on the nuclear envelope has been identified
(160, 161). Activation of these receptors may mediate alternative effects than
receptors expressed on the cell membrane. Furthermore, this identifies a possible
intracrine action of PGE2 and would enable a PGE2 to mediate direct regulation of
gene transcription (162). Regulation of eNOS via nuclear located EP3 receptors has
been shown in cerebral microvessel endothelial cells. This action is not thought to be
cell surface receptor mediated (162).
1.15.1.1 EP1
EP1 receptor distribution in the mouse has been reported in the kidney, lung and
stomach (163). The EP1 receptor elicited effects include contraction of smooth
muscle; in tissues such as the respiratory tract and the myometrium, and
neurotransmitter release (164). Pain elicited by PGE2 is thought to be mediated in
part via the EP1 receptor (165). EP1 receptors are coupled with Gq and activation
results in increased intracellular Ca2+ levels (149). Interestingly an EP1 splice variant
receptor with six transmembrane domains has been demonstrated in the rat (rEPl-
variant) that binds PGE2. Co-expression of the rEPl-variant with either rat EP1
9+
receptor or EP4 receptor in CHO cells resulted in a reduced Ca or cAMP
accumulation respectively (166). It has been hypothesised that the rEPl-variant
receptor may alter the efficiency of signal coupling of EP receptors and limit the
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action of PGE2 (166). A six transmembrane splice variant of the FP receptor has been
described in the human (153).
1.15.1.2 EP2
The EP2 receptor is the least abundantly expressed of the EP receptors (149). In the
mouse, EP2 receptor expression has been confirmed in various tissues including the
uterus, spleen and lung. The EP2 receptor has been shown to be involved in
ovulation, implantation and inflammation. The mediated effects by EP2 are thought
to be inhibitory (164). Activation of the EP2 receptor results in increased cAMP
generation via coupling to Gs (167). Recently, cross communication with the
epidermal growth factor receptor (EGFR) and EP2 has been reported resulting in the
activation of the MAPK pathway (168). The EP2 receptor can be upregulated as
demonstrated in macrophages treated with LPS (169). Gonadotropins in uterine
luminal epithelial cells have also been shown to induce EP2 mRNA expression
(170). EP2 mRNA expression is upregulated in a mouse model for familial
adenomatous polyposis (171)(FAP). Moreover, PGE2 via the EP2 receptor was
demonstrated to up regulate COX-2 and thereby promote a feed forward mechanism
to further enhance PGE2 synthesis (171). In contrast with EP4, following short term
ligand binding, the EP2 receptor does not undergo desensitisation (172). This may
indicate EP2 is important in mediating prolonged responses to PGE2 (172).
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1.15.1.3 EP3
EP3 receptor expression is highest in the kidney, uterus, adrenal gland and stomach
tissues (149). Effects mediated via the EP3 receptor include smooth muscle
contraction, modulation of neurotransmitter release, inhibition of gastric acid
secretion and contributes to the maintanence of renal function (164). There are
currently eight identified EP3 splice variants which arise from alternative C terminal
splicing (149, 173). Activation of the EP3 receptor is associated either with a Gs
mediated increase in cAMP or a Gj linked decrease in cAMP depending on the splice
variant (149). The physiological significance of the EP3 splice variants remains to be
established, however, there is evidence that the splice variants are expressed in a
tissue dependant manner (174). Internalisation of EP3 receptor on ligand binding is
dependant on the splice variant (173). This may indicate differences in the
physiological functions between the splice variants depending on whether the PGE2
is secreted over a short or prolonged period of time (173). The expression ofmultiple
EP3 splice variants has been reported in the myometrium and the ratio of expression
of the EP3 variants varies in gravid human myometrium (158, 175). This implicates
EP3 receptor signalling in myometrial contractility (175). Furthermore, this suggests
that a balance of expression for EP3 receptors is important. EP3 elicited effects have
been implicated in a model of tumour angiogenesis and growth (176). Further studies
would be required to determine if an altered ratio of EP3 splice variants is observed
in pathological conditions.
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1.15.1.4 EP4
Initially, two receptors were cloned and termed EP2 (149). Further studies
demonstrated one receptor to be sensitive to butaprost and the other insensitive. The
receptor cloned by Honda et al (177) and insensitive to butaprost was termed EP4.
The butaprost sensitive receptor remained classed as the EP2 receptor (143, 177,
178). As with the EP2 receptor, activation of the EP4 receptor results in increased
cAMP generation. EP4 receptors have a higher affinity for PGE2 than EP2. However,
in response to exogenous PGE2, HEK cells overexpressing EP4 receptors
demonstrate lower cAMP generation than HEK cells overexpressing EP2 receptors
(179). EP4 mRNA expression is highest in the small intestine but is present in
various other tissues including the lung, kidney uterus and brain (180). There is
evidence from in vitro studies in rat colon epithelial cells and EP4 knockout mice
linking EP4 receptors with maintenance of gastric integrity (181, 182). Vasodilatory
effects and a role in closing the ductus arteriosus have been described for the EP4
receptor (149).
1.15.2 FP Receptors
PGF2a elicits its effects via the FP receptor and is important in reproductive systems
(148). FP receptor expression has been reported to be greatest in the corpus luteum
(144). Recently, the temporal expression and signalling of FP receptors within the
human endometrium has been described (183). A FP splice variant receptor has been
identified in a number of species. FP splice variant expression has been described in
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ovine corpus luteum; namely the FPA and FPB variants (184), bovine corpus luteum
and most recently, a human FP splice variant (hFPs) has been identified (150, 153).
Interestingly, Northern blot and immunohistochemical studies have demonstrated
alternative ligand mediated internalisation of the FPA and FPB receptors (185) hFPs
at mRNA and protein level in tissues such as the heart, skeletal muscle and the
placenta (153). The newly reported hFPs and bovine FP splice variants appear to
exist as six transmembrane receptors; with an extracellular carboxyl terminus, as
opposed to the previously described seven transmembrane FP receptor. The function
and physiological significance of the truncated hFPs receptor has yet to be elucidated
(153). Activation of the FP receptor results in Gq coupled signaling, activation of
phospholipase CI3 (PLCB), release of inositol triphosphate (IP3) and diacylglycerol.
Signaling of the FP receptor resulting in the activation of Rho in a Gq independent
manner has also been described (186). Recently, studies from our laboratory have
demonstrated transactivation of EGFR resulting in activation of the MAPK (187).
Mutation of the FP receptor in mice is associated aberrant parturition thus further
confirming a role for FP mediated effects in reproduction (188).
1.15.3 IP Receptors
PGI2 mediates its actions via the EP receptor. PGI2 is the predominant prostaglandin
produced by endothelial cells and its actions oppose those of TXA2. The IP receptor
can couple with Gs, Gq or Gj. which results in an elevation of cAMP,
phosphoinositide turnover and an inhibition of cAMP respectively. However,
coupling with Gs and activating cAMP turnover is the predominant signalling
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pathway activated (148, 149). Alternative C terminal modifications allows for the
coupling to multiple signalling pathways (148). The IP receptor undergoes agonist
mediated desensitisation by the phosphorylation of the C terminal via a PKC
dependent mechanism. Additionally, studies have demonstrated the intemalisation of
the IP receptor by a PKC independent process (148). IP receptor expression has been
confirmed in the neurons of the dorsal root ganglia; including those that express
substance P, indicating a role in the mediation of pain. In the kidney, IP receptors
have demonstrated in the glomerulus suggesting an involvement in glomuerular
filtration (144). Recently, IP receptors have been termporally localised in the human
endometrium (189).
1.15.4 DP Receptors
PGD2 exerts its functions via the DP receptors DPI and the recently discovered
CRTH2 (DP2) receptor (151, 190, 191). Previously, the DP receptor has been
reported to be expressed at low levels in most tissues (149). PGD2 mediated effects
have been shown to play a role in a wide range of physiological and pathological
conditions (190). PGD2 is known to be involved in the allergic response and have
central nervous system actions; including an involvement in sleep (190). Activation
of the DP receptor increases intracellular cAMP and Ca levels (149). There is some
evidence that signalling of the CRTH2 receptor is cell specific and may lead to
alternative intracellular events in different cells (192). K562 cells (an
erythroleukemia cell line) and Jurkat cells (a human leukaemia cell line) have been
transfected with CRTH2. Activation of CRTH2 in K562 cells is associated with
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• 21 • •increased Ca levels. In contrast, activation of Jurkat cells was not accompanied
2+with Ca mobilisation (192). Moreover, various studies have reported that PGD2 can
signal via Gs, Gq, and Gj coupled receptors (151, 190).
1.15.5 TP Receptors
TXA2 mediates its actions via the TP receptor which exists as multiple splice variants
in humans; TPa and TP/3 (193). The TP receptor is expressed in tissues supplied with
a rich vasculature; such as the lung, kidney and heart, and also those related with
immune function; including the spleen and thymus (144). The actions of
thromboxane include contraction of smooth muscle and a mediator of platelet
aggregation (149, 193). The TP receptor couples to a number ofG proteins including
Gq, Gs and Gi this results in activation of PLC-/3 and IP3 / DAG turnover, increased
intracellular cAMP and reduced cAMP generation respectively (148).
1.16 PPAR Receptors
Mediation of prostaglandin actions via GPCRs is well accepted. The presence of
COX-2 in the nuclear envelope has led to the possiblity that prostaglandins once
synthesised may mediate effects via nuclear receptors. In addition to the nuclear
localised EP receptors (160, 161), there is evidence that COX-2 products may elicit
effects via the peroxisome proliferators-activated receptors (PPARs). The PPARs are
nuclear located receptors. Three isoforms of the PPAR receptors have been
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identified, namely, PPARa, PPARo//3 and PPARy and these are closely homologous
members of the nuclear hormone receptor superfamily (156).
Ligands for PPARs include fatty acids, prostaglandins, NSAIDs and anti-diabetic
drugs (194). Upon activation by ligand binding, the receptors form a heterodimer
with the retinoid X receptor and bind to PPAR responsive elements resulting in gene
regulation. In addition, PPARy has been demonstrated to block AP-1 and NFk/3
transcription (195). PGJ2 is a dehydration product of PGD2 and the 15-deoxy
metabolite of PGJ2 (15d- PGJ2) has been demonstrated to be a ligand for the PPARy
receptor and widely studied. PPARymediated effects are generally thought to be anti
inflammatory and pro apoptotic (156). The dependence of 15d- PGJ2 on the synthesis
of PGD2 has been hypothesised to result in delayed synthesis and therefore act in the
resolution of inflammation (156). PPARy ligands have been shown to inhibit the
secretion of inflammatory mediators from mast cells (156). Inhibition of COX-2
expression and PGE2 synthesis by PPARy ligands was observed in human epithelial
cells stimulated with phorbol 12-myristate 13-acetate (PMA) (196). In colon cancer
cell lines and a mouse model of colonic inflammation, PPARy ligands reduced
cytokine production. These observations have led to the suggestion that PPARy
ligands may be of therapeutic use (156).
There is however some controversy surrounding PGJ2 and whether it is produced
endogenously and at high enough concentrations to activate PPARy (157). Another
metabolite of PGJ2; A12- PGJ2 has been detected in urine and this has been taken by
some as evidence of endogenous dehydration of PGD2 to its metabolites (197). Since
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NSAIDs can act as ligands for the PPAR receptors, this has further limited the study
of the relationship between COX and PPAR.
1.17 Some Prostaglandin Elicited Actions in Physiology and Pathology
The involvement of prostaglandins in physiological and pathological states has been
recognised for some time, recent prostanoid receptor knock out mice studies have
helped to begin unravelling the molecular pathways that elicit prostanoid actions (see
table 1.1) for a summary of these studies.
Genotypes Phenotypes
DP (-/-) Decreased allergic responses in ovalbumin-induced bronchial asthma
EP1 (-/-) Decreased aberrant foci formation to azoxymethane
EP2 (-/-) Impaired ovulation and fertilisation
Salt-sensitive hypertension
Vasopressor or impaired vasodepressor response to intravenous PGE2
Loss of bronchodilation with PGE2
Impaired osteoclastogenesis in vitro
EP3 (-/-) Impaired febrile response to pyrogens
Impaired duodenal bicarbonate secretion and mucosal integrity
Enhanced vasodepressor response to intravenous infusion of PGE2
Disappearance of indomethacin-sensitive urine diluting function
EP4 (-/-) Patent ductus arterosus
Impaired vasodepressor response to intravenous infusion of PGE2




Decreased acetic acid writhing
TP(-/-) Bleeding tendency and resistance to thromboembolism
Table 1.1 Major phenotypes of prostanoid receptor knockout mice (reproduced from Kobayashi and
Narumiya (198))
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1.17.1 Reproduction
1.17.1.1 Uterine Function
The predominant prostaglandins synthesised in the endometrium are PGE2 and
PGF2a. Small amounts of TXA2, PGD2 and PGI2 are also synthesised (4, 199). The
prostanoids produced in the endometrium may have a number of roles. Prostanoids
are thought to be important in vascular function. Both PGE2 and PGI2 are
vasodilatory, conversely, PGF2a and TXA2 cause vasoconstriction (73). Furthermore,
myometrial contractility is under the influence of prostanoids. PGE2 and PGI2 inhibit
myometrial contractility whilst PGF2a induces contractility (4, 199).
1.17.1.2 Ovulation
The importance of prostaglandins in normal ovulation is demonstrated by COX-2
knockout mice which display multiple reproductive failures including impaired
ovulation (80). Lutenising Hormone (LH) promotes COX-2 expression and
ultimately prostaglandin synthesis. Successful ovulation and rupture of the follicle
depends in part on COX-2 induction (200).
1.17.1.3 Luteolysis and Parturition
In ewes, COX activity and PGF2a are both seen to increase prior to the onset of
luteolysis (201). Disruption of the FP receptor in mice results in failed parturition
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(202). PGF2a is an important mediator of luteolysis. It has been suggested that
PGF2amay induce luteolysis through apoptosis of luteal cells. A correlation between
FP mRNA expression and luteal cell apoptosis in pseudopregnancy has been
demonstrated (202).
1.17.2 Gastrointestinal Function
The importance of prostaglandins in maintaining gastric integrity is partly
demonstrated by epidemiological evidence that gastric ulcers and irritation are
associated with long term NSAID use. The cytoprotective prostaglandins are thought
to be predominantly derived from COX-1 activity (116). In a mouse model of
induced gastric lesions with HCl/ethanol, the cytoprotective effect of taurocholate
was reduced by indomethacin but not NS398. The same study demonstrated the
protective effect mediated by prostaglandins was via the EP1 receptor (203). The
importance of EP4 elicited effects in cytoprotection have also been reported (181).
Radiation injury in mice results in reduced crypt stem cell number which is
augmented with the non selective COX inhibitor indomethacin. The further reduction
in crypt stem cell number is not observed with NS398, a non selective COX-2
inhibitor (73). The gastric actions of PGI2 and PGE2 are vasodilation, enhanced
cytoprotective gastric fluid flow and inhibition of gastric acid production (204).
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1.17.3 Renal Function
Prostaglandins are crucial for maintaining renal function (159). Prostaglandins
demonstrate multiple roles within the kidney and this is highlighted by the
expression of various prostaglandin receptors in the kidney (159). Prostaglandins are
important in the control of rennin release, the regulation of vascular tone and the
control of tubular function. PGE2, PGI2, PGF20; and TXA2 are all synthesised within
the kidney (205). Whilst prostaglandins derived from COX-1 are thought to be
important for preserving normal renal function, mice with a disrupted COX-2 gene
and not COX-1 display renal dysfunction that leads to death (81). The relative
importance and contribution of COX-2 derived prostaglandins in the human kidney
has yet to be established.
1.17.4 CNS
Within the central nervous system, prostaglandins are involved in various systems
including sleep, fever generation, and are implicated in the control of the autonomic
nervous system and sensory processing (205). PGD2 and PGE2 are both found at high
levels within the brain. PGD2 and PGE2 have opposing actions on sleep; PGD2
induces sleep, conversely, PGE2 reduces sleep (205).
Injection of PGE2 intracerebroventricularly induces fever in wild type mice. NSAIDs
such as aspirin and indomethacin reduce fever indicating a role for COX derived
products in fever generation (206). Mice lacking the EP3 receptor do not display an
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elevated temperature in response to PGE2 or IL-1/3; which is thought to mediate its
fever inducing effects via PGE2. This study suggests EP3 is important in mediating a
febrile response (206).
1.18 COX-2 and Prostaglandin Mediated Effects That May be Involved in
Endometrial Function
As described in section 1.3. The endometrium undergoes cyclical angiogenesis,
apoptosis and proliferation with menstruation involving an inflammatory like
mechanism. Numerous studies have demonstrated overexpression of COX-2 and the
accompanied increased prostaglandin synthesis is associated with the promotion of
angiogenesis, an inhibition of apoptosis, and enhanced cellular proliferation.
1.18.1 COX Enzymes and Prostaglandins in Angiogenesis
There have been many studies investigating the relationship between the COX
enzymes and prostaglandins in angiogenesis. An in vitro model demonstrated co-
culture of rat intestinal epithelial cells overexpressing COX-2 and endothelial cells
results in enhanced synthesis of prostaglandins, and increases angiogenic factor
expression such as VEGF (138, 207). Once synthesised, the angiogenic factors act in
a paracrine manner to promote microvascular tube formation and endothelial cell
migration (138). Overexpression of COX-1 in HeLa cells was associataed with
upregulated angiogenic factors (60). Other in vitro studies have confirmed
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upregulation of angiogenic factors and their receptors by prostaglandins such as
PGE2, PGI2 and PGF2a (168, 207-210). In a murine model of FAP, a direct
relationship between COX-2, EP2 and angiogenic factor expression and microvessel
density in intestinal polyps has been demonstrated. In the same study, EP2 knockout
mice displayed a reduction in the size of the intestinal polyps concurrent with
reduced COX-2, PGE2 and angiogenic factor expression (171, 211). This study
implicates the EP2 receptor in mediating the pro angiogenic actions of PGE2. Other
studies have shown EP3 and EP4 to be involved in angiogenesis (176, 212). PGE2
may therefore elicit its angiogenic actions via multiple EP receptors. Recently the
downstream signalling pathways activated by prostaglandins and linked to enhanced
angiogenic factor secretion have been investigated. In Ishikawa cells, overexpression
of EP2 or FP treatment with exogenous PGE2 causes an enhanced secretion of VEGF
by transactivation of the EGFR receptor and the ERK-1/2 pathways (168, 208).
These studies demonstrate prostaglandins can act in an autocrine / paracrine manner
to upregulate the synthesis of angiogenic factors and thus promote angiogenesis.
1.18.1.1 Antiangiogenic factors and Cathepsin D
In addition to proangiogenic factors, a number of endogenous antiangiogenic factors
have also been identified including endostatin, angiostatin and thrombospondin-1
(213). It is thought that angiogenesis requires a balance of proangiogenic and
antiangiogenic factors (214). In-vivo antiangiogenic factors are commonly
proteolytic fragments of larger precursor proteins with distinct functions. Angiostatin
and endostatin are cleaved fragments of plasminogen and collagen XVIII
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respectively (213). The plasminogen structure contains 5 kringle domains (see figure
1.5). Cleavage of plasminogen at Arg560-Val561 gives rise to proangiogenic plasmin
(215). Alternative cleavage of plasminogen gives rise to antiangiogenic fragments.
Kringles 1-3,(K1-K3), K1-K4; angiostatin and K5 all display antiangiogenic
properties (215-217). Angiostatin has been demonstrated to be proteolytically
derived from plasminogen by MMPs 3, 7, 9 and 12 and cathepsin D (218-220).
The cathepsins are lysosomal proteases with one of three active-site amino acids.
Cathepsins B, C, H, F, K, L, O, S, V, and W are cysteine proteases. Cathepsins D and
E have an aspartic residue and Cathepsin G a serine residue in the active site (221).
The cathepsins exhibit high a high homology with the plant protease papain and
display optimum activity at an acidic pH (222). The role of cathepsins is not limited
to protein turnover. It has been demonstrated that cathepsins contribute to
neovascularisation of endothelial cells, antigen presentation and cellular proliferation
(221). Cathepsins D, B and L are thought to act collectively to promote a
carcinogenic state (223). Studies have shown an enhanced expression of cathepsin D
in estrogen receptor positive breast cancer (221). Furthermore, cathepsin D is thought
to be a prognostic marker for reduced survival. Interestingly, in endometrial cancer, a
reduced cathepsin D expression has been associated with a poor prognosis (224). To
date overexpression of COX-2 and prostaglandins in the regulation of antiangiogenic
factors has not been reported on.
48
Chapter 1 General Introduction
Plasminogen
NH2 K.1 K2 K3 K4 K5 COOH
K1 K2 K3 K4
K1 K2 K3 Antiangiogenic Fragments
K5
Figure 1.5 Schematic representation of the generation of antiangiogenic angiostatin fragments by the
proteolytic action of agents such as cathepsin D on plasminogen.
1.18.2 Apoptosis
Apoptosis or programmed cell death is a key process in the shedding of the
endometrium. There are a variety of pro and anti apoptotic genes and a balance of
expression is important in maintaining normal tissue homeostasis (225). Apoptosis
induced by members of the bcl-2 family of proteins is mediated by cytochrome C
release from mitochondria (225). Upregulation of the anti apoptotic bcl-2 gene has
been demonstrated in various tumours (225). Overexpression of COX-2 in epithelial
cells has been shown to increase the expression of the bcl-2 protein and inhibit
apoptosis. This effect was reversed with the administration of NSAIDs (137).
Upregulated COX-2 is associated with a three fold increase in the duration of the G1
phase and reduced cyclin D1 which may contribute to the observed reduction in
apoptosis (226). Treatment with NSAIDs can induce apoptosis as demonstrated in
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patients with FAP and cervical cancers (227, 228). A further action ofNSAIDs may
be to inhibit Akt/PKB in the PI-3 kinase pathway. It is suggested that these actions
are independent ofCOX-2 (229, 230). Mutations in tumour suppressor genes such as
p53 are commonly seen in cancers including endometrial (44). An in vitro model has
demonstrated overexpression of mutated p53 in mouse embryo fibroblasts results in
enhanced COX-2 expression coincident with elevated PGE2 secretion (231). Thus
mutations in p53 may contribute to the overexpression ofCOX-2 observed in variety
of tumours. Aberrant expression of bcl-2 has been described in endometriotic
endometrial tissue. These studies suggest that inhibition of apoptosis mediated by
COX-2 and prostaglandins may contribute to tumour progression and benign
gynaecological pathologies.
1.18.3 Proliferation
Overexpression of COX-2 and the resultant elevation in prostaglandin synthesis has
been demonstrated to promote cellular proliferation (137, 232, 233). The
proliferative effects of the prostaglandins are mediated via diverse pathways. In
endometrial tissue and cell lines, PGE2 and PGF2a have been shown to induce
proliferation via the ERK-1/2 pathway and a PLC dependant pathway respectively
(183, 234). Of the four PGE2 receptors, the HES cell line; an endometrial epithelial
cell line, only expresses EP4. It has been suggested that in this that PGE2 mediated
proliferative effect is therefore via EP4 signalling (234). Treatment of cells with
NSAIDs has been shown to inhibit cellular proliferation. (235-237). Epidermal
growth factor induces COX-2 expression and this is concomitant with enhanced
50
Chapter 1 General Introduction
mitogenesis. Inhibition of either epidermal growth factor or COX-2 reduces
mitogenesis (237). PGE2 has been demonstrated to induce COX-2 expression via the
activation of the Ras MAPK pathway (238). It was suggested that the proliferative
action of PGE2 is mediated in part by upregulating COX-2 and therefore initiating a
feed forward mechanism (238). Thus within the endometrium, PGE2 and PGF2a may
be important in cellular proliferation and re-growth of the endometrium post
menstruation.
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1.19 Aims and Objectives of Thesis:
As detailed in section 1.6.1, excessive blood loss during menstruation
(mennorhagia), dysmenorrhoea often associated with painful menstruation and
endometriosis are common benign uterine pathologies. These gynaecological
complaints are considerable reproductive health problems for women and also place
a financial burden on healthcare. Research into the underlining molecular
mechanisms of these conditions could lead to improved and less invasive therapies.
The molecular mechanisms of these gynaecological conditions are poorly
understood. However, a role for cyclooxygenase enzymes and its products the
prostaglandins (such as prostaglandin E2) has been observed. Elevated binding sites
for prostaglandins and an altered ratio of prostaglandins synthesised in endometrium
from women with benign conditions as mentioned above relative to those from
normal endometrium have previously been described. Moreover, first line treatment
for menorrhagia and dysmenorrhoea is often the use of NSAIDs which act by
inhibiting the COX enzymes. However the role of COX and its products in the
human endometrium has yet to be elucidated.
As described in sections 1.6.1 and 1.13, COX-2 and its products the prostaglandins
have been associated with a range of gynaecological conditions and implicated in
promoting angiogenesis within a tumour environment. This thesis examines the
hypothesis that COX-2 and its products the prostaglandins may play a role in the
promotion of vascular function within the human endometrium.
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The specific aims of the research were to:
1) Investigate the temporal expression and signalling of the prostaglandin E2
pathway in the normal human endometrium across the menstrual cycle. This
was determined using a variety of techniques in endometrial tissue samples
collected from across the menstrual cycle as described in chapter 3.
2) Investigate the role of cyclooxygenase-2 and prostaglandin E2 in Ishikawa
cells, an endometrial epithelial cell line. This was achieved by stably
transfecting Ishikawa cells with cyclooxygenase-2 cDNA in either the sense
or antisense directions and determining prostaglandin synthesis, receptor
expression and signalling as detailed in chapter 4.
3) To investigate the potential role of cyclooxygenase-2 in regulation of
endometrial angiogenesis. This was investigated by cDNA array technology
in combination with in vitro studies using the Ishikawa COX-2 stable cell line
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Materials and Methods
2.1 Reagents and Suppliers
All reagents unless otherwise specified were purchased from Sigma Chemical
Company (Dorset, UK). Ishikawa cells were purchased from European Collection of
Cell Culture. Dulbecco's modified Eagle's medium nutrient mixture F-12 was
purchased from Life Technologies (Gibco, Life Technologies Ltd, Paisly, UK),
Foetal calf serum and penicillin-streptomycin was purchased from PAA (PAA
Laborotaries Ltd., Yeovil, UK). The following antibodies used for Western Blotting
were purchased from Santa Cruz Biotechnology, inc. (Autogenbioclear, Wiltshire,
UK): COX-1 goat polyclonal (sc-1752), COX-2 goat polyclonal (sc-12745),
cathepsin D goat polyclonal (sc-6486), plasminogen (sc-15034), P-actin (sc-1616).
Anti-goat-alkaline phosphatase antibody was purchased from Sigma (Sigma
Chemical Company, Dorset, UK). The EP2 and EP4 antibodies used for
immunohistochemistry were purchased from (Caymen). Cloning cylinders, G418 and
indomethacin were purchased from Sigma (Sigma Chemical Company, Dorset, UK).
NS398 was purchased from Calbiochem (Calbiochem, Beeston, Nottingham, UK).
The ECF chemiluminescence system was purchased from Amersham (Amersham,
Little Chalfont, Bucks, UK). Enzymes were purchased from Boehringer Mannheim
(Buckinghamshire, UK) or Promega (Southampton, UK)
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2.2 Endometrial Tissue Collection
Ethical approval was obtained from the Lothian research ethics committee and
written informed consent was obtained from all the patients before tissue collection.
Endometrial biopsies were collected using an endometrial suction curette (Pipelle,
Laboratoire CCD, Paris, France) from women with regular menstrual cycles at
different stages of the menstrual cycle see section 3.2. Full thickness biopsies were
collected across the menstrual cycle from women undergoing hysterectomies for
benign gynaecological indications. Once collected, the tissue, was either snap frozen
on dry ice and stored at -70°C for RNA extraction, fixed in neutral buffered formalin,
and wax imbedded for immunohistochemical analyses or placed in RPMI (containing
2 mmol/ litre L-glutamine, 100 U penicillin and 100jig/ml streptomycin) for in vitro
culture. All subjects reported regular menstrual cycles (cycle length 25-35 days) and
no women had received a hormonal preparation in the 3 months preceding biopsy
collection. Biopsies were dated according to stated last menstrual period and were
confirmed by histological assessment according to criteria of Noyes et al (15).
Furthermore, circulating oestradiol and progesterone concentrations at the time of
biopsy were consistent for both stated last menstrual period and histological
assignment of menstrual cycle stage.
2.3 Cell Culture
General sterile cell culture techniques were employed. Unless otherwise stated,
Ishikawa cells were grown in culture media supplemented with 10% Fetal Calf
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Serum (FCS) and 1% Penicillin/ Streptomycin and maintained at 37°C, 5% CO2. The
cells were generally passaged twice a week. Once the cells reached full confluency,
the cells were washed twice with PBS, rinsed briefly with trypsin and then placed in
the incubator for 5 minutes allowing the cells to detach from the flask. The cells were
resuspended in 5ml of culture media and 1ml was transferred to a new 75ml flask
with 14ml of media and maintained as the stock. The remaining 4mls of cell
suspension was used to seed out fresh experiments.
2.4 Protein
2.4 1 Protein Extraction From Cells
Cells were grown to the desired confluency as indicated in section 4.2 in 6 well
plates, the media was aspirated and the cells were washed twice with PBS, 2mls of
serum free media was then added to each well to synchronise the cells overnight.
Following overnight starvation, the cells were washed twice with ice cold PBS and
lysed on ice in 200pl buffer (containing 150mM NaCL, 50mM Tris pH 7.4, lOmM
EDTA, 0.6% NP40, ImM Na3V04, 10% glycerol, lOpg/ml Pepstatin, ImM PMSF)
for 5 minutes. The wells were scraped using a clean plastic cell scraper, this was
followed by repeated pipetting up and down of the cell suspension to ensure
complete lysis. The lysates were clarified by centrifugation at 14000g for 15 minutes
at 4°C to pellet cell debris. The supematants were collected by pipette and stored at -
70°C in fresh tubes until further use.
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2.4 2 Protein Quantification
Protein concentrations were quantified using the modified Lowry method (Bio-Rad
D2 protein Assay kit; Bio-Rad Laboratories, Hemel Hempstead, UK). A standard
curve using bovine serum albumin (BSA, Promega,Southampton, UK) was
constructed. BSA was diluted in water and 1:50 lysis buffer to a concentration of
200pg. The standard (200pg/ml) was then serially diluted 6 times in water and 1:50
lysis buffer. The standards at concentrations of 200pg/ml, lOOpg/ml, 50pg/ml,
25pg/ml, 12.5pg/ml, 6.25pg/ml, 3.125pg/ml and Opg/ml were used to construct the
standard curve. Samples were diluted 1:50 in water. The standards and samples
(25pi) were pipetted to wells in duplicate on a 96 well plate. To this, 25pi reagent A
(+ 20 pi reagent S per ml reagent A used; supplied with the kit) followed by lOOpl
reagent B were added. The plate was incubated at room temperature to allow for
colour development for approximately 15 minutes. The absorbance was measured at
690nm using a Multiscan® MCC/340 plate reader. Average protein concentrations of
samples were determined from the standard curve constructed by extrapolation using
the Assay Zap software (Biosoft).
2.4 3 SDS-PAGE
SDS-PAGE was performed using pre-cast gels with a gradient of 4-20% Tris
Glycine, with 15 wells (Novex Invitrogen). Unless otherwise stated 15pg of protein
sample (extracted and quantified as described above) was used for SDS-PAGE. The
15pg samples were pipetted into tubes and diluted in distilled H20 (dH20) to a
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volume of 20pl and a further 5pl of 5X protein loading buffer (ImM Tris pH6.8,
50% glycerol, 1% SDS, 12.5% j3 Mercaptoethanol, 0.01% Bromo phenol Blue) was
added to each sample. Thus giving a sample volume of 25pi to be transferred to each
well on the gel. Prior to loading on the gel, the samples were boiled at 95°C for 5
minutes using a pre-heated hot block. Before use, the wells of the pre-cast cassettes
were marked with pen on the outside of the cassettes to aid loading the gel, the
cassettes were then gently rinsed with dH20 following the removal of the plastic
comb. Once the gels were set up in the gel tank according to the manufacturers
instructions, running buffer (25mM Tris-HCL, 0.2M glycine, 0.1% SDS) was poured
in between the two gels and the pre prepared samples were loaded into the individual
wells. 12p.l of the pre stained See Blue protein marker (Novex) was loaded to the
first well on each gel. The migration of proteins was then monitored along side the
protein molecular marker. The gels were run at a constant 40mA per gel for
approximately 90 minutes. The pre cast gels were cracked open using a palette knife
and the gels transferred to a clean glass plate. The gel wells were then cut off and
discarded in preparation for immunoblotting as described below.
2.4 4 Western Blotting
Following electrophoresis, the proteins were transferred from the gel to PVDF
membrane. The pre cut PVDF membrane was prepared by initially placing it in
100% Methanol for 30s, transferring it to dH20 for 1 minute to reduce its
hydrophobicity and finally in transfer buffer (25 mM Tris/HCl, 0.192 M glycine,
20% methanol) for 2 minutes. The gel and PVDF membrane were sandwiched
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between 8 pieces of Whatman paper pre cut to the same size as the gel and PVDF
membrane; four on top and four underneath, which had also been equilibrated in the
transfer buffer for 2 minutes. The sandwich of gel, PVDF and Whatman paper was
placed on the blotter and any air bubbles were removed by rolling a clean pasteur
pipette over the stack. Using a semi dry blotter (BIO-RAD), proteins were
transferred for lhr at a constant 12V. Following immunoblotting, the PVDF
membrane was immersed in 100% methanol for 30s to restore its hydrophobicity and
allowed to dry for 15 minutes. The membrane was then blocked in TNS Tween
(50mM Tris-HCl, 150mM NaCl and 0.05% (v/v) Tween 20) containing 5% skimmed
milk powder to bind to any unbound protein sites for lhr at room temperature on a
shaker. The membrane was then incubated on a shaker over night at 4°C with the
primary antibody of interest; diluted in TNS Tween 5% fat free milk powder.
Following this incubation the membrane was washed 3 times with TBS Tween for 10
minutes at room temperature on the shaker. The membrane was then incubated with
the relevant secondary antibody linked to alkaline phosphatase diluted in TBS Tween
5% skimmed milk powder for lhr at room temperature on the shaker. Finally the
membrane was then washed 3 times as above. Following the manufactures
instructions, the membrane was revealed using the ECF chemiluminessence system.
ECF solution was pippetted onto the membrane. The membrane was left in the dark
for 10 minutes, following this incubation, the ECF solution was removed from the
membrane by allowing the solution to run off the membrane onto Whatman paper.
The membrane was then left to dry in the dark for a further 15 minutes and then
visualised by phosphorimager analysis. Proteins were semi quantified by
densitometry using STORM 860 system (Molecular Dynamics, Amersham
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Biosciences, Buckinghamshire, United Kingdom). The molecular weight of the
protein bands observed were determined by comparing with the mobility of the
SeeBlue standard.
2.5 RNA
2.5.1 RNA Extraction From Cells and Endometrial Tissue
2.5.1 1 Cells
Cells were grown to the desired confluency in 6 well plates (as described in chapter
4.2 the media was aspirated from the wells and the wells were washed twice with
PBS. Serum free media (2ml) was then added to each well and the plates were
incubated overnight to synchronise the cells. Following the starvation, the wells
containing the cells were washed twice with cold PBS. RNA was then extracted from
cells using Tri Reagent (Sigma). Tri Reagent 1ml was added to each well and
repeated pipetting up and down ensured that complete dissociation occurred. The
plates were allowed to stand for 10 minutes at room temperature and the contents of
the wells were transferred to RNase free tubes.
2.5.1.2 Endometrial Tissue
RNA was extracted from endometrial tissue also using Tri Reagent, according to the
manufacturers instructions. Endometrial tissue was homogenised using an Ultra-
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Turrak T8 homogeniser (IKA Labortechnik) for approximately 1 minute in 1ml of
Tri Reagent per 100 mg of tissue and allowed to stand for 10 minutes at room
temperature.
For both cells and endometrial tissue, chloroform (200pl per 1ml Tri Reagent) was
added to each tube. The tubes were shaken vigorously for 15 seconds and allowed to
stand at room temperature for a further 10 minutes. Following this, the tubes were
centrifuged at 14 000 X g for 20 minutes at 4°C. The aqueous supernatant containing
the RNA was transferred to fresh RNase free tubes and 500pl isopropanol /ml Tri
Reagent used was added to precipitate the RNA. The tubes were inverted and
allowed to stand for 10 minutes at room temperature before centrifugation at 14 000
x g for 20 minutes at 4°C. The supernatant was discarded and 1ml 75% ethanol in
DEPC water /ml Tri Reagent used was added to each tube. The tubes were vortexed
briefly to wash the RNA pellet and then centrifuged for 10 minutes at 10 000 x g,
4°C. The supernatants were discarded and the tubes were inverted and left to stand on
a RNAse free surface to allow the pellets to dry. The RNA was then resuspended in
25pi DEPC water by warming the tubes at 65°C for 5 minutes followed by repeated
pipetting up and down. The resuspended RNA was then transferred to fresh RNAse
free tubes and stored at -70°C for quantification.
2.5.2 RNA and DNA Quantification and Quality determination
RNA samples were diluted 1:10 in DEPC water and the absorbance at 260 and
280nM was measured using a spectrophotometer. The concentration of RNA or
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DNA for each sample was determined using the Beer Lambert law A=sbc (where A
is the absorbance, s is the molar absorbtivity, b is the path lenth of the sample and c
is the concentration of the compound (RNA) in the solution). Assuming the
relationship of an optical density (OD) absorbance reading of 1 at 260nM = 40 pg/ml
RNA and 50 pg/ml for double stranded DNA the concentration of RNA was
calculated as follows. The 260nM absorbance reading was multiplied by 40pg/ml
and then 10 to allow for the dilution factor. The samples were considered pure with
limited protein contamination when the ratio of the absorbance readings at 260nM
and 280nM was greater than 1.69. The ratio was obtained by dividing the reading at
260nM by the absorbance reading at 280nM
2.5.3 Reverse Transcription
Prior to reverse transcription, the RNA samples were DNAse I treated (Gibco)
according to the manufacturers instructions. RNA (lpg) samples was added to
DNAse reaction buffer (1 jlxI), DNAse I (1U) made up to a final volume of lOpl and
briefly vortexed. The samples were incubated at room temperature for 15 minutes.
The DNAse I was inactivated by the addition of EDTA (lpl 25mM) followed by 10
minutes incubation at 65°C on a pre-heated hot block. RNA extracted from tissue or
cells was reversed transcribed using a mix of 5.5mM MgC^, 0.5mM each
deoxynucleotide triphosphates, 2.5pM random hexamers, ribonuclease inhibitor (0.4
U /ml) and 1.25 U/ml Multiscribe reverse transcriptase (TaqMan GeneAMP RNA
PCR kit, PE Applied Biosystems, Warrington, UK). A fresh reverse transcription
mix was made prior to each reverse transcription reaction. Template RNA (400ng)
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was added to reverse transcription mix aliquoted in separate tubes (16pl) to a final
volume of 20pl. A tube containing no reverse transcriptase and one with no template
were used as negative controls to confirm there was no genomic DNA
contamination. A tube containing RNA from a late secretory endometrial tissue
sample was used as a positive control. Following gentle mixing of the tubes using a
vortex, the tubes were incubated as follows, 60 minutes at 25°C, 45 minutes at 48°C
and 95°C for 5 minutes. The transcribed cDNA was then stored at -20°C until further
use.
2.5.4 Polymerase Chain Reaction (PCR)
PCR is a technique that allows the amplification of a DNA sequence of interest that
lies between two known sequences. The principles of PCR are as follows. In the
presence of deoxynucleotide triphosphates (dNTPs), magnesium and reaction buffer,
5' and 3' primers with sequences complementary to the region that lies at the end of
the DNA sequence of interest are extended by the action of DNA polymerase. The
PCR reaction occurs when the samples are placed through a cycle of different
temperatures. Initially, the double stranded DNA is heated to 95°C to denature the
DNA and produce single stranded DNA. Following denaturing, the reaction
temperature is reduced to between 40°C and 60°C to allow for the primers to anneal
to the single stranded DNA. Finally, DNA synthesis occurs when the temperature is
increased to the optimum temperature for DNA polymerase to extend the primers.
Theoretically, the target sequence of interest is doubled after each PCR cycle. Real
Time Quantitative PCR enables the quantification of a sequence of interest. In
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addition to the reaction mixture outlined above for a PCR reaction, a probe
containing a reporter dye at the 5' end and a quencher dye at the 3' end is introduced.
In the presence of the sequence of interest, the probe anneals in between the forward
and reverse primers, the 5' 3' nuclease activity of the Taq DNA polymerase cleaves
the probe. Separation of the reporter dye from the quencher results in a measurable
increase in fluorescence. An increase in fluorescence detected is indicative of an
elevation in the PCR product of interest.
2.5.5 Real Time Quantitative PCR
To investigate the RNA expression of the prostaglandin EP receptors, real time
Quantitative PCR was utilised. Real time quantitative PCR was performed using a
PCR mix which consisted of IX mastermix, forward and reverse primers for the
sequence of interest, (300nM), the relevant probe (200nM) and ribosomal 18s
forward, reverse and probe (50nM all from PE Applied Biosystems). 48pl of PCR
reaction mix was aliquoted to separate tubes and 2pl (40pg) of reverse transcribed
cDNA was added and gently mixed by vortex. Samples (24pl) were pipetted in
duplicate into wells on a PCR plate along with the positive and negative controls
from the reverse transcription reaction. Furthermore, a negative control for the PCR
containing 2pl H20 and no cDNA was also pipetted in duplicate on the PCR plate.
The wells were sealed using optical lids and the PCR was carried out using an ABI
Prism 7700 (PE Applied Biosystems). 18s rRNA was used as an internal standard to
normalise the samples to RNA loading. Results were expressed relative to the
positive standard run on each PCR.
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5' - CCT TCC TCC TGT GCC TGA TG - 3'
5' - ACA ATC TCA TTT GAA TCA GGA AGC T - 3'




5' - AGA TGG TGG GCC AGC TTG T - 3'
5' - GCC ACC AAC ACC AGC ATT G - 3'




5'- GAC CGT TTA CCT GCA GCT GTA - 3'
5' - TGA AGT TGC ACC CGA GCA - 3'




5' - GAC GGC CAT TCA GCT TAT GG - 3'
5' - TTG AAG ATC ATT TTC AAC ATC ATT ATC A - 3'




5' - ACG CCG CCT ACT CCT ACA TG - 3'
5' - AGA GGA CGG TGG CGA GAA T - 3'




5' - GCA GCT GCG CTT CTT TCA A - 3'
5' - CAC TGT CAT GAA GAT TAC TGA AAA AAA
TAC-3'




5' - CGG CTA CCA CAT CCA AGG AA - 3'
5' - GCT GGA ATT ACC GCG GCT - 3'
5' - TGC TGG CAC CAG ACT TGC CCT C - 3'
Table 2.1 Sequences for primers and probes used for quantitative RT PCR
2.6 cAMP Turnover
cAMP turnover in response to exogenous PGE2 was measured in endometrial tissue,
Ishikawa wild type, COX-2 sense and COX-2 antisense cells, for descriptions of the
preparation and treatment of the tissue and the cells see sections 3.2.3 and 4.2.9.
cAMP turnover was quantified using a cAMP competitive ELISA kit (Biomol,
Affiniti, Exeter, UK) according to the manufacturer's instructions and normalized to
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protein concentrations of the homogenate. Briefly, the assay was performed in a 96
well goat anti-rabbit IgG coated microtiter plate. The cAMP standard curve was
constructed as instructed by the manufacturer. The standard was diluted four times in
a ratio of 1:4 in HC1 (0.1M). The standards at concentrations of 200 pmol/ml, 50
pmol/ml, 12.5 pmol/ml, 3.13 pmol/ml and 0.78 pmol/ml were used to construct the
standard curve. The standards and samples (lOOpl) were pipetted into the 96 well
plate. The alkaline phosphatase-cAMP conjugate and polyclonal rabbit-cAMP
antibody were then added to the wells (50pi 1 of each solution). The plate was then
incubated at room temperature for 2 hours on a plate shaker at approximately 500
rpm. Following this, the contents of the plate was aspirated and the plate washed
three times with the wash buffer provided (TBST containing sodium azide). To
develop the assay, the conjugate and p-Npp (p-Nitrophenyl Phosphate, Disodium
Salt) substrate were added to the wells (5pi and 200pl respectively) and the plate
incubated at room temperature for 1 hour. The reaction was quenched with 50pl of
stop solution (trisodium phosphate in water) provided with the kit. The absorbance
was measured at 405 nm using a Multiscan® MCC/340 plate reader. Average cAMP
concentrations of samples were determined from the standard curve constructed by
extrapolation using the Assay Zap software (Biosoft). Protein concentrations were
quantified using the modified Lowry method (Bio-Rad D2 protein Assay kit; Bio-
Rad Laboratories, Hemel Hempstead, UK) as described in section 2.4.2.
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2.7 Statistical Analysis
Statistical analysis of the data in this study was carried out by ANOVA using
StatView 5.0 (Abacus Concepts, Berkeley, CA).
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human Endometrium
Chapter 3 PGE2 and EP2/EP4 Expression and Signalling
3.1 Introduction
Two predominant isoforms of the cyclooxygenase enzymes have been identified
(73). COX-1 is constitutively expressed, classically associated with physiological
function and has recently been shown to be inducible in certain cancers (65, 90-92).
COX-2 is the readily inducible form of the enzyme and is commonly associated with
inflammation and pathological conditions including tumorigenesis (73, 79, 94). The
COX enzymes catalyse the conversion of arachidonic acid to PGH2 which is
ultimately converted to prostanoids. There are five endogenous prostanoids namely
PGD2, PGE2, PGF2a, prostacyclin (PGI2) and thromboxane A2(149). Arachidonic
acid, once released from the membrane phospholipids is converted to the prostanoid
intermediate PGH2 by the COX enzymes. PGH2 acts as a substrate for the synthases
specific to each prostanoid such as PGE synthase (PGES) for PGE2 (239, 240). A
number of distinct isoforms of PGES have currently been described. These include
mPGES-1 and mPGES-2 which are both membrane bound, cPGES is the cytosolic
isoform and GST-p a glutathione S-transferase isoform and these have been shown
to preferentially couple with either COX-1 or COX-2 (70). Once synthesized,
prostaglandins mediate their effects via prostaglandin specific G protein coupled
receptors. For instance, PGE2 elicits its effects via its seven trans-membrane G
protein-coupled receptors, of which four have been identified (EP1, EP2, EP3 and
EP4). These receptors signal via alternate and in some cases opposing signaling
pathways (149, 154). EP1 receptor activation leads to elevated insositol-tris-
phosphate and Ca2+ levels, activation of both EP2 and EP4 results in increased
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intracellular cAMP levels and depending on the splice variant, EP3 activation either
decreases or increases cAMP levels (149).
Recent studies have demonstrated a role for COX enzymes and prostaglandins (PGs)
in the regulation of epithelial cell growth and angiogenesis. In vivo and in vitro
studies in epithelial cells, including human glandular endometrial Ishikawa cells,
have demonstrated a role for COX-2 and its products such as PGE2 in epithelial cell
function. In those studies, elevated COX-2 and prostanoids, including PGE2 have
been shown to facilitate enhanced cellular proliferation, reduce apoptosis and
increase the expression of angiogenic factors such as vascular endothelial growth
factor (VEGF) (65, 137, 138, 183, 207, 209, 211, 233, 234). Once synthesised, the
angiogenic factors act in a paracrine manner to promote endothelial cell migration
and microvascular tube formation (138). In the human endometrium, COX enzyme
expression has been localised to epithelial and perivascular cells. Furthermore, PGE2
synthesis and COX expression are maximal during the menstrual and proliferative
phases (4, 23, 102, 241, 242). Recent studies have reported the temporal expression
and signalling of two COX product receptors: PGF2a receptor, FP and the IP2
receptor, EP in the human endometrium (183, 189).
The aim of this study was to investigate the temporal expression and signalling of the
prostaglandin E2 pathway in the normal human endometrium across the menstrual
cycle. mPGES-1 and PGE2 were localised using immunohistochemical techniques
(Peformed by Dr S. Milne). The expression of two PGE2 receptors, namely EP2 and
EP4, were localised and quantified using immunohistochemistry and quantitative RT
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PCR respectively. Finally the functional signalling of these receptors in response to
exogenous PGE2 was determined by measuring the generation of cAMP using an
ELISA.
3.2 Materials and Methods
3.2.1 Immunohistochemistry
The site of mPGES-1, PGE2, EP2 receptor and EP4 receptor expression was
localised in endometrial sections (5pM) by immunohistochemistry from across the
menstrual cycle. For PGE2 and mPGES-1, n=9 proliferative phase and n=9 secretory
phase, EP2 and EP4 localisation; n=6 proliferative phase and n=6 secretory phase).
Tissue was collected as described in section 2.2 and mounted onto glass slides.
Sections were de-waxed in xylene (2x5 mins) and then re-hydrated in graded
ethanol for 20 seconds at each concentration as follows: 100% Ethanol, 95% Ethanol
and 70% Ethanol. The sections were then rinsed in water. An antigen retrieval step
was carried out for mPGES-1, EP2 and EP4 localisation. For antigen retrieval, the
slides were pressure cooked in sodium citrate buffer (0.01M , pH 6.0) for 5 minutes.
Following pressure cooking, the slides were left to cool to room temperature for 20
minutes before rinsing in water until the slides were cool. Unless otherwise stated, all
washes of the tissue samples were performed on a rocker for 5 minutes. All slides
were then washed in Tris buffered Saline (TBS; Tris-HCl (50 mM), NaCl (150mM),
pH 7.4). A peroxidase detection system was used for immunodetection therefore in
order to block endogenous endoperoxidase activity, the slides were incubated with
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3% H2O2 in methanol for 20 minutes at room temperature on a rocker. The tissue
samples were washed in TBS prior to being blocked with swine serum (10% in TBS
and 5% BSA) for 30 minutes at 25°C. The normal serum was removed by draining
the slide on paper tissue, and any excess surrounding the tissue was wiped away. The
slides were covered with Gelbond film (Flowgen, Rockland, ME, USA),
hydrophobic side down and incubated overnight in a humidified chamber at 4°C with
the primary antibody (either PGE2 or mPGES-1 or EP2 or EP4). The rabbit anti -
PGE2 antibody (kindly supplied by Professor R W Kelly, MRC Human Reproductive
Sciences Unit, Edinburgh, UK) at a dilution of 1:100, rabbit anti - PGE synthase,
rabbit anti- EP2 and rabbit anti EP4 antibodies were used at a dilution of 1:250
(Caymen Chemicals). The antibodies were diluted in normal swine serum (10% in
TBS) and BSA (5%). Preabsorption of the antibody with PGE synthase blocking
peptide (at a ratio of antibody to peptide 1:10) was used for the mPGES-1 negative
control, preabsorption of the antibody with PGE2 was the PGE2 negative control and
normal rabbit IgG was used for the EP2 and EP4 controls. All the negative controls
demonstrated negligible immunoreactivity. Following overnight incubation with the
primary antibodies, the tissue sections were washed twice in TBS. The slides were
then probed with swine anti-rabbit secondary IgG (Dako) for 30 minutes, 1:500
dilution (in normal swine serum (10% in TBS) and BSA (5%)) at 25°C. The tissue
sections were washed twice in TBS and then incubated for 30 minutes with the pre-
prepared streptavadin peroxidase complex (Dako). The peroxidase solution was
prepared according to the manufacturers instructions in TBS (50 mM, pH 7.6; no
NaCl) and at least 20 minutes before use. Following this, the slides were washed
twice. To visualise bound antibody, the tissue sections were incubated with 3,3-
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diaminobenzidine solution (DAB) prepared according to the manufacturers
instructions (Dako) for approximately 10 minutes. The colour development was
monitored microscopically and the reaction was quenched by washing in water. The
tissue sections were then counterstained and mounted as follows. The slides were
counterstained in haematoxylin for between 30 seconds and 4 minutes. Following a
brief wash in water, the sections were rinsed briefly in acid alcohol again washed in
water and then blued in Scott's tap water. Following a final wash in water, the slides
were dehydrated in graded alcohol washes at 70% ethanol, 95% ethanol and 100%
ethanol each for 5 minutes. Prior to being coverslipped with pertex (Cellpath, Hemel
Hempstead, UK) the slides were cleared in histoclear and xylene each for 5 minutes.
3.2.2 Quantitative RT PCR
To investigate the expression of EP2 and EP4 receptors in the human endometrium,
quantitative RT PCR was performed as described in section 2.5.5. Tissue samples
were collected from across the menstrual cycle (n=9; Mid Proliferative, n=5; Late
proliferative, n=7; early secretory, n=6; mid secretory, n=6 late secretory). Briefly,
the RNA was extracted from the tissue samples using Tri Reagent (section 2.5.1.2).
The RNA was reverse transcribed as described in section 2.5.3. The cDNA
expression was measured by real time quantitative RT PCR. Data were analysed
using Sequence Detector version 1.63 (Applied Biosystems) according to the
manufacturer's instruction.
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3.2.3 cAMP Measurement
Endometrial biopsies from across the menstrual cycle (n=6 from each of the
following phases; proliferative, early and midsecretory phase) were finely minced
with scissors and incubated in Petri dishes for 1.5 hours in RPMI media (2ml)
containing 10% FCS, 2 mmol/liter L-glutamine, 100 IU penicillin, 100 pg
streptomycin and 3 pg/ml indomethacin at 37°C in a humidified 5% C02 incubator.
The phosphodiesterase inhibitor 3-isobutyl-l-methylxanthine (IBMX) was added to
the tissue media to a final concentration of ImM for a further 30 minutes at 37°C
prior to treatment with PGE2. PGE2 (300nM) was added to the tissue culture media
for 5 minutes. The control samples were treated the same but received no PGE2. The
tissue samples were harvested by centrifugation at 2000 x g. The supernatant was
discarded by pipette and the tissue homogenised in 10ml HC1 (0.1M) per gram of
tissue. The cAMP concentration was determined as described in section 2.6 and was
normalised to protein concentration determined as described in section 2.4.2.
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3.3 Results
3.3.1 Expression of mPGES-1 and PGE2 Synthesis in Endometrial
Tissue
Membrane bound Prostaglandin E Synthase-1 (mPGES-1) was spatially and
temporally localised in the endometrium by immunohistochemistry (see figure 3.1).
mPGES-1 immunoreactivity was shown to vary according to the uterine region and
stage of the menstrual cycle. mPGES-1 staining was demonstrated in the glandular
epithelial cells (G) and endothelial cells (arrowed) of both the basalis and
functionalis layers of the endometrium. Stromal staining of mPGES-1 was
predominantly seen in the functionalis layer as opposed to the basalis layer where
little immunoreactivity in the stromal cells was detected. The stromal
immunoreactivity appeared to be temporally expressed with reduced staining in the
late secretory phase (e) compared with other stages of the cycle. mPGES-1 was also
localised to the myometrium with staining only visible in the endothelial cells.
Viewed as a cross section (f), mPGES-1 expression was demonstrated in endothelial
and glandular epithelial cells across the uterine section. Strong immunoreactivity in
the stromal region of the functionalis layer was shown; with a reduction in stromal
staining across the uterine section with limited staining in the myometrial fibroblasts.
PGE2 synthesis in the human uterus was localised by immunohistochemistry (see
figure 3.2). Spacial and temporal expression of PGE2 in the uterus was demonstrated
to show a similar pattern of immunoreactivity to mPGES-1. PGE2 synthesis in the
76
Chapter 3 PGE2 and EP2/EP4 Expression and Signalling
glandular epithelial cells (G) and endothelial cells (arroweed) was detected in both
the basalis (a) and functionalis (b) layers of the endometrium. Limited stromal
staining was detected in the basalis layer, conversely in the functionalis layer, there
was strong staining in the stromal region. Likewise with mPGES-1, there is a marked
reduction in PGE2 immunoreactivity in the stromal region during the late secretory
phase (e) compared with other stages of the menstrual cycle. However, PGE2
expression in the glandular and endothelial cells remains similar throughout the
menstrual cycle. Full thickness endometrial biopsies (f) demonstrate a gradient in
PGE2 expression with maximal immunoreactivity in the functionalis layer in multiple
cell types and limited PGE2 synthesis detection in the myometrium in only the
endothelial cells.
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Figure 3.1 Immunohistochemical localisation ofmPGE synthase-1 in the basalis and functionalis
regions of the human endometrium. Lower PGE synthase immunoreactivity was detected in the
stromal compartment of the basalis than in the functionalis region (a and b are the basalis and
functionalis regions, respectively, of endometrial tissue collected during the midproliferative phase).
In the functionalis region, PGE synthase immunoreactivity was detected at all stages of the menstrual
cycle and was localised to glandular epithelial (G), stromal and endothelial (denoted by arrows) cells
(c, late proliferative; d, early secretory; e, late secretory). Inset in e, A section that was stained with
preadsorbed PGE synthase antibody (negative control). F, Full thickness uterine tissue, collected
during the late proliferative phase, demonstrating spatial changes in PGE synthase immunoreactivity
between basalis and functionalis regions of the endometrium and the myometrium. Inset in f,
Endothelial cell mPGE synthase-1 immunoreactivity within the myometrial compartment. Scale bars:
e and inset, 100 pm; f, 500pm
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Figure 3.2 Immunohistochemical localization of PGE2 in the basalis and functionalis regions of the
human endometrium. Lower PGE2 immunoreactivity was detected in the stromal compartment of the
basalis than in the functionalis region (a and b are basalis and functionalis regions, respectively, of
endometrial tissue collected during the mid-proliferative phase). In the functionalis region, PGE2
immunoreactivity was detected at all stages of the menstrual cycle and was localized to glandular
epithelial (G), stromal and endothelial (denoted by arrows) cells (c, late proliferative; d, early
secretory; e, late secretory). Inset in e, Section that was stained with preadsorbed PGE2 during the late
proliferative phase (negative control), demonstrating spatial changes in PGE2 immunoreactivity
between basalis and functionalis regions of the endometrium and the myometrium. Inset in f.
Endothelial cell PGE2 immunoreactivity within the myometrial compartment. Scale bars: e and inset,
100 pm; f, 500 pm
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3.3.2 Expression of EP2 and EP4 Receptors in Endometrial Tissue
The expression of two PGE2 receptors, namely EP2 and EP4 were quantified by
quantitative RT PCR analysis. Using immunohistochemistry, the receptors were
localised and the possible sites of action of PGE2 within the endometrium identified.
Analysis by quantitative RT PCR demonstrated that the EP4 receptor mRNA (see
figure 3.3B) was significantly higher in the biopsies from the late proliferative phase
(0.162+/- 0.034; n=5) of the menstrual cycle compared with the early, mid and late
secretory phase samples (0.075 ± 0.024, 0.063 ± 0.014 and 0.07 ± 0.033;
respectively, P<0.05). Whilst the EP2 receptor mRNA displayed a trend of being
elevated in biopsies from the mid to late secretory phase (see figure 3.3A), this effect
was not significant. It is however, important to take into account that the biopsies are
of a heterogeneous cell population. If the individual cell populations were separated,
EP2 receptor expression may show a significant change in expression across the
menstrual cycle for a specific cell type.
Immunohistochemistry studies localised EP2 receptor expression in the glandular
epithelial cells (G), endothelial cells (arrowed) and stromal cells of the endometrium
across the menstrual cycle (see figure 3.4). EP4 receptor expression was also
demonstrated in the glandular epithelial cells, endothelial and stromal cells (see
figure 3.5). However, staining for EP4 was weak across the menstrual cycle except in
the late proliferative phase when the immunoreactivity was stronger. EP2 and EP4
receptor expression was shown to be present in both the functionalis and basalis
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regions of the endometrium. Preadsorbing with IgG abolished immunoreactivity.
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Figure 3.3 Quantitative RT PCR demonstrating relative expression of EP2 (A) and EP4 (B) receptors
in midproliferative (MP; n=9), late proliferative (LP; n=5), early secretory (ES; n=7), midsecretory
(MS; n=6) and late secretory (LS; n=6) endometrial biopsies. The data are presented as mean ± SEM.
* denotes statistical significance relative to other stages of the menstrual cycle (P < 0.05)
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Figure 3.4. Immunohistochemical localization of EP2 receptor detected in human endometrial tissue.
EP2 expression is detected in glandular epithelial cells denoted by G. endothelial denoted by arrow
and stromal cells during the proliferative phase (A-C) and Secretory phase (D-F) of the menstrual
cycle. Inset in A is a negative control (Rabbit IgG). Scale bar is 100 pm.
82
Chapter 3 PGE? and EP2/EP4 Expression and Signalling
Figure 3.5. Immunohistochemical localization of EP4 receptor detected in human endometrial
tissue. (A-C, Proliferative phase and D-F, Secretory phase) EP4 expression is detected in glandular
epithelial cells denoted by G, endothelial denoted by arrow and stromal cells during the late
proliferative phase of the menstrual cycle (C). Only very weak immunoreactivity was detected in
other phases of the menstrual cycle. Inset in C is a negative control (IgG). Scale bar is 100 pm.
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3.3.3 Functional Signalling of EP2/EP4 Receptors in Endometrial Tissue
Activation of EP2 and EP4 receptors by PGE2 results in the generation of cAMP
(149). To investigate the signalling functionality of the receptors in the endometrium,
cAMP accumulation in response to exogenous PGE2 was measured by ELISA (see
figure 3.6). cAMP generation was significantly higher (P<0.05) in biopsies from the
proliferative phase of the cycle as compared with the mid and late secretory tissue
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Figure 3.6 Fold induction of cAMP production in endometrial biopsies collected from proliferative
(PROL; n=6) early secretory (ES; n=6) and midsecretory (MS; n=6) stages of the menstrual cycle
after stimulation with 300nM PGE2. The data are presented as mean ± SEM. * denotes statistical
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This study has demonstrated and localised the expression of mPGES-1 and its
product PGE2 by immunohistochemistry to the stromal, epithelial and endothelial
cells of the human endometrium. During the course of my PhD, further forms of
PGES have been identified and antibodies have recently become available. Further
studies to localise the sites of expression of other PGES isoforms would be
interesting to compare their expression. mPGES-1 expression and PGE2 synthesis
was demonstrated across the menstrual cycle with reduced staining in the late
secretory phase of the menstrual cycle. This is in agreement with previous in-vitro
studies which have confirmed endometrial epithelial and stromal cells can synthesise
PGE2 (243). Furthermore, a reduced PGE2 biosynthetic capacity has been observed
during the late secretory phase (244). PGE2 is synthesised in cells by the action of the
COX enzymes (73). The COX enzymes have previously been localised in the
endometrium to epithelial and perivascular cells (4, 23, 102). To investigate the
possible sites of action of PGE2, expression and localisation of two of its G-protein
coupled receptors, namely EP2 and EP4 were investigated by immunohistochemistry
and quantitative RT PCR. EP2 and EP4 receptor expression was localised to
epithelial, endothelial and stromal cells of the endometrium. This observation is
confirmed by previous studies localising EP2 receptor mRNA and EP4 receptor
mRNA to the epithelial and vascular cells of the endometrium using in situ
hybridisation (245). Recent studies have demonstrated other prostanoid receptors to
be temporally expressed in the endometrium. FP receptor expression has been
reported to be maximal during the mid to late proliferative phase of the menstrual
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cycle and predominantly expressed in the glandular epithelial cells (183). Whilst,
maximal IP receptor expression is seen during the menstrual phase of the cycle and is
localised to glandular epithelial, stromal and endothelial cells (189). The expression
of PGE2 receptors on multiple cell types within the endometrium suggests PGE2 acts
in an autocrine / paracrine manner. This observation further supports the suggested
autocrine / paracrine action of PGE2 previously suggested in the female reproductive
tract (65).
EP2 receptor and EP4 receptor expression and functionality were investigated by RT
PCR and quantified cAMP generation in response to exogenous PGE2 respectively.
Expression of the EP4 receptor was demonstrated to be significantly elevated in the
proliferative phase of the menstrual cycle. cAMP accumulation was also significantly
higher in tissues from the proliferative phase compared with those from the secretory
phase of the menstrual cycle. The EP4 receptor is associated with Gs coupled
signalling and results in enhanced cAMP generation (149). This suggests the
enhanced cAMP generated in response to PGE2 in the proliferative phase is due to
the elevated EP4 receptor expression.
The exact role of COX and its products within the endometrium remains to be
elucidated. However, numerous studies have implicated COX and its products
including PGE2 in the inhibition of apoptosis, mitogenesis and angiogenesis (65, 137,
138, 211). In vitro studies in Ishikawa, cells, an endometrial epithelial cell line, have
demonstrated both PGE2 and PGF2a enhance cellular proliferation via diverse
signalling pathways (183, 234). Overexpression of COX-2 in a rat intestinal
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epithelial cell line is associated with elevated PGE2 which is accompanied with
enhanced proliferation and an inhibition of apoptosis via upregulation of
antiapoptotic genes (137, 138). A similar mechanism may regulate proliferation of
cells in the reproductive tract. The endometrium ofmenstruating women undergoes a
28 day cycle. During the cycle, the functionalis layer is shed followed by re-growth,
resulting in cellular proliferation and angiogenesis during the proliferative phase of
the menstrual cycle. Angiogenesis continues during the secretory phase culminating
with menstruation when endometrial cells undergo apoptosis. Apoptosis in the
glandular epithelial cells of the endometrium has been demonstrated to be very low
in the proliferative phase and maximal in the late secretory and menstrual phases of
the cycle (246). Elevated levels of the anti apoptotic gene bcl-2 have been reported in
the proliferative phase of the menstrual cycle compared with the secretory phase and
localised to glandular epithelial cells (36, 247, 248). These studies suggest PGE2 may
play a role in the control of apoptosis within the endometrium.
Overexpression of COX-2 in epithelial cells accompanied by elevated PGE2 levels
increases angiogenic factor expression (138, 207). Once synthesised, the angiogenic
factors such as Vascular Endothelial Growth Factor (VEGF) act in a paracrine
manner to promote microvascular tube formation and endothelial cell migration
(138). Within the endometrium, VEGF has been localised to glandular epithelial cells
across the menstrual cycle (249, 250). Furthermore, overexpression of EP2 receptor
in Ishikawa cells has recently been demonstrated to induce VEGF expression and
secretion (168). The data reported in these recent studies suggest that PGE2 within
the endometrium may play a role in regulating epithelial cell proliferation and uterine
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angiogenesis; via the upregulation of growth factors such as VEGF, especially in the
proliferative phase when EP4 receptor expression is maximal.
The expression of EP2 and EP4 in endothelial cells in the human endometrium as
demonstrated by this study suggests PGE2 may play a direct role in endothelial cell
function. Treatment of endothelial cells with a selective COX-2 inhibitor results in
decreased microvascular tube formation (251). Co-treatment with PGE2 partially
reverses this observation. This further supports a role for PGE2 in mediating
endothelial cell and vascular function by acting on its EP receptors both on epithelial
and endothelial cells. Regulation of vascular function via EP receptors in epithelial
cells is indirect. The regulation is potentiated by the PGE2 - EP receptor mediated
regulation of expression of angiogenic genes such as VEGF in these cells (138).
In summary, this study has localised the expression of mPGES-1 and PGE2 and two
of its receptors, namely EP2 and EP4 within the human endometrium on multiple
cell types. The EP2 and EP4 receptors were demonstrated to be functional with
maximal expression and signalling of the EP4 receptor during the proliferative phase
of the menstrual cycle. Whilst the exact role for PGE2 remains to be elucidated,
PGE2 may play a role in inhibiting apoptosis, mediating cellular proliferation and
angiogenesis within the human endometrium via an autocrine / paracrine action .
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Chapter 4 Differential gene expression in COX-2 sense and COX-2 antisense cells
4.1 Introduction
The COX-2 8.3 kb gene is located on chromosome 1, and is an immediate early-
response gene that gives rise to a gene product of 4.5kb. COX-2 is rapidly induced
following stimulation of quiescent cells by growth factors, oncogenes, and phorbal
esters (94, 231, 252-254). COX-2 has a molecular weight of 72kDa and is a
glycosylated integral membrane protein located in the endoplasmic reticulum and the
nuclear membrane (76). Numerous studies have demonstrated that overexpression of
COX-2 in epithelial cells is associated with enhanced production of angiogenic
factors (138, 207, 209, 255). These factors act in a paracrine manner to promote
endothelial cell migration and microvascular tube formation (138). Furthermore, in
vivo and in vitro models have directly demonstrated COX-2 products including
PGE2, PGF2a and PGI2 induce VEGF expression (207, 209, 210, 256). In the female
reproductive tract a role for COX enzymes and its prostaglandin products in normal
and pathological angiogenesis, epithelial and endothelial cell fucntion has been
proposed (4, 23, 61, 62, 102, 183, 187, 189, 245, 257). In the human endometrium
expression/synthesis and signalling ofCOX-2, PGE2, and EP receptors co-localise in
glandular epithelial and endothelial cells of the normal and neoplastic endometrium
(4, 23, 61, 62, 102, 183, 187, 245, 257). Moreover, overexpression of COX enzymes
in epithelial cells of the reproductive tract has been shown to promote the expression
of various angiogenic factors (65).
Excessive blood loss during menstruation (menorrhagia), defined as > 80ml blood
lost per menstrual cycle, with no observed uterine pathology affects 10% of women
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of child bearing age. Dysmenorrhoea; which is often associated with painful
menstruation and endometriosis; where uterine tissue is found within the pelvic
pertitoneum and other extra-uterine sites, are common benign uterine pathologies.
These gynaecological complaints are considerable reproductive health problems for
women and also place a financial burden on healthcare (43).
A role for COX enzymes has been proposed in benign and neoplastic pathologies of
the endometrium such as endometriosis, dysmenorrhoea, heavy menses and
endometrial carcinoma (2, 5, 6, 54, 55, 61, 258, 259). Furthermore, several studies
have associated heavy menses with abnormalities in prostanoid production such
PGE2 from the uterus (2, 54, 258). PGE2 synthesis and PGE2 binding sites in uterine
tissues are greater in women diagnosed with heavy menses compared to women with
normal blood loss (2-4, 260, 261). Elevated levels of PGI2 have been shown in
menstrual blood collected from women with menorrhagia (54, 262, 263).
Furthermore, a shift in the balance of prostanoids synthesised in women with heavy
blood loss has been suggested (2, 263). Menorrhagia has been associated with
increased synthesis ofPGI2 relative to thromboxane A2 and elevated PGE2 relative to
PGF2tr The elevated prostanoids detected in menstrual flow of patients with heavy
menses has lead to the administration of COX enzyme inhibitors as a means of
therapy (264). COX enzyme inhibitors such as ibuprofen have been shown to reduce
menstrual blood loss (263). This suggests that the degree or duration of menstrual
bleeding in women diagnosed with menorrhagia is augmented following elevation of
vasodilatatory factors by COX enzyme products. Interestingly, COX-2 has been
shown to preferentially metabolise arachidonic acid to PGE2 and PGI2 (86).
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An elevated level of PGE2 and PGF2a in the menstrual fluid of women with
dysmenorrhoea has been demonstrated compared with women with pain free
menstruation (5, 55). A role for COX products in dysmenorrhoea is further
implicated by the observation in in-vitro studies where prostanoids released by
endometrial explants in response to arachidonic acid is elevated in dysmenorrheic
tissue compared with tissue from pain free menstruating women (56). A direct role
for prostaglandins in endometriosis remains to be established, but elevated COX-2
expression in endometriotic tissue has been reported (6). Futhermore, the peritoneal
fluid of infertile women with endometriosis demonstrates higher levels of
prostanoids (7). In endometrial adenocarcinomas, an elevation in COX-2 expression
coinciding with enhanced synthesis and secretion of PGE2, expression and signalling
of EP receptors, FP receptors and PPAR has been demonstrated (61, 62, 187).
This study was designed to investigate the potential role of COX-2 in regulating
endometrial epithelial cell function. The specific aims of the study were to examine
the effect of COX-2 overexpression in an endometrial epithelial cell line (Ishikawa)
on PGE2 and PGF2a secretion, FP and EP receptor expression, and EP receptor
signaling. The final aim of this study was to identify genes regulated by COX-2 that
may be associated with endometrial function and angiogenesis.
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4.2 Materials and Methods
4.2.1 Cell Culture
Ishikawa wild type, COX-2 sense and COX-2 antisense cells were routinely
maintained in DMEM nutrient mixture F-12 with Glutamax-1 and pyridoxine,
supplemented with 10% fetal bovine serum and 1% antibiotics (500 U/ml penicillin
and 500ug/ml streptomycin) at 37°C and 5% CO2 (v/v). In addition, COX-2 sense
and COX-2 antisense cells were maintained in media containing 800pg/ml G418
(Calbiochem, Nottingham, UK).
4.2.2 Construction of Plasmids
The pIRES2 plasmid containing COX-2 cDNA in either the sense or antisense
directions was constructed by Dr Kurt Sales, MRC Human Reproductive Sciences
Unit, Edinburgh.) Briefly, the pBS(SK-)PSHI vector containing the full length COX-
2 gene (kindly supplied by Dr Stephen Prescott, University of Utah, Salt Lake City -
UT) was used as the template plasmid. The COX-2 cDNA was excised from the
template plasmid and ligated at the EcoRl site of the pIRES2 vector (Clontech, see
Appendix 2). The size of the insert in pIRES2 was confirmed by HINDIII digestion
and the orientation of the COX-2 cDNA insert was determined by dideoxy DNA
sequencing using sequence specific primers for pIRES2.
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4.2.3 Large Scale Plasmid DNA recovery - Maxiprep
Bacterial cultures (100ml) for pIRES2 COX-2 sense and pIRES2 COX-2 antisense
were set up overnight in the presence of kanamycin (30^g/ml). The following day,
large scale plasmid recovery was carried out using the endoffee™ plasmid maxi kit
(Qiagen) according to the manufacturers instructions. Briefly, the bacterial cells were
harvested by centrifugation at 6000 x g for 15 min at 4°C. The pelletted cells were
resuspended in 10ml buffer PI (Tris-HCl; 50mM pEl 8.0, EDTA; lOmM and RNase
A; lOOpg/ml). The cell pellet was resuspended by repeated pipetting up and down.
To lyse the cells, 10ml buffer P2 (NaOH; 200mM and SDS; 1%) was added and the
cells were incubated at room temperature for 5 minutes. To neutralize the cell lysate,
10ml buffer P3 (potassium acetate; 3M, pEl 5.5) was added. The lysate was then
transferred to a QIA filter, incubated for 10 minutes at room temperature and then
filtered. Following this, 2.5ml of buffer ER (Qiagen) was added and the filtered cell
lysate incubated on ice for a further 30 min. The filtered lysate was then applied to a
pre-equilibrated QIAGEN- tip™. The filtered lysate was then washed twice with
30ml buffer QC (NaCl; ImM, MOPS; 50mM pH 7.0, and isopropanol; 15%) and the
DNA eluted with buffer QN (NaCl; 1.6mM, MOPS 50mM pH7.0 and isopropanol;
15%). The eluted DNA was precipitated by adding 10.5ml isopropanol and then
immediately centrifuged at 15 000 x g for 30 min at 4°C. The supernatant was
removed and the remaining DNA pellet was washed with 15 ml ethanol (70%) and
then centrifuged at 15 000 x g for 15 min at 4°C. Finally, the DNA pellet was air
dried and redissolved in 200pl buffer TE (Tris-HCl; lOmM pH 8.0 and EDTA;
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ImM). The DNA concentration was then determined by spectrophotometry as
described in section 2.5.2.
4.2.4 Transfection of Ishikawa Cells and Selection of Clones
4.2.4.1 Preliminary Transfection Studies
Initial studies were performed in HES cells (kind gift from Dr Douglas Kniss, Ohio
State University, Columbia); an endometrial epithelial cell line, to establish a COX-2
overexpressing cell line using the Clontech Tet-Off™ system. Using the Tet-Off
system, once transfected, the cells are maintained in cell culture medium containing
either tetracycline or a tetracycline derivative. The Tet-Off system allows for a
transfected gene of interest to be transcribed only when tetracycline or doxycycline
(DOX); a tetracycline derivative, is removed from the cell culture medium. The first
attempt to establish a COX-2 Tet-Off system successfully generated HES cell clones
transfected with the COX-2 cDNA in the sense direction. However, when screening
these clones, COX-2 protein expression was not upregulated in the absence ofDOX.
Hygromycin (200pM) and G418 (800pg/ml) were used to select cells containing the
pTet-Off and pTRE2 (containing the COX-2 cDNA in the sense direction), vectors.
The concentrations of hygromycin and G418 were reduced to lOOpM and 600pg/ml
respectively in an attempt to prevent the successfully transfected cells from dying.
However, six successive efforts to establish a HES COX-2 Tet-Off system were
unsuccessful as all the cells died within 4 weeks of transfection and during the
selection process.
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As establishing a HES COX-2 Tet-Off model proved unsuccessful, the pIRES2
vector containing COX-2 in either the sense or antisense directions was then used to
set up a stable COX-2 overexpressing system in HES cells (method as described in
section 4.2.4.2). During the selection process with G418, a large number of COX-2
sense and COX-2 antisense colonies grew. 25 colonies were picked in the COX-2
sense direction and 25 colonies in the COX-2 antisense direction were picked. COX-
2 protein expression by the colonies was determined by Western blot analysis. Two
COX-2 sense clones demonstrated overexpression of COX-2 and one COX-2
antisense clone displayed a reduced but detectable level of COX-2 protein. To
confirm functionality of the transfected COX-2 cDNA, PGE2 and PGF2a synthesis
was measured by ELISA as described in section 4.2.7. PGE2 secretion was
significantly increased (P<0.05) in the culture media of both HES COX-2 sense
clones S7 and S17 (2559.88 ± 533.50 pg/ml and 837.17 ± 29.58 pg/ml respectively)
relative to the HES COX-2 AS clones (675.07 ± 238.22 pg/ml). Co-culture of the
cells with the COX-2 specific inhibitor NS398 significantly reduced (P<0.05) the
PGE2 generation in the COX-2 sense clones S7 and S17 relative to those treated with
AA alone (389.68 ± 155.94 pg/ml and 150.09 ± 35.14 pg/ml respectively)
Interestingly, PGF2a was only significantly elevated (P<0.05) in one HES COX-2
sense clone, S7, relative to the HES COX-2 antisense clone (489.85 ± 42.39 pg/ml
and 182.30 ± 36.33 pg/ml respectively). Co-culture of the S7 COX-2 sense cells with
NS398 significantly reduced (P<0.05) PGF2a secretion in the culture medium relative
to COX-2 sense cells treated with AA alone (173.38 ±33.09 pg/ml).
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Having established a COX-2 overexpressing model in the HES cells, a number of
experiments were performed to investigate differential expression of growth factors
and altered proliferative rates. VEGF, bFGF, Ang-1, Ang-2 and PGES protein
expression were all undetectable in HES WT, COX-2 sense and COX-2 antisense
cells as measured by Western Blot. An initial proliferation studies using BrdU
incorporation performed according to the manufacturer's instructions (Roche
Diagnostics GmbH, Mannheim, Germany) showed no difference between the COX-2
sense and the COX-2 antisense cells and these studies were not pursued further.
Since only one HES COX-2 sense clone displayed significantly elevated PGFia
secretion and the HES COX-2 antisense clone expressed detectable COX-2 protein,
it was decided to investigate establishing a COX-2 overexpressing model in a
different cell line. Performing a transient transfection in Ishikawa cells; an
endometrial epithelial cell line, demonstrated a marked increase in COX-2 protein
expression in the COX-2 sense cells relative to Ishikawa wild type and an
undetectable level of COX-2 protein in Ishikawa COX-2 antisense cells. Ishikawa
cells were then transfected with the pIRES2 vector containing COX-2 in either the
sense or antisense directions as described in section 4.2.4.2 and all further studies in
this thesis were performed using this model.
4.2.4.2 Ishikawa Studies
Ishikawa cells (European Collection of cell culture, Centre for applied Microbiology,
Wiltshire, UK) were transfected with the pIRES2 vector containing COX-2 cDNA
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(lpg) in either the sense or antisense directions as follows. Ishikawa cells were
seeded at a density of 120 000 in 12 well plates in complete media (1ml per well).
The cells were allowed to attach overnight at 37°C in a humidified 5% CO2
incubator. The following day, the Ishikawa cells were transfected (6 wells in the
COX-2 sense direction and COX-2 antisense direction respectively) using pfx-5
(Invitrogen) in a ratio of 9:1 pfx-5:cDNA diluted in optimem (Gibco). Control cells
were also incubated in optimem alone and optimem containing pfx-5. Transfection
efficiency was assessed by transfecting ishikawa cells with pcDNA6/V5/His/LacZ
(Invitrogen). Transfected and control cells were incubated for 4 hours at 37°C in a
humidified 5% CO2 incubator. The media was aspirated and replaced with complete
media. Cells were allowed to grow for 48 hours. The transfected cells were then
seeded in large flasks together with Ishikawa wild type cells in a ratio of 1:10. To
select the successfully transfected cells, the cells were incubated in complete media
containing G418 (800pg/ml). In order to establish when all untransfected cells had
died, one flask was seeded as a control with Ishikawa wild type cells in complete
media in the presence of G418 (800pg/ml). The media was aspirated every two to
three days on all cells and replaced with fresh complete media containing G418
(800pg/ml). This routine was maintained until the untransfected cells had died and
the G418 selected clones had grown to an appropriate size to be picked, whilst
remaining separate colonies. The clones were picked using cloning cylinders
(Sigma). Briefly, the cylinders were placed around a colony, the cells were
trypsonised and the individual colonies transferred to separate wells on a 24 well
plate. A total of 120 clones with COX-2 cDNA in the sense direction and 60 clones
with the COX-2 in the antisense directions were picked. The clones were maintained
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in 6 well plates as described in section 2.3 and 4.2.1. All the clones were screened for
COX-2 protein expression by Western blot analysis. Based on the COX-2 protein
expression, four clones containing COX-2 cDNA in the sense direction and 2 clones
containing COX-2 cDNA in the antisense directions namely S22, S26, S47 and S72;
AS 15 and AS47 respectively were chosen. These clones were used to measure PGE2
and PGF2a secretion. Following this study, all further investigations were performed
using the COX-2 sense 72 clone and the COX-2 antisense 15 clone as these
generated the highest and lowest levels of PGE2 and PGF2a respectively. Initial BrdU
incorporation and apoptosis ELISA studies (Roche Diagnostics GmbH, Mannheim,
Germany) indicated there were no differences in proliferation or apoptosis between
the COX-2 sense cells and the COX-2 antisense cells and these studies were not
pursued further.
4.2.5 /?-Galactosidase Assay
Transfection efficiency was assessed using /3-Galactosidase (X-gal) with the
Ishikawa cells tranfected with the pcDNA6/V5/His/LacZ (Invitrogen) cDNA grown
for 48 hours. The media was aspirated and the cells were then washed three times
with phosphate buffered saline (PBS) and then fixed with 0.2% glutaraldehyde / 2%
formaldehyde in PBS for 5 min. The fixing solution was then aspirated and the cells
washed three times in PBS. Finally, the cells were incubated overnight at 37°C in the
presence of the staining solution (K3Fe(CN)6; 5mM, K4Fe(CN)6; 5mM, MgCl2;
2mM, X-gal; lmg/ml). The following day, those cells successfully transfected were
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stained blue. The transfection efficiency was calculated by counting the number of
blue cells and expressed as a percentage of the total cells.
4.2.6 Protein Extraction and Western Blot Analysis
Protein extraction, quantification and Western blot analysis were performed as
described in section 2.4. Briefly, Ishikawa wild type, COX-2 sense and COX-2
antisense cells were seeded at a density of 7.5xl05 cells in six well plates, allowed to
attach for 24 hours in complete media and then cultured in serum free media
overnight to reach the desired confluency of 70% (n=4 independent experiments). A
total of 20pg protein for cathepsin D expression and 40pg protein for COX-2, COX-
1 and (3-actin, were denatured and subjected to SDS-PAGE on 4-12% Tris-glycine
gels (Invitrogen, Paisley, UK). The proteins were transferred onto PVDF membrane
and blocked for 1 hour in TBS-Tween (50mM Tris-HCl, 150mM NaCl and 0.05%
(v/v) Tween 20 containing 5% skimmed milk powder). The membranes were probed
with one of the following antibodies: COX-2 (sc-1745; at dilution of 1:1000), COX-1
(sc-1752; at dilution of 1:500), cathepsin D (sc-6486; at dilution of 1:2000), (3-actin
(sc-1616; at dilution of 1:1000) or Plasminogen (sc-15034; at dilution of 1:500)
overnight followed by rabbit antigoat conjugated to alkaline phosphatase secondary
antibody at a dilution of 1:30 000 (Sigma, Poole, UK). All the primary antibodies
were purchased from Santa Cruz Biotechnology (Autogenbioclear, Whiltshire, UK).
The membranes were developed and revealed by phosphorimager analysis using the
ECF chemifluorescence system according to the manufacturer's instructions
(Amersham Biosciences UK Ltd, Little Chalfont, UK). The molecular weights of the
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proteins were determined by comparing mobility on the gel with a molecular weight
standard (Invitrogen, Paisley, UK). Proteins were quantified by densitometry using
STORM 860 system (Molecular Dynamics, Amersham Biosciences,
Buckinghamshire, UK). Relative expression of cathepsin D protein was calculated by
normalising with |3-actin and expressed as mean ± SEM.
4.2.7 PGE2 and PGF2a assay
Ishikawa wild type, COX-2 sense and COX-2 antisense cells were seeded in 6 well
plates at a cell density of 2.5 X105 cells per well. Cells were left to attach overnight
in complete media (2ml). The following day, the complete media was aspirated and
the cells washed twice with PBS (2ml), the PBS was aspirated by pipette and
replaced with serum free media (2ml) overnight. Arachidonic acid to a final
concentration of (5pg/ml) was added to the media the following day ± NS398
(lOpM), the COX-2 selective inhibitor, and the cells were incubated for a further 48
hours. The media was then aspirated by pipette and transferred to an eppendorf tube
for analysis. For the PGE2 assay, 1ml of media was removed as described and added
to 1ml ofmethyloximating solution (Methyloxyamine buffer, pH 5.6) to stabilize the
PGE2. The samples were stored at -20°C until further use. PGE2 and PGF2a secretion
in the culture media was assayed using an ELISA as described by Denison et al
(265). Initially, 96 well plates (amine-binding plates; Costar, High Wycombe, United
Kingdom) were coated with donkey antirabbit antibody and were then coated with
rabbit IgG (lmg/ml diluted in PBS with 1% carbonate buffer, pH 9.6) at 200pl/well
for 16 hours at 4°C. The solution was aspirated and blocking solution (50mM
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glycine, 10 mg/ml BSA) was added to the wells (25pl/well) for 2 hours at 23°C.
Following washing, donkey antirabbit serum (Scottish Antibody Production Unit,
Carluke, United Kingdom) was added to each well before washing and air drying.
The plates were stored at 4°C with desiccant. The link was prepared by ether
extraction and purified by reverse phase chromatography using 20mg of synthetic
PGE2, 320|il of dry dimethylformamide, 3pl butylchlororomate and 0.05nM
biocytin. The link and antisera were diluted 1:1.5X106 in PO4 0.5M pH8.0 and 1:50
000 in ELISA buffer (150mM NaCl, lOOmM Tris-HCl, 0.05% Tween 20, 50mM
phenol red, 1 mM 2-methylisothiazolone, ImM bromonitrodioxane, 2mM EDTA,
2mg/ml BSA to a final pH of 7.2) respectively. For the PGF2a assay, the ELISA
buffer contained no Tween. The standard (5120pg/ml) was then serially diluted 9
times in buffer. For the PGE2 assay, the standards were diluted in ELISA buffer
containing 25% MOX and Tween, the PGF2a standards were diluted in ELISA buffer
alone. The standards at concentrations of 5120pg/ml, 2560pg/ml, 1280pg/ml,
640pg/ml, 320pg/ml, 160pg/ml, 80pg/ml, 40pg/ml, 20pg/ml and lOpg/ml were used
to construct the standard curve. Samples and synthetic standards (lOOpl) were added
in duplicate to the plate followed by 50pl of the diluted link and 50pl of the diluted
antisera to all wells except for the non specific binding (NSB) and the maximum
binding B0 control wells. Link (50pl) and ELISA buffer (lOOpl) alone were added to
the NSB wells, for the B0 wells, link (50pl), ELISA buffer (lOOpl) and antisera
(50pl) were added. The plates were incubated overnight at 4°C. The following day,
the contents of the wells were aspirated and the plates washed 4 times, once for 30
seconds on an orbital shaker. Following the wash, lOOpl /well of streptavidin-
peroxidase (0.2 U/ml) was added to each well on the plate. The plates were incubated
102
Chapter 4 Differential gene expression in COX-2 sense and COX-2 antisense cells
for 20 minutes at 23°C on an orbital shaker. Plates were then washed and 200pl/well
of the substrate (0.3 g/liter urea-hydrogen peroxide, 0.1 g/1 tetramethylbenzene in 100
raM sodium acetate, pH 6.0) was added for 10 minutes. The reaction was stopped
with lOOpl / well sulphuric acid (1 M). The absorbance was measured at 450 nm
using a Multiscan® MCC/340 plate reader. Average PGE2 and PGF2a concentrations
of the media samples were determined from the standard curve constructed by
extrapolation using the Assay Zap software (Biosoft).
4.2.8 Quantitative RT PCR
Quantitative RT PCR was performed as described in section 2.5.5. Briefly, to
quantify the overexpression of COX-2, Ishikawa wild type and COX-2 sense cells
were subjected to quantitative RT PCR. The effect ofCOX-2 on EP and FP receptor
expression, was investigated by quantitative RT PCR in Ishikawa wild-type, COX-2
sense clone 72 and COX-2 antisense clone 15 cells. A possible autocrine action of
PGE2 on EP receptor expression was investigated with Ishikawa wild type cells. For
all experiments, 5xl05 cells were seeded in 6 well plates and allowed to attach for 24
hours in complete media, and then cultured in serum free media overnight. The
experiments to quantify the expression of COX-2 and determine the effect ofCOX-2
on EP and FP receptor expression were performed in the absence ofNS398 as recent
data has suggested NS398 can upregulate the expression of EP receptors (266). To
identify a possible autocrine action of PGE2 on EP receptor expression, Ishikawa
wild type cells were cultured in serum free media containing the non selective COX
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inhibitor indomethacin (3pg/ml). Cells were harvested with Tri-Reagent and the
RNA isolated and reverse transcribed as described in section 2.5
4.2.9 cAMP Turnover
Functionality of the EP receptors was investigated by measuring cAMP generation
in Ishikawa wildtype, COX-2 sense and COX-2 antisense cells. Cells (2 x 105) were
seeded in complete media (2ml/well) in 6 well plates. Cells were allowed to grow
for 24 hours. The cells were then washed twice with PBS, and then synchronised by
incubating overnight with serum free medium. The following morning, the culture
medium was aspirated and replaced with serum-free medium containing IBMX
(Sigma) to a final concentration of 1 mM for 1.5 hours at 37°C. Cells were then
stimulated with 0 or 100 nM PGE2 for 10 minutes. Following stimulation, the
medium was removed and the cells lysed in HC1 (0.1 M). cAMP concentration was
quantified by ELISA using a cAMP kit (Biomol) as described in section 2.6 and
normalised to protein concentration of the lysate. Protein concentrations were
determined using a protein assay kit as described in section 2.4.2 The data are
presented as mean ( ± SEM), fold induction of cAMP in COX-2 sense and antisense
cells after treatment with PGE2 where fold induction was calculated relative to the
wild-type samples. The intra- and interassay coefficients of variation were 8.3% and
11.6% respectively.
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4.2.10 cDNA array Analysis
Differential gene expression in the COX-2 sense and antisense cells was assessed
using cDNA array analysis. COX-2 sense and COX-2 antisense cells were grown to
approximately 70% confluency in complete media. The media was aspirated by
vacumn suction and the cells were washed twice with PBS (5ml) and then cultured in
serum free media overnight. Following overnight culture, the media was aspirated by
vacumn suction and the cells were then harvested by washing twice with PBS (10ml)
followed by 5ml trypsin-EDTA (0.1% trypsin and 0.04% EDTA in PBS). The flasks
of cells were then incubated for 5 minutes at 37°C. Subsequently, the cells were
resuspended in PBS (10ml) and counted using a heamacytometer. Following this, the
cells were pelleted by centrifugation for 5 minutes, 1000 rpm. The supernatant was
aspirated by pipette and the cells were snap frozen on dry ice and stored at -70°C.
The cell pellets were sent to Clontech Laboratories Inc. (Palo Alto, CA, USA) for
custom cDNA array analysis using the Atlas plastic human 8K Microarray service
(www.clontech.com).
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Figure 4.1 Schematic flow diagram for the cDNA array hybridasation procedure (reproduced from the
Clontech Plastic Microarray Users Manual)
The procedure for performing the cDNA array was briefly as follows (see figure 4.1).
Initially RNA was extracted from the cells of the COX-2 sense and the COX-2
32 i • i •antisense cells. cDNA probes were synthesised, labelled with ~P and then hybridised
to the array. The arrays were visualised using a phosphorimager and were analysed
using Atlaslmage software and expressed as a comparison between the COX-2 sense
and COX-2 antisense cells.
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4.2.11 Determination of Angiostatin Generation
Ishikawa wild type, COX-2 sense and COX-2 antisense cells were seeded in 6 well
plates at a density of 3.5xl05, allowed to attach for 24 hours in complete media
(2ml). The cell media was aspirated by pipette and the cells were washed twice with
PBS (2ml) and then cultured in serum free media (1.5ml) overnight (n=3 independent
experiments). Following overnight culture, the media was collected, by pipette,
transferred to a centrifuge tube and spun at 1000 rpm for 5 minutes to pellet any cell
debris. The supernatant was aspirated by pipette transferred to a new centrifuge tube
and stored at -20°C until further use. In order to investigate the differential cleavage
of plasminogen to angiostatin by the 3 cell lines, WT, AS and S, the previously
frozen media was thawed on ice, aliquots of the thawed cell media (lOOpl) were
pippetted into centrifuge tubes and incubated with 25pg /ml plasminogen at 37°C in
a water bath for 0, 4, 8 or 24 hours. In order to investigate whether cathepsin D
mediates the cleavage of plasminogen to angiostatin, lOOpl of media from COX-2
antisense cells were incubated in a centrifuge tube in the presence or absence of 1 pM
pepstatin A, a cathepsin D inhibitor (Sigma, Poole, UK) for 8 hours at 37°C in a
water bath. Subsequently, a total of 20pl of each reaction was denatured and
subjected to SDS-PAGE on 4-12% Tris-glycine gels (Invitrogen, Paisley, UK) as
described in section 2.4.3. The generation of angiostatin from plasminogen was
assessed by Western blot analysis and probed with a plasminogen antibody as
described in sections 2.4.4 and 4.2.6
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4.3 Results
4.3.1 COX-2 and COX-1 Protein Expression in Wild Type and
Transfected Cells
Stable transfection of the Ishikawa human endometrial epithelial cells with the
pIRES2 vector containing COX-2 cDNA in the sense direction resulted in the
overexpression of COX-2 protein. Of the COX-2 sense clones picked, Western blot
analysis revealed strong COX-2 protein expression detected as 71 kDa band in 24 of
the COX-2 sense cell clones (S) compared with the COX-2 antisense (AS) and wild
type (WT) cells (see figure 4.2A). Basal levels of COX-2 were detected in the wild
type Ishikawa cells that on transfection with COX-2 antisense cDNA was reduced to
undetectable levels in 3 of the COX-2 antisense cell clones, (see figure 4.2A). Stable
transfection of the COX-2 cDNA in either the sense or antisense direction had no
effect on COX-1 protein expression (see figure 4.2B); no difference was detected in
COX-1 protein levels between the wild type, COX-2 sense or COX-2 antisense cell
lines used for the ongoing studies.
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Figure 4.2 Western blot analysis of 40ug protein from wild-type Ishikawa cells (WT) and Ishikawa
cells stably transfected with COX-2 cDNA in the sense (S) clone S72 or antisense (AS) clone AS 15
directions. A, Specific bands for COX-2 and /3-actin proteins were detected at approximately 72 and
46 kDa, respectively. B, COX-1 and /3 -actin proteins were detected by specific bands at 71 and
46kDa respectively.
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4.3.2 Relative COX-2 mRNA Expression in COX-2 Sense Cells and Wild
Type Cells
To quantify the COX-2 overexpression, quantitative RT PCR was performed on
Ishikawa wild-type and the COX-2 sense 72 clone cells (see figure 4.3). The relative
COX-2 mRNA expression was significantly increased (p<0.05) in the COX-2 sense


















Figure 4.3 Relative expression of COX-2 mRNA in Ishikawa wild type (WT) cells and Ishikawa cells
stably transfected with COX-2 in the sense direction (S). The data are mean ±- SEM, n=3. * denotes
statistical significance relative to WT (P < 0.05)
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4.3.3 PGE2 and PGF2a Secretion
In order to confirm functionality of the transfected cDNA, PGE2 and PGF2a synthesis
were measured by ELISA in four COX-2 sense clones, two COX-2 antisense clones
and Ishikawa wild type cells (see figure 4.4). PGE2 secretion was significantly
increased (P<0.05) in the culture media of the COX-2 sense clones compared with
the COX-2 antisense clones. The COX-2 sense 72 clone generated the highest level
of PGE2 into the culture media (2391.25 ± 311.09 pg/ml) compared with wild type
and COX-2 antisense 15 clone which generated the lowest level of PGE2 (359 ±
71.54 pg/ml and 78.96 ± 50.9 pg/ml respectively). Co-culture of the cells with the
specific COX-2 enzyme inhibitor NS398 abolished the increased secretion of PGE2
in the COX-2 sense cells. Similarly, PGF2a secretion was significantly elevated in the
COX-2 sense clones relative to the COX-2 antisense clones, the highest and lowest
levels ofPGF2a detected were in the COX-2 sense 72 clone and the COX-2 antisense
15 clone respectively. The PGF2a generation by the COX-2 sense 72 clone was
significantly increased (p<0.01) (1996.73 ± 361.03 pg/ml) relative to the wild type
and COX-2 antisense 15 cells (561.30 ± 114.45 pg/ml and 175.80 ± 38.79 pg/ml
respectively). The increased secretion of PGF2a was abolished when the cells were
co-cultured with the COX-2 selective inhibitor NS398.
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Figure 4.4 The functionality of the transfected COX-2 was assessed by ELISA to measure PGE2
secretion (A) and PGF2a secretion (B) by wild-type (WT), COX-2 antisense (AS) and COX-2 sense
(S) cell clones into culture media following incubation with 5 pg arachidonic acid (AA) for 48h in the
presence or absence 10 uM of the COX-2 enzyme inhibitor NS398. The data are mean ± SEM of n =
4 experiments. ** denotes statistical significane relative to AA treated Wild Type, ** denotes
statistical significance relative to AA treated in same cell type (P < 0.05).
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4.3.4 Effect of COX-2 Overexpression on EP and FP Receptor
Expression
In order to maximise the effects observed, all further studies were performed using
the COX-2 antisense 15 clone and the COX-2 sense 72 clone; which generated the
lowest and highest levels of PGE2 and PGF2a in response to arachidonic acid
respectively. To investigate the effect of COX-2 overexpression on EP and FP
receptors, real time quantitative RT PCR was performed to quantify the expression of
FP, EP1, EP2, EP3 and EP4 receptors (see figure 4.5 A, 4.5 C). Relative expression
of EP2 and EP3 mRNA (compared to expression levels detected in wild type cells)
was significantly higher (P<0.05) in the COX-2 sense cells compared with COX-2
antisense cells (EP2 receptor: 3.73 + 0.43 vs 1.19 + 0.39 for COX-2 sense and
antisense cells respectively; EP4 receptor: 2.35 ± 0.3 vs 1.03 ± 0.105 for COX-2
sense and antisense cells respectively). EP1 mRNA was not detectable in any of the
cell lines and EP4 and FP receptor expression showed no significant differences
between the COX-2 sense and antisense cells.
4.3.5 cAMP Generation
Functionality of the EP receptors was investigated by measuring the generation of
cAMP in COX-2 sense, COX-2 antisense and wild type cells in response to treatment
with lOOnM PGE2 for 10 minutes (see figure 4.5B). Fold induction of cAMP relative
to that measured in wild type cells was significantly higher (P<0.05) in the COX-2
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sense cells compared with the COX-2 antisense cells (2.57 + 0.16 vs 0.88 + 0.33 for
COX-2 sense and antisense cells respectively).
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Figure 4.5 (A) Relative expression of EP2, EP3 and EP4 receptors in Ishikawa cells stably
overexpressing COX-2 in either the sense (S) or antisense (AS) directions. Relative expression was
determined by dividing expression detected in COX-2 sense and antisense cells by expression
detected in wild-type cells. The data are mean ± SEM of n=3 experiments. * denotes statistical
significance relative to AS (P< 0.05). (B), ELISA for cAMP generation. Fold induction of cAMP
generation in COX-2 antisense (AS) and COX-2 sense (S) cells following treatment with lOOnM
PGE2 for 10 min. Fold induction is calculated by dividing cAMP generation in wild-type cells. The
data are mean ± SEM of n = 4 experiments. * denotes statistical significance (P < 0.05). (C), Relative
expression of FP receptors in COX-2 sense (S) and antisense (AS) cells. Relative expression was
determined as described for A. The data are mean ± SEM of n=3 experiments.
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4.3.6 Autocrine Action of PGE2 on EP Receptor Expression
To investigate a possible autocrine action of PGE2 on its EP receptors in endometrial
epithelial cells, we measured EP receptor expression in wild type cells following
overnight culture in the presence of the non selective COX inhibitor indomethacin
and treatment with exogenous PGE2 (lOOnM) for 0,4,6,24 hours (see figure 4.6).
Using real time quantitative RT PCR, EP2 mRNA expression was significantly
higher (1.56 ± 0.28 P < 0.05) following 4 hour treatment of PGE2 compared with
untreated wild type cells. There was no significant difference in EP3 and EP4 RNA
expression following treatment with PGE2. EP1 RNA expression was undetectable
both pre and post culture with PGE2.
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EP2 EP3 EP4
Figure 4.6 Relative expression of EP2, EP3 and EP4 receptors in wild-type Ishikawa cells following
overnight culture in the presence of the non selective COX inhibitor indomethacin and stimulation
with exogenous PGE2 for 0, 4, 6, 24h. Relative expression was determined by dividing expression
detected in cells treated with PGE2 by expression detected in untreated cells. The data are mean ±
SEM of n = 3 experiments. * denotes statistical significance relative to the Oh time point (P < 0.05).
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4.3.7 Differential Gene Expression
Differential gene expression between COX-2 sense and COX-2 antisense cells was
investigated using RNA extracted from the two cell lines and the Clontech Atlas
human 8K microarrays. Eighty one genes demonstrated differential expression
between the two cell lines (see Appendix I) for the complete list of genes
demonstrating differential expression).
Interestingly, COX-2 amd growth factors associated with its overexpression such as
VEGF were not shown to be differentially expressed. It is plausible that whilst a
significant over expression of COX-2 in the COX-2 sense cells relative to the COX-2
antisense cells was demonstrated (see 4.3.1 and 4.3.2), the overall expression of
COX-2 and VEGF was below the level of detection of the microarray system.
Furthermore, the manufacturers report that a number of false negative and false
positive results are observed with the technique.
Of the genes demonstrated to be differentially expressed, one of the greatest
differences observed was cathepsin D.
4.3.7.1 Cathepsin D Expression
Cathepsin D mRNA expression demonstrated a 6.7 fold difference between the
COX-2 sense and the COX-2 antisense cells as determined by Atlas array analysis;
cathepsin D RNA expression was reduced in the COX-2 sense compared with the
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COX-2 antisense cells (see figure 4.7 A). Western blot analysis conducted using
proteins extracted from the 3 cell lines confirmed lower cathepsin D protein
expression in the COX-2 sense and elevated expression in the COX-2 antisense cells
compared with the wildtype cells. Cathepsin D protein expression in COX-2 sense
and COX-2 antisense was 0.8 ± 0.13 and 1.68 ± 0.39 fold relative to wildtype cells.
The difference in cathepsin D expression was 2.16 ± 0.22 fold lower in the COX-2
sense compared with antisense cells p<0.05 (see figure 4.7 B and figure 4.7 C).
119
Chapter 4 Differential gene expression in COX-2 sense and COX-2 antisense cells
A
Antiserise Sense
Figure 4.7, (A), Atlas plastic 8K Human cDNA array image following hybridysation with cDNA
from untreated COX-2 antisense and COX-2 sense cells. Arrows correspond to cathepsin D position.
(B), Western blot analysis of 20 ug protein isolated from untreated Ishikawa wild-type (WT), COX-2
antisense (AS) and COX-2 sense (S) cells. The blot was probed with cathepsin D antibody that
detected procathepsin D (1), pseudocathepsin D (2) and cathepsin D (3) protein expression at 52 kDa,
51kDa and 32 kDa respectively. (C), Relative expression of cathepsin D in COX-2 antisense and
COX-2 sense cells normalised for /3-actin and expressed relative to expression detected in wild-type
cells. Bands were semiquantified as outlined and presented as mean ± SEM relative expression of n =
4 experiments. * denotes statistical significance relative to AS (P < 0.05).
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4.3.8 Cleavage of Plasminogen to Angiostatin
We investigated the potential effect of differential cathepsin D expression in the
three cell lines, on cleavage of plasminogen to angiostatin. Plasminogen was cultured
in the media collected from COX-2 sense, COX-2 antisense and wild type cells for 0,
4, 8 and 24 hours. Using anti-plasminogen antibody and Western blot analysis,
plasmin was detected at 66 kDa and angiostatin bands were detected at 36 and 32
kDa which are within the reported range of 32 - 50 (220, 267). Angiostatin
production was elevated at 4, 8 and 24 hours following culture of plasminogen in
media collected from COX-2 antisense cells compared with wild type cells.
However, angiostatin production was reduced to undetectable levels when
plasminogen was incubated in the culture media collected from COX-2 sense cells
(see figure 4.8). Interestingly, plasminogen appears to be diminishing after 4 hours
in the COX-2 sense cells without being accompanied with angiostatin production.
There was no detectable angiostatin production in serum free conditioned media
taken from COX-2 sense cells at an earlier time point of 2 hours (data not shown)
suggesting it is not due to an earlier production of angiostatin. Furthermore, other
studies have demonstrated undetectable angiostatin production by serum free
conditioned media cultured with plasminogen is accompanied with an apparent
diminished plasminogen level (220).
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Figure 4.8 Generation of angiostatin following incubation of 25 pg/ml plasminogen for 0, 4, 8, and
24 h in serum - free conditioned media collected from Ishikawa wild - type, COX-2 antisense and
COX-2 sense cells. Angiostatin production was detected by Western blot analysis using 20 pi of
media. Plasminogen and angiostatin were detected at expected molecular masses of 97 and 36/32 kDa
respectively.
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4.3.9 Inhibition of Plasminogen Cleavage to Angiostatin by Pepstatin A
In order to confirm that the cleavage of plasminogen to angiostatin is mediated by
cathepsin D, the incubation experiments were repeated by incubating plasminogen in
COX-2 antisense conditioned media in the presence of the cathepsin D inhibitior
pepstatin A. Co- incubation of plasminogen and cathepsin D in the conditioned
media from COX-2 antisense cells for 8 hours resulted in inhibition of angiostatin
production (see figure 4.9).
0 Vehicle Pepstatin A
Angiostatin
Figure 4.9 Inhibition of angiostatin generation by pepstatin A following incubation of 25 ug/ml
plasminogen in media collected from COX-2 antisense cells in the presence or absence of 1 uM
pepstatin A for 8h. Angiostatin production was detected by Western blot analysis using 20 ul of
media. Plasminogen and angiostatin were detected at expected molecular masses of 97 and 36/32 kDa
respectively.
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4.4 Discussion
In this study, an endometrial epithelial cell line stably overexpressing COX-2 has
been established. COX-2 protein and mRNA expression was higher in the sense
clones compared with the antisense and wild type. Overexpression of COX-2 in the
Ishikawa endometrial epithelial cells was associated with elevated secretion of PGE2
and PGF2q: that was abolished by the COX-2 selective inhibitor NS398. This is in
agreement with other studies that have demonstrated increased prostanoid generation
in response to the overexpression of COX-2 (138). Similar expression of COX-1
protein was detected in all three cell lines, suggesting that COX-1 expression is not
regulated by COX-2. Treatment of the cells with NS398 reduced PGE2 and PGF2a
secretion in wild-type, COX-2 sense and COX-2 antisense cells and for PGE2 to
almost undetectable levels. This suggests that PGE2 secretion in the wild-type, COX-
2 sense and COX-2 antisense cell lines is predominantly a result of COX-2 activity.
COX-2 overexpression was also associated with increased EP2/EP3 receptor
expression and signaling with no effect on EP1/EP4 and FP receptor expression.
Interestingly, EP4 and FP receptors are known to internalize following treatment
with agonist, conversely EP2 and EP3; depending on the isoform, do not display
internalization (172, 173, 268-270). To investigate a possible autocrine action of
PGE2 on its EP receptors we measured EP receptor expression in wild type cells
following treatment with PGE2. EP2 mRNA expression was significantly higher
following 4 hour treatment of PGE2 compared with untreated wild type cells. There
was no significant difference in EP3 or EP4 mRNA expression. This is in agreement
with other studies and suggests PGE2 acts in an autocrine/paracrine manner to up-
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regulate EP2 receptor expression Since PGE2 did not upregulate EP3 receptor
expression in this model, EP3 receptor expression is likely to be regulated by another
COX-2 product (271). Furthermore, recent studies have demonstrated cultured media
from endometrial epithelial cells upregulate COX-2 and PGE2 expression in
endometrial stromal cells (272). The COX-2 sense cells also displayed significantly
higher fold induction of cAMP relative to the COX-2 antisense cells. The EP2
receptor is associated with Gs coupled signaling and results in enhanced cAMP
generation (149). The net increase in cAMP in response to exogenous PGE2 in the
COX-2 sense cells suggests an overall balance towards Gs coupled signaling in
response to exogenous PGE2 is favored. Hence, these data confirm that prostanoids
such as PGE2 secreted in response to COX-2 regulate the expression of their
receptors and regulate gene expression in an autocrine/paracrine manner.
To identify differential gene expression between the COX-2 sense and the COX-2
antisense cells we employed cDNA array analysis. We demonstrated reduced
cathepsin D mRNA and protein expression in the COX-2 sense cells compared with
wild type and antisense cells. In the human endometrium, cathepsin D expression has
been localised to glandular and stromal cells and glandular expression has been
shown to be highest during the secretory phase of the menstrual cycle (273). The
elevated expression of cathepsin D is thought to be positively regulated by
progesterone. However, cathepsin D expression remains elevated in the mid to late
secretory phase despite a reduction in progesterone receptor activity. This has
prompted the suggestion that cathepsin D expression is also under the control of
other factors (274). Our data demonstrating that cathepsin D expression is inhibited
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via a COX-2 mediated action suggests COX-2 may be one of those factors. COX-2
expression in the human endometrium is highest during the late secretory and
proliferative phases of the menstrual cycle (23) when cathepsin D levels have been
reported to be at their lowest. Interestingly, elevated COX-2 and reduced cathepsin D
have independently been associated with a poor prognosis in reproductive tract
carcinoma (224, 275, 276). Moreover, COX-2 has been shown to be induced in
endometrial adenocarcinomas (61, 62, 257). Hence it is plausible to suggest that
increased COX-2 may be an indicator of low cathepsin D expression.
Cathepsin D is known to cleave plasminogen to angiostatin. Angiostatin is a potent
endogenous antiangiogenic factor which is proteolytically derived from plasminogen
(277). Angiostatin inhibits vasodilation, proliferation and migration of endothelial
cells and endothelial tube formation possibly via the induction of apoptosis in
endothelial cells (266, 277-280). In human prostate carcinoma cells cathepsin D has
been shown to proteolytically cleave plasminogen to angiostatin (215). We initially
investigated the generation of angiostatin from plasminogen in conditioned media
collected from COX-2 sense, COX-2 antisense cells and wild type. Angiostatin
accumulation was reduced to undetectable levels in the media from COX-2 sense
cells and elevated in the media from the COX-2 antisense cells compared with the
wild type cells supporting a role for cathepsin D in the generation of angiostatin in
endometrial epithelial cells. The differential cleavage of plasminogen to cathepsin D
in the three cell lines is reflective of the varying degrees of COX-2 expression. Co-
incubation of plasminogen in conditioned media from antisense cells with the
cathepsin D inhibitor, pepstatin A reduced angiostatin formation. This suggests that
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the cleavage of plasminogen to angiostatin is mediated in part by cathepsin D. Other
proteolytic enzymes which can cleave plasminogen to angiostatin include matrix
metalloproteinases (MMPs) 3,7,9 and 12 (218-220, 281).
Overexpression of COX-2 and prostanoid receptors such as EP2 play a role in
angiogenesis by promoting the formation of pro-angiogenic factors (168, 211). Once
synthesised the angiogenic factors act in a paracrine manner on endothelial cells to
promote enhanced cell migration and tubular formation (138). However, it is now
well accepted that the promotion of an angiogenic environment is the result of a
balance in the production of angiogenic and anti angiogenic factors (214). The data
presented herein demonstrate an alternative pathway by which COX-2 can regulate
angiogenesis in endometrial epithelial cells through inhibition of production of
antiangiogenic factors. Recently, inhibition of COX-2 has been demonstrated to up
regulate the generation and expression of antiangiogenic factors endostatin and
thrombospondin-1 (282, 283). Conversely, the data presented herein demonstrate that
overexpression of COX-2 inhibits the generation of the antiangiogenic factors such
as angiostatin. However, the underlying cellular mechanisms and molecular
pathways by which COX-2 down regulates cathepsin D expression resulting in
reduced angiostatin generation remains to be elucidated.
In conclusion the data outlined here demonstrate overexpression of COX-2 results in
a concomitant induction of PGE2 secretion and EP2/EP3 receptor expression. COX-2
inhibits cathepsin D expression in endometrial epithelial cells via an unknown
mechanism, which contributes to an inhibition of the formation of angiostatin. These
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data outline a novel function of COX-2 in promoting a pro angiogenic environment




Chapter 5 Discussion and Conclusions
5.1 Discussions and Conclusions
As discussed in section 1.7, a role for the cyclooxygenase enzymes and their
products the prostaglandins has been described in benign and neoplastic
gynaecological conditions. The synthesis of PGE2 ultimately depends on the actions
of the COX enzymes and PGE synthase. Within the human endometrium, previous
studies have localised expression of COX enzymes to epithelial and perivascular
cells with maximal expression in the menstrual and proliferative phases (23, 102,
241).
Initial studies for this thesis were performed to localise the expression and site of
synthesis of PGE synthase and PGE2 within the human endometrium.
Immunohistochemical analysis using paraffin wax-embedded endometrial tissue
samples collected from across the menstrual cycle demonstrated mPGES-1
expression and PGE2 synthesis in endothelial, epithelial and stromal cells of the
human endometrium. PGE2 acts via its G-protein coupled receptors EP1-EP4 (149).
Possible sites of action of PGE2 in the human endometrium were investigated by
immunohistochemistry and quantitative RT PCR for two of its receptors namely EP2
and EP4. In various models, PGE2 acting via its EP2 and EP4 receptors has been
associated with elevated expression of angiogenic factors, cellular proliferation and
inhibition of apoptosis via a variety of intracellular pathways (168, 284, 285). The
endometrium across the menstrual cycle undergoes phases of proliferation and
apoptosis with angiogenesis seen throughout the cycle. These studies demonstrated
EP2/EP4 receptors localized to glandular epithelial and endothelial cells.
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Furthermore, EP2/EP4 receptors displayed temporal upregulation with significantly
elevated EP4 receptor expression in the late proliferative phase of the menstrual
cycle. EP2/EP4 receptor activation results in the generation of cAMP. Maximal EP4
receptor expression was associated with significantly higher accumulation of cAMP
in response to exogenous PGE2. More recent studies in our laboratory have
confirmed the temporal expression and signalling of other COX products namely
PGF2o, and PGI2 via their respective FP and IP receptors in the human endometrium
(183, 189). These observations further confirm a role for the COX enzymes and
prostaglandins in mediating endometrial cell function. However, the role of each of
the prostanoid receptors in endometrial physiology remains to be established. Within
the human endometrium, the expression of prostaglandins is partly under control of
progesterone. Progesterone limits available prostaglandin by positively regulating the
expression of the prostaglandin metabolising enzyme; prostaglandin dehydrogenase
(PGDH) (286). Progesterone may also inhibit the synthesis of COX-2 (287, 288).
There is increasing evidence that the NFk/3 pathway can up regulate COX-2
expression; it is thought the effects of progesterone on COX-2 are mediated via this
pathway (107, 108, 289).
In order to investigate further a role for COX-2 in endometrial epithelial cell
function, we constructed a stable COX-2 overexpressing cell model in Ishikawa cells
which is an endometrial epithelial cell line. The cells were transfected with COX-2
cDNA in either the sense or antisense directions and selected by antibiotic treatment.
Overexpression of COX-2 in the COX-2 sense cells was confirmed by Western blot
analysis and quantitative RT PCR. Western blot analysis revealed strong COX-2
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protein expression in the COX-2 sense cells compared with the Ishikawa wild type
and COX-2 antisense cells. Functionality of the transfected COX-2 cDNA was
assessed by ELISA to measure PGE2 and PGF2„ synthesis. Both PGE2 and PGF2a
secretion was significantly elevated in the COX-2 sense cells relative to the Ishikawa
wild type and COX-2 antisense cells. Furthermore, co-culture of the cells with the
specific COX-2 inhibitor, NS398 reduced the increase in PGE2 and PGF2a secretion.
PGE2 was reduced to almost undetectable levels in the wild-type, COX-2 sense and
COX-2 antisense cells suggesting PGE2 secretion in these cells is predominantly as a
result ofCOX-2 activity.
As mentioned above, PGE2 and PGF2a act via their G protein coupled receptors,
EP1-EP4 and FP respectively. The effect of COX-2 overexpresion on EP1-EP4 and
FP receptor expression was assessed by quantitative RT PCR. The relative
expression of both EP2 and EP3 receptors was significantly elevated in the COX-2
sense cells compared with the antisense cells suggesting COX-2 products act in an
autocrine/ paracrine manner to up-regulate EP receptor expression. This is in
agreement with other studies demonstrating overexpression of COX is associated
with up regulated EP receptor expression(65, 290). Neither EP4 nor FP receptors
were upregulated in the COX-2 sense cells. In other in vitro models, overexpression
of COX enzymes has been associated with elevated EP4 receptors (65). Previous
studies have demonstrated that EP4 and FP receptors both undergo internalisation
upon agonist activation (172, 269). In this overexpressing COX-2 model,
internalisation of EP4 and FP receptors thus reducing the number of ligand binding
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sites may be acting to prevent an up regulation of these receptors by an autocrine
action, thereby maintaining the receptor expression at basal level.
The enhanced expression of EP2 and EP3 receptors was concomitant with a net
increase in cAMP in response to exogenous PGE2 in the COX-2 sense cells relative
to the Ishikawa wild type and COX-2 antisense cells. EP2 receptors signal via Gs.
However, there are multiple EP3 splice variants that are coupled with Gs or Gi.
These data suggest that in our model system, an overall balance toward Gs coupled
signalling in response to PGE2.
A possible autocrine effect of PGE2 on its EP receptor expression was confirmed by
the upregulation of EP2 receptors in response to PGE2 treatment in Ishikawa wild
type cells, pre-treated with the non selective COX inhibitor indomethacin. This
autocrine/paracrine effect of PGE2 on EP receptor expression is supported by other
studies demonstrating PGE2 upregulates EP2 receptor expression with no effect on
EP4 (271). Interestingly, PGE2 has also been shown to enhance COX-2 expression
probably via a cAMP dependent pathway (291). It is suggested that PGE2 augments
its actions in a feed forward mechanism not only by regulating the expression of its
receptors but also by modulating the expression of the rate limiting enzyme (COX-2)
in its synthesis.
In order to determine a role for COX-2 in endometrial epithelial cells, cDNA array
technology was employed to determine which genes were differentially regulated
between the COX-2 sense and the COX-2 antisense cells. Cathepsin D was identified
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as one of the differentially expressed genes. Cathepsin D mRNA and protein
expression were reduced in the COX-2 sense cells compared with the COX-2
antisense cells. In the endometrium, glandular expression of Cathpesin D is highest
during the secretory phase of the menstrual cycle and thought to be positively
controlled in part by progesterone (273, 274). These data suggests COX-2 may be
another regulatory factor of cathepsin D within the human endometrium.
Angiostatin is a potent anti-angiogenic factor and one of a number of endogenous
antiangiogenic factors; including endostatin and thrombospondin-1. Angiostatin is
proteolitically derived from plasminogen and contains the first 3 or 4 kringle
domains of plasminogen (277). Plasminogen is initially cleaved to plasmin which
can act in a pro-angiogenic manner to promote endothelial cell migration (292).
Further cleavage results in the formation of angiostatin which displays
antiangiogenic behaviour. Angiostatin inhibits vasodilation, proliferation and
migration of endothelial cells (277-280, 293). The mechanisms by which angiostatin
inhibits angiogenesis are not fully understood. By binding to the integrin avfi3
receptor, angiostatin inhibits plasmin mediated cell migration (294). Angiostatin has
also been shown to inhibit the phosphorylation of ERK1/2 by hepatocyte growth
factor (295). Other binding sites for angiostatin that have been identified include the
Fi-Fo ATP synthase expressed on endothelial cell surface and angiomotin (296,
297). There is also evidence that angiostatin can directly affect tumour cell function
by the down regulation of VEGF expression (298).
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Conditioned medium of human prostate carcinoma cells has been demonstrated to
cleave plasminogen to angiostatin by the actions of mature and pro-cathepsin D
(215). In our COX-2 overexpressing model, angiostatin accumulation in media was
elevated in the COX-2 antisense cell and abolished in the COX-2 sense cells relative
to Ishikawa wild type cells. Inhibition of cathepsin D with pepstatin A reduced
angiostatin generation in the media from COX-2 antisense cells. These data support a
role in part for cathepsin D in generating angiostatin.
Angiostatin was originally identified in the urine and serum of tumour baring mice.
Most studies to date have investigated angiostatin expression in pathological states.
Recently, the expression of angiostatin was identified in healthy gingiva by
immunohistochemistry (299). This gives rise to the suggestion that angiostatin is
endogenously produced in non tumour environments.
To date, no studies have investigated the expression of angiostatin within the normal
endometrium, however, thrombospondin-1 expression has been demonstrated and
shown to inhibit the migration of endothelial cells. Furthermore, the expression of
thrombospondin-1 was restricted to the secretory phase of the menstrual cycle and its
expression shown to be positively linked to progesterone (300). As discussed
previously, COX expression in the human endometrium is lower during the secretory
phase than the menstrual and proliferative phases of the menstrual cycle. Although
currently there is no evidence to support the idea, it is plausible that COX-2 may play
a role in the regulation of thrombospondin-1 expression in the endometrium.
Endostatin is the cleaved product from collagen XVIII (301). Inhibition of COX-2
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has been associated with up regulated expression of endostatin (282). Interestingly,
endostatin itself has been shown to inhibit the mRNA expression of growth factors
such as VEGF, NFk(3 and COX-2 and up regulate thrombospondin-1 (302). In
patients with endometrial cancer, the ratio of VEGF: endostatin was shown to be
elevated in late stages of the disease compared with disease free subjects (303).
Further circumstantial evidence of a role for COX-2 in the regulation of endostatin
comes from the observation that hypoxia which has been demonstrated to induce
COX-2 expression is associated with elevated VEGF expression and an inhibition of
endostatin generation (304, 305).
It is now well accepted that the promotion of an angiogenic environment is the result
of the balance in production of angiogenic and antiangiogenic factors (214). The
underlying molecular mechanisms in the control of endogenous formation of
antiangiogenic factors and their mechanisms of action have yet to be elucidated. It is
hypothesised that in gynaecological conditions associated with elevated COX-2
enzyme expression, vascular function may be promoted through overexpression of
angiogenic factors and reduced production of antiangiogenic factors such as
angiostatin. Furthermore, localised modulation of antiangiogenic factors including
angiostatin within the human endometrium may provide alternative therapies for
benign gynaecological conditions associated with aberrant vascular function. In a
murine model of endometriosis, transient overexpression of angiostatin, in the
peritoneum delivered by a replication-deficient adenovirus vector eradicated
established endometriosis (306).
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5.2 Conclusions and Future Studies
In conclusion, this thesis has demonstrated the temporal expression and signalling of
the prostaglandin E2 pathway in the normal human endometrium across the menstrual
cycle. PGE2, mPGES-1 and EP2/EP4 receptors have been localised to multiple cell
types in the human endometrium. Overexpression of COX-2 in an endometrial
epithelial cell line results in an induction of PGE2 and PGF2q; expression concomitant
with elevated EP2 and EP3 receptor expression. Furthermore, a possible autocrine
action of PGE2 on its EP receptor expression has been identified. COX-2 inhibits
cathepsin D via an unknown mechanism which contributes to an inhibition of the
formation of the antiangiogenic factor angiostatin. These data outline a novel
function of COX-2 in promoting a proangiogenic environment through the
suppression of production of antiangiogenic factors such as angiostatin. Thus in a
pathological state, enhanced expression of COX-2 may not only promote
angiogenesis via the upregulation of pro angiogenic factors as seen by other studies
(138, 168, 207, 209), but could augment this action by inhibiting the production of
endogenous antiangiogenic factors.
This thesis identified a novel function of COX-2 in maintaining a pro angiogenic
environment by inhibiting cathepsin D expression and subsequent production of the
antiangiogenic factor angiostatin. The mechanism and prostanoid receptors involved
in the regulation of cathepsin D by COX-2 have yet to be elucidated.
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As described in section 1.19, this thesis sought to explore the hypothesis that COX-2
and its products the prostaglandins play a role in endometrial vascular function.
PGE2 was localised to various cells of the human endometrium including endothelial
cells. Overexpression of COX-2 in endometrial epithelial cells resulted in reduced
angiostatin; an antiangiogenic factor, generation. An enhanced production of growth
factors such as VEGF has previously been reported in COX-2 overexpression
models. Interestingly, the expression of VEGF mRNA as investigated by microarray
technology was not upregulated by the overexpression COX-2 in Ishikawa cells, an
endometrial epithelial cell line. As discussed in section 4.3.7 it is plausible this is due
to the limitations of the technique. Further studies using alternative techniques such
as ELISA to examine VEGF protein expression are needed to investigate further the
role of COX-2 overexpression on VEGF and other pro angiogenic growth factor
expression in endometrial epithelial cells. As detailed in section 5.2.2, further studies
are also required to investigate the expression of angiostatin by the endometrium.
This thesis, however, identified a novel putative role for COX-2 and the
prostaglandins in promoting endometrial vascular function by reducing
antiangiogenic factor generation.
5.2.2 Future Studies
The profile of prostanoid receptors expressed in benign endometrial pathologies
compared with the normal endometrium has yet to be established. If aberrant
receptor expression in endometrial pathologies is confirmed, this will give an insight
into the receptors which contribute to endometrial pathology. Furthermore, selective
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inhibition of receptor activity may abolish the vascular dysfunction thought to be
associated with benign gynaecological conditions. Previous studies in our laboratory
have demonstrated the upregulation of EP and FP receptor expression and signalling
in endometrial and cervical carcinomas (60, 62, 187). These receptors have been
shown to induce the expression of the angiogenic factors VEGF in the female
reproductive tract (168). This has led to the suggestion that inhibition of specific
prostaglandin receptors could be a mode for therapy in gynaecological conditions.
EP receptor signalling has been demonstrated to play an important function in
colorectal carcinogenesis with the specific EP receptor activity varying according to
the stage of tumorigenesis. Furthermore, it is thought that inhibition of the EP
receptors may provide an important therapeutic role in colorectal cancer (307).
As described previously, there are a host of endogenous antiangiogenic factors
including angiostatin, endostatin and thrombospondin-1. The expression of these
factors in non pathological states has not been fully determined. The endometrium is
unusual in the fact it regularly undergoes angiogenesis. Characterisation of the
expression of antiangiogenic factors and the processes involved in the regulation of
their expression in the normal endometrium and the molecular pathways by which
antiangiogenic factors mediate their effects will provide deeper understanding of the
control of physiological angiogenesis.
Finally, characterisation of prostanoid receptor expression in benign gynaecological
conditions relative to the normal endometrium and their role in the control of pro
angiogenic and antiangiogenic factors would ultimately lead to the identification of
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novel targets for therapies. This would hopefully result in improved treatment for
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Expression, Localization, and Signaling of PGE2 and
EP2/EP4 Receptors in Human Nonpregnant
Endometrium across the Menstrual Cycle
STUART A. MILNE, GABRIELLE B. PERCHICK, SHEILA C. BODDY, and HENRY N. JABBOUR
Medical Research Council Human Reproductive Sciences Unit, Centre for Reproductive Biology, Edinburgh, United
Kingdom EH3 9ET
This study was designed to elucidate the sites of synthesis and
action of PGE2 in the nonpregnant human uterus across the
menstrual cycle. The sites of expression of PGE synthase and
synthesis of PGE2 were investigated by immunohistochemis-
try using full thickness uterine biopsies. Expression of PGE
synthase and synthesis of PGE2 were localized to glandular
epithelial and endothelial cells in both basalis and functio-
nalis regions of the human endometrium. By contrast, stromal
staining was predominantly localized in the functionalis
layer. Some cyclical variation in expression of PGE synthase
and PGE2 synthesis was observed, with reduced expression/
synthesis detected in the stromal compartment of the func¬
tionalis during the late secretory phase of the menstrual cycle.
Subsequently, we assessed the site of action of PGE2 by in¬
vestigating the expression of two PGE2 receptor isoforms,
namely EP2 and EP4. Cyclical variation in endometrial EP2
and EP4 receptor mRNA expression was quantified by Taq-
Man quantitative RT-PCR using RNA isolated from endome¬
trial tissue collected across the menstrual cycle. No differ¬
ences in EP2 receptor mRNA expression were detected;
however, EP4 receptor mRNA expression was significantly
higher in late proliferative stage (P < 0.05) than in early, mid,
and late secretory stage endometrium. Expression patterns of
EP2 and EP4 receptors were localized by nonradioactive in
situ hybridization using fluorescein isothiocyanate end-
labeled oligonucleotide probes. Expression of both receptors
was observed in endometrial glandular epithelial and vascu¬
lar cells, with no notable spatial or temporal variation. Fi¬
nally, signaling of EP2/EP4 receptors was assessed by inves¬
tigating cAMP generation in vitro after stimulation with
PGE2. Endometrial cAMP generation in response to PGE2 was
significantly greater in proliferative tissue compared with
early and midsecretory stage tissue (3.77 ± 0.85 vs. 1.96 ± 0.28
and 1.38 ± 0.23, respectively; P < 0.05). In conclusion, this
study demonstrates glandular and vascular coexpression of
PGE synthase, PGE2, EP2, and EP4 receptors and suggests an
autocrine/paracrine role for PGE2 in epithelial/endothelial
cell function in the human endometrium. (J Clin Endocrinol
Metab 86: 4453-4459, 2001)
PCs ARE part of the eicosanoid family and consist of fiveendogenous members, termed PGD2, PGE2/ PGF2(1,
prostacyclin, and thromboxane A2 (1). Initially in the PG
synthesis pathway, the enzyme cyclooxygenase (COX) gen¬
erates PGH2 from arachidonic acid. To date, there are two
identified isoforms of the COX enzyme, COX-1 and COX-2.
COX-1 is constitutively expressed in many tissues and cell
types and generates PG for normal physiological function. By
contrast, the expression of COX-2 is rapidly induced after the
stimulation of quiescent cells by growth factors and phorbol
esters (2). Once synthesized, PGH, serves as a substrate for
specific PG synthase enzymes (3-7). The PG synthase en¬
zymes are named according to the PG they produce, such
that PGE2 is generated by PGE synthase and PGF2„ by PGF
synthase. Once synthesized, PG mediate their actions via
seven-transmembrane G protein-coupled receptors. These G
protein-coupled receptors have been cloned in humans and
are denoted DP, EP, FP, IP, and TP according to their en¬
dogenous PG ligand (1, 8). Only the EP receptor has been
shown to possess diverse receptor subtypes, of which there
are now four members, termed EP1, EP2, EP3, and EP4. EP1
receptors activate phospholipase C and mobilization of the
inositol trisphosphate pathway, EP2 and EP4 receptors ac¬
tivate adenylate cyclase and the cAMP/protein kinase A
Abbreviations: COX, Cyclooxygenase; dNTP, deoxy-NTP; FITC, flu¬
orescein isothiocyanate; PG, prostaglandin.
pathway, whereas EP3 receptor activation can both inhibit
adenylate cyclase and activate phospholipase C (1).
Recent studies have demonstrated a role for COX enzymes
and PG in the regulation of epithelial cell growth and an-
giogenesis. COX-2 expression and PGE2 synthesis are asso¬
ciated with increased cellular proliferation and resistance to
apoptosis (9, 10). Moreover, expression of COX-2 and syn¬
thesis of PGE2 in epithelial cells enhance the expression of
angiogenic factors that act in a paracrine manner to induce
endothelial cell migration and microvascular tube formation
(11). COX-2 expression and PGE2 synthesis have also been
associated directly with endothelial cell function (12). Treat¬
ment of endothelial cells with selective COX-2 inhibitors has
been shown to reducemicrovascular tube formation, and this
effect is partially reversed by cotreatment with PGE2 (11,13).
In the human endometrium, COX-2 enzyme expression
and PGE2 synthesis have been associated with vascular func¬
tion. COX enzyme expression and PGE2 synthesis arc max¬
imal during the menstrual and proliferative phases and are
localized to epithelial and periv ascular cells (14-18). Further
evidence for a role for PGE2 in vascular function of the
endometrium can be deduced from observations in women
suffering from excessive blood loss at menstruation (mon¬
orrhagia). In this group of women, a positive relationship
between the volume of blood loss and PGE2 release in utero
has been reported (19).
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The aims of this study were to characterize the site of
synthesis and action of PGE2 in human endometrium across
the menstrual cycle. This was assessed by investigating the
cyclical changes in expression, localization, and functional
signaling of PGE synthase, PGE2, and two PGE receptors,
namely EP2 and EP4. The data from this study demonstrate
epithelial and endothelial expression/synthesis of PGE syn¬
thase, PGE2/ and EP2 and EP4 receptors in the human en¬
dometrium. Furthermore, cAMP production in response to
PGE2 is higher in proliferative phase than secretory phase
endometrium. These data strongly suggest a role for PGE2 in
uterine epithelial cell function and angiogenesis, possibly
through autocrine/paracrine signaling between endometrial
epithelial and endothelial cells.
Materials and Methods
Patients and tissue collection
Endometrial biopsies (n = 33) at different stages of the menstrual
cycle were collected with an endometrial suction curette (Pipelle, Labo-
ratoire CCD, Paris, France) from women with regular menstrual cycles
(25-35 d). In addition, full thickness endometrial biopsies (n = 18) at all
stages of the menstrual cycle (n = 3 from early, mid, and late prolifer¬
ative and n = 3 from early, mid, and late secretory) were collected from
women undergoing hysterectomy for benign gynecological indications.
Shortly after pipelle suction or hysterectomy, tissue was either snap-
frozen in dry ice and stored at — 70 C (for RNA extraction), fixed in
neutral buffered formalin, and wax embedded (for immunohistochem-
ical analyses) or placed in RPMI 1640 (containing 2 mmol/liter L-glu-
tamine, 100 U penicillin, and 100 /Ag/ml streptomycin) and transported
to the laboratory for in vitro culture. All subjects reported regular men¬
strual cycles (cycle length, 25-35 d), and no woman had received a
hormonal preparation in the 3 months preceding biopsy collection.
Biopsies were dated according to stated last menstrual period and were
confirmed by histological assessment according to criteria of Noyes and
co-workers (20). Furthermore, circulating E2 and progesterone concen¬
trations at the time of biopsy were consistent for both stated last men¬
strual period and histological assignment of menstrual cycle stage. Eth¬
ical approval was obtained from Lothian research ethics committee, and
written informed consent was obtained from all subjects before tissue
collection.
Immunohistochemistry
Endometrial sections (5 /am) from across the menstrual cycle (n = 18)
were dewaxed in xylene and rehydrated using decreasing grades of
ethanol. An antigen retrieval step of 5 min of pressure cooking in 0.01
m sodium citrate buffer, pH 6.0, was carried out for PGE synthase. After
rinsing in PBS, endogenous peroxidase activity was quenched with 3%
H2Oz in methanol. Nonimmune swine serum (10% serum in PBS) was
applied for 20 min before overnight incubation at 4 C with primary
antibody. An avidin-biotin peroxidase detection system was then ap¬
plied (DAKO Corp., High Wycombe, UK) with 3,3'-diaminobenzidine
as the chromagen. Sections were counterstained with Harris's hema¬
toxylin before mounting. Rabbit antihuman PGE synthase antibody
(Cayman Chemicals, Ann Arbor, MI) was used at a 1:250 dilution, and
rabbit anti-PCE2 antibody (supplied by Prof. R. W. Kelly, Medical Re¬
search Council Human Reproductive Sciences Unit, Edinburgh, UK)
was used at a dilution of 1:100. Preabsorption with PGE synthase-
blocking peptide (100 /Ag/ml: Cayman Chemicals) was the PGE synthase
negative control, and preabsorption with excess PGE2 was the PGE2
negative control. Both preabsorbed antibody preparations produced
negligible immunoreactivity. All treatments were carried out at room
temperature unless otherwise specified. The immunohistochemistry
was repeated for each antibody at least three times.
In situ hybridization
Custom synthesis oligonucleotide double fluorescein isothiocyanate
(FITC)-labeled cDNA probes for EP2 and EP4 receptor were obtained
from Biognostik (Cottingen, Germany). Sections (5 /am) were cut onto
gelatin-coated SuperFrost slides (BDH Laboratory Supplies, Poole, UK)
from full thickness human uterine biopsies collected across the men¬
strual cycle (n 18). Tissue was dewaxed in xylene and rehydrated
using increasing concentrations of ethanol before proteinase K treatment
(100 /Ag/ml in 100 mM Tris-HCl pH 7.6, containing 50 mM EDTA) for 15
min at 37 C to enhance cDNA probe access. After washing in diethyl-
pyrocarbonate-H20, hybridization mixture (25 /xl; supplied with probe)
was added to each section, and slides were incubated for 4 h at 30 C
before adding cDNA probe (6 U/ml hybridization mix) and incubating
overnight at 30 C. Posthybridization washes of 1 X SSC (standard saline
citrate) for 5 min (twice) and 0.1 x SSC at 39 C for 15 min (twice) were
completed before detecting the FITC-labeled probe using standard im-
munohistochemical reagents (TSA Biotin System, NEN Life Science
Products, Hounslow, UK). Endogenous peroxidase activity was first
blocked with 3% H202 in methanol for 30 min before incubating sections
with blocking buffer for 30 min. Conjugated anti-FITC-horseradish per¬
oxidase (Roche Molecular Biochemicals, Mannheim, Germany) was
added in blocking buffer, and the sections were incubated for 60 min.
After washing, biotinyl tyramide amplification reagent was applied to
each slide and incubated for 15 min. Streptavidin-horseradish peroxi¬
dase was applied after washing and incubated for 30 min, and probe
localization was visualized with 3,3'-diaminobenzidine. Control oligo¬
nucleotide double FITC-labeled cDNA probes containing the same pro¬
portion of cysteine (C) and guanine (G) bases as the EP2 and EP4 receptor
probes were included to assess background hybridization. All treat¬
ments were carried out at room temperature unless otherwise specified.
Taqman quantitative RT-PCR
Endometrial RNA samples were extracted from endometrial biopsies
(n = 33) using Tri-Reagent (Sigma, Poole, UK) following the manufac¬
turer's guidelines. Once extracted and quantified, RNA samples were
reverse transcribed using MgCl2 (5.5 mM), deoxy (d)-NTPs (0.5 mM
each), random hexamers (2.5 /xm), ribonuclease inhibitor (0.4 U//a1), and
multiscribe reverse transcriptase (1.25 U//a1; all from Applied Biosys-
tems, Warrington, UK). The mix was aliquoted into individual tubes (16
/xl/tube), and template RNA was added (4 /xl/tube of 100 ng//xl RNA).
Aftermixing by brief centrifugation, samples were incubated for 90 min
at 25 C, 45 min at 48 C, and 5 min at 95 C. Thereafter, cDNA samples
were stored at -20 C. A tube with no reverse transcriptase was included
to control for any DNA contamination.
To measure cDNA expression, a reaction mix was prepared containing
TaqMan buffer (5.5 mM MgCl2,200 /am dATP, 200 /am dCTP, 200 /am dGTP,
and 400 /am dUTP), ribosomal 18S forward and reverse primers and probe
(all at 50 nM), forward and reverse primers for EP receptor (300 nM), EP
receptor probe (100 nM), AmpErase UNG (0.01 U//a1), and AmpliTaq Gold
DNA Polymerase (0.025 U//d; all from Applied Biosystems). After mixing,
48 /a1 were aliquoted into separate tubes, and 2 /a1 /replicate (40 ng) cDNA
were added and mixed before placing duplicate 24-/a1 samples into a PGR
plate. A no template control (containing water) was included in triplicate.
Wells were sealed with optical caps, and the PGR reaction was carried out
using an ABI Prism 7700 (Applied Biosystems). EP receptor primers and
probe for quantitative PGR were designed using the PRIMER express
program (Applied Biosystems). The sequences of the EP2 receptor primers
and probe were: forward, 5'-GAC CGC TTA CCT GCA GCT GTA C-3';
reverse, 5'-TGA AGT TGC AGG CGA GCA-3'; and probe (6-carboxy fluo-
roscein labeled), 5'-CCA CCC TGC TGC TGC TTC TCA TTG TCT-3'. The
sequences of the EP4 receptor primers and probe were: forward, 5'-ACG
CCG CCT ACT CCT ACA TG-3'; reverse, 5'-AGA GGA CGG TGG CGA
GAA T-3'; and probe (6-carboxy fluorescein labeled), 5'-ACG CGG GCT
TCA GCT CCT TCC T-3'. The ribosomal 18S primers and probe sequences
were: forward, 5'-CGG CTA CCA CAT CCA AGG AA-3'; reverse, 5'-GCT
GGA ATT ACC GCG GCT-3'; and probe (VIC labeled), 5'-TGC TGG CAC
CAG ACT TGC CCT C-3'. Data were analyzed and processed using Se¬
quence Detector version 1.6.3 (Applied Biosystems) as instructed by the
manufacturer. Briefly, the software calculates the reaction cycle number at
which fluorescence reaches a determined level for both 18S control and
EP2/EP4 receptor. This is the relative abundance for EP2/EP4 receptor, and
by comparing this to an internal positive control, relative expression can be
determined. Results are expressed as relative expression to an internal
positive standard included in all reactions.
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Whole tissue cAMP assay
Endometrial biopsies from all stages of the menstrual cycle (n = 18;
n = 6 from proliferative, early, and midsecretory phases) were minced
finely with scissors and incubated in 2 ml RPMI (Sigma) medium con¬
taining 10% FCS, 2 mmol/liter L-glutamine, 100 IU penicillin, 100 pg
streptomycin, and 3 pg/ml indomethacin for 1.5 h at 37 C in a humid¬
ified 5% C02 incubator. Tissue specimens were incubated in the same
medium containing isobutylmethylxanthine (Sigma) to a final concen¬
tration of 1 mM for 30 min at 37 C before adding 300 nM PGE2. Control
tissue was treated similarly, but received no PGE2. Tissue was harvested
by centrifugation at 2000 X g, the supernatant was discarded, and the
tissue was homogenized in 0.1 M HC1. The cAMP concentration was
quantified by ELISA using cAMP kits (Biomol, Affiniti, Exeter, UK) and
was normalized to protein concentration of the homogenate. Protein
concentrations were determined using protein assay kits (Bio-Rad Lab¬
oratories, Inc., Hemel Hempsted, UK). Data are presented as the fold
induction of cAMP after treatment with PGE2, where fold induction was
calculated relative to the control samples.
Statistics
Where appropriate, data were subjected to statistical analysis with
ANOVA and Fisher's protected least significant difference tests (Stat-
View 4.0, Abacus Concepts, Inc., Berkeley, CA), and statistical signifi¬
cance was accepted at P < 0.05.
Results
Spatial localization of PGE synthase in full thickness en¬
dometrial biopsies demonstrated marked differences in PGE
synthase expression between distinct uterine regions (Fig. 1,
a-f). In the functionalis layer, PGE synthase immunoreac-
tivity was expressed in glandular epithelial, stromal, and
endothelial cells (Fig. 1, b-e). Temporally, within the func¬
tionalis layer PGE synthase immunoreactivity only varied in
the late secretory phase, where reduced staining of stromal
cells was observed (Fig. le). Compared with the functionalis
region, little stromal staining for PGE synthase was detected
in the basalis compartment throughout the menstrual cycle;
however, comparable immunoreactivity for PGE synthase
was observed in epithelial and endothelial cells of this region
(Fig. la). In the myometrial region, only endothelial cells
were immunopositive for PGE synthase (Fig. If, inset). When
viewed as a cross-section, PGE synthase was expressed in all
epithelial and endothelial cells throughout the uterus, but
stromal cell immunoreactivity diminished from strong stain¬
ing in the functionalis layer to minimal immunoreactivity in
the myometrial fibroblasts (Fig. If).
Within cells, particularly functionalis stromal cells, PGE
synthase immunoreactivity was predominantly cytoplasmic,
with strong perinuclear localization (Fig. 1, b and c). Peri¬
nuclear PGE synthase expression was consistent with the
literature, where the majority of PGE synthase activity elutes
in the nuclear membrane fraction (21).
Spatial and temporal syntheses of PGE2 in the uterus were
assessed by immunohistochemistry. In the functionalis layer,
PGE2 synthesis was detected in epithelial, stromal, and en¬
dothelial cells (Fig. 2, b-f), with less apparent stromal cell
immunoreactivity in late secretory tissue (Fig. 2e). As ob¬
served with PGE synthase expression, PGE2 synthesis in the
basalis region was minimal in the stromal compartment,
whereas epithelial and endothelial immunoreactivities were
unchanged. Full thickness endometrial biopsies clearly dem¬
onstrated the gradient in PGE2 synthesis from strong im-
Fic. 1. Immunohistochemical localization of PGE synthase in the
basalis and functionalis regions of the human endometrium. Lower
PGE synthase immunoreactivity was detected in the stromal com¬
partment of the basalis than in the functionalis region (a and b are
the basalis and functionalis regions, respectively, of endometrial tis¬
sue collected during the midproliferative phase). In the functionalis
region, PGE synthase immunoreactivity was detected at all stages of
the menstrual cycle and was localized to glandular epithelial (G),
stromal, and endothelial (denoted by arrows) cells (c, late prolifera¬
tive; d, early secretory; e, late secretory). Inset in e, A section that was
stained with preadsorbed PGE synthase antibody (negative control),
f. Full thickness uterine tissue, collected during the late proliferative
phase, demonstrating spatial changes in PGE synthase immunore¬
activity between basalis and functionalis regions of the endometrium
and the myometrium. Inset in f, Endothelial cell PGE synthase im¬
munoreactivity within the myometrial compartment. Scale bars:
e and inset, 100 jam; f, 500 pm.
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Fig. 2. Immunohistochemical localization ofPGE2 in the basalis and
functionalis regions of the human endometrium. Lower PGE2 immu-
noreactivity was detected in the stromal compartment of the basalis
than in the functionalis region (a and b are basalis and functionalis
regions, respectively, of endometrial tissue collected during the mid-
proliferative phase). In the functionalis region, PGE2 immunoreac-
tivity was detected at all stages of the menstrual cycle and was
localized to glandular epithelial (G), stromal, and endothelial (denot¬
ed by arrows) cells (c, late proliferative; d, early secretory; e, late
secretory). Inset in e, Section that was stained with preadsorbed PGE2
antibody (negative control), f, Full thickness uterine tissue, collected
during the late proliferative phase, demonstrating spatial changes in
PGE2 immunoreactivity between basalis and functionalis regions of
the endometrium and the myometrium. Inset in f, Endothelial cell
PGE2 immunoreactivity within the myometrial compartment. Scale
bars', e and inset, 100 pm; f, 500 pm.
munoreactivity in cells of the functionalis layer to weak stain¬
ing in the myometrium, where no fibroblast PGE2 synthesis
was observed. In the myometrium, similar to PGE synthase
expression, PGE2 synthesis was detected only in endothelial
cells (Fig. 2F, mset).
Quantitation of EP2 receptor mRNA expression in endo¬
metrial biopsies demonstrated no significant change in ex¬
pression across the menstrual cycle (Fig. 3a). EP4 receptor
mRNA expression, in contrast, was significantly higher (P <
0.05) in late proliferative biopsies (0.162 ± 0.034; n = 5) than
in early (0.075 ± 0.024; n = 7), mid (0.063 ± 0.014; n = 6), and
late (0.07 ± 0.033; n = 6) secretory phase samples (Fig. 3b).
It is noteworthy that receptor expression in these experi¬
ments was investigated in a heterogeneous population of
uterine cells, and it is conceivable that variation in receptor
expression across the menstrual cycle may be different in
specific target cells.
The site of action of PGE2 was investigated by conducting
in situ hybridization for EP2 and EP4 receptors. The expres¬
sion of both receptors was localized in the epithelial and
vascular regions of human endometrium (Fig. 4, a-h). Fur¬
thermore, epithelial and vascular EP2 and EP4 receptor ex¬
pression was present at all stages of the menstrual cycle in
both the basalis and functionalis regions of the endometrium.
Vascular EP2 and EP4 receptor mRNA expression was lo¬
calized in both endothelial (Fig. 4, a and c, for EP2; Fig. 4, b
and d, for EP4) and perivascular cells throughout the endo¬
metrium (Fig. 4g for EP2; Fig. 4h for EP4).




LP B MS LS





Stage of the menstrual cycle
Fig. 3. Quantitative RT-PCR demonstrating relative expression of
EP2 (a) and EP4 (b) receptors in midproliferative (MP; n = 9), late
proliferative (LP; n = 5), early secretory (ES; n = 7), midsecretory
(MS; n = 6), and late secretory (LS; n = 6) endometrial biopsies.
Results are expressed as the mean ± sem of relativemRNAexpression
levels. Different letters denote statistical difference (P < 0.05).
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Fig. 4. In situ hybridization of EP2 (a,
c, e, and g) and EP4 (b, d, f, and h)
receptors in the human endometrium.
EP2 and EP4 receptor expressions were
localized to the glandular (G), stromal,
and vascular (V) compartments of the
human endometrium during the prolif¬
erative (a-d) and secretory (e-h)
phases of the menstrual cycle. Insets in





cAMP generation in response to exogenous treatment with
PGE2 was assessed in endometrial biopsy specimens col¬
lected across the menstrual cycle. cAMP generation in pro¬
liferative tissue was significantly higher (3.77 ± 0.85-fold;
n = 6; P < 0.05) than that detected in early secretory (1.96 ±
0.28-fold; n = 6) or midsecretory (1.38 ± 0.23-fold; n = 6)
tissue (Fig. 5).
Discussion
The data presented in this manuscript demonstrate the
expression and localization of PGE synthase and its product,
PGE2, in stromal, epithelial, and endothelial cells of the hu¬
man endometrium across the menstrual cycle. PGE synthase
expression and PGE2 synthesis were detected at all stages of
the menstrual cycle, with apparent reduced expression/syn¬
thesis during the late secretory phase. This is in agreement
with previous studies, which have localized COX expression
in epithelial and perivascular cells of the human endome¬
trium (14, 16-18). Moreover, culture studies have demon¬
strated that both epithelial and stromal cells can synthesize
PGE2 in vitro (22) and that the PGE2 biosynthetic capacity of
the endometrium is reduced in the late secretory phase (23).
The sites of action of PGE2 were elucidated using in situ
hybridization studies for two receptor subtypes, namely EP2
and EP4. EP2 and EP4 receptor expression was localized in
epithelial and vascular cells of human endometrium. These
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PROL ES MS
Stage of the menstrual cycle
Fig. 5. Fold induction of cAMP production in endometrial biopsies
collected from proliferative (PROL; n = 6), early secretory (ES; n =
6), and midsecretory (MS; n = 6) stages of the menstrual cycle after
stimulation with 300 nM PGE2. Results are expressed as the mean £
sem fold cAMP induction. Different letters denote statistical difference
(P < 0.05).
data indicate that PGE2 acts in an autocrine/paracrine man¬
ner within multiple cellular compartments of the human
endometrium.
In premenopausal women, the human endometrium un¬
dergoes phases of proliferation and apoptosis during suc¬
cessive menstrual cycles. These phases are observed pre¬
dominantly in the functionalis layer of the endometrium,
which is shed atmenstruation before regenerating during the
proliferative phase of the subsequent menstrual cycle. Inter¬
estingly, stromal expression of PGE synthase and synthesis
of PGE2 are predominantly localized in the functionalis layer
of the endometrium and are minimal in the basalis and
myometrial regions. The exact role of PGE2 in the human
endometrium is not fully elucidated, but previous studies
suggest a crucial role for PGE2 in cellular mitogenesis and
survival. In colon epithelial cells, overexpression of COX-2
and enhanced synthesis of PGE2 have been shown to pro¬
mote the proliferation and survival of cells through inhibi¬
tion of apoptosis (9, 10). The latter effect is mediated via
up-regulated expression of antiapoptotic genes such as bcl-2
(10). It is plausible that in the human endometrium, PGE2
may be activating similar mechanisms that promote glan¬
dular epithelial cell proliferation and/or survival. This is
supported by recent data confirming higher expression of
bcl-2 in the proliferative compared with secretory phase en¬
dometrium and its localization to glandular epithelial cells
(24-26). PGE2 function in glandular epithelial cells may also
be associated with the regulation of uterine angiogenesis.
Overexpression of COX-2 and increased production of PGE2
in epithelial cells have been associated with the expression of
angiogenic factors, such as vascular endothelial growth fac¬
tor, which, in turn, act in a paracrine manner to induce
endothelial cell migration and microvascular tube formation
(11). In the human endometrium, vascular endothelial
growth factor expression is localized to the glandular epi¬
thelial cells throughout the menstrual cycle (27, 28), and
PGE2 has been shown previously to up-regulate the expres¬
sion of vascular endothelial growth factor in a number of
different cell types via cAMP (29-32).
Expression of EP2/EP4 receptors in perivascular and en¬
dothelial cells suggests a possible role for PGE2 in vascular
function and angiogenesis in the human endometrium. PGE2
induces vasodilatation via perivascular EP2/EP4 receptors
(1), whereas activation of EP receptors on endothelial cells
may regulate angiogenesis. Endometrial angiogenesis takes
place throughout the menstrual cycle, as measured by en¬
dothelial cell proliferation, with a significantly elevated en¬
dothelial cell proliferative index in the functionalis compared
with the basalis phase (33). Recently, COX-2 and PGE2 have
been linked directly with endothelial cell function and an¬
giogenesis (12). Treatment of endothelial cells with selective
COX-2 inhibitors has been shown to reduce microvascular
tube formation, and this effect is partially reversed by co-
treatment with PGE2 (13). Hence, it is feasible that in vivo
angiogenesis in the endometrium may be regulated by PGE2
via an epithelial-endothelial and an endothelial-endothelial
cell interaction. This is supported by the data presented in
this study, which localized the site of expression of PGE
synthase, PGE2, and EP2/EP4 receptors to epithelial and
endothelial cells of the endometrium.
Measuring cAMP generation in human endometrium after
treatment with PGE2 assessed functional signaling of EP2/
EP4 receptors. A significantly higher cAMP generation was
observed in proliferative compared with secretory endome¬
trium. This enhanced signaling is associated with greater
expression of EP4 receptors in the proliferative phase. The
increased cAMP generation observed during the prolifera¬
tive phase may mediate the mitogenic effect of PGE2 on
glandular epithelial and endothelial cells. PGE2 has been
shown previously to induce epithelial cell proliferation via
the cAMP/protein kinase A pathway (34).
Further evidence of a role for PGE2 in uterine vascular
function can be derived from studies of menorrhagia. Non¬
steroidal antiinflammatory drugs, which inhibit PG synthe¬
sis, are the treatment of choice to alleviate excessive blood
loss in women reporting menorrhagia (35). Interestingly,
increased binding of PGE2, suggesting increased receptor
expression, has been observed in the uteri of patients re¬
ported to suffer from menorrhagia (36). Moreover, treatment
with fenamates (nonsteroidal antiinflammatory drugs) to re¬
duce menstrual blood loss also reduces PGE2-binding sites
within the uterus (37). Together these data indicate an in vivo
relationship between EP receptor expression and menstrual
blood loss.
In conclusion, the data presented herein confirm the ex¬
pression of PGE synthase, PGE2, and functional EP2 and EP4
receptors in epithelial and endothelial cells of human endo¬
metrium. In addition, we observed increased EP4 receptor
and PGE2-induced cAMP production in proliferative phase
tissue. We hypothesize that PGE2 is an integral modulator of
cell proliferation and/or differentiation within the endome¬
trium and acts as an autocrine/paracrine factor between
epithelial and endothelial cells.
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Cyclooxygenase-2 Overexpression Inhibits Cathepsin
D-Mediated Cleavage of Plasminogen to the Potent
Antiangiogenic Factor Angiostatin
GABRIELLE B. PERCKICK AND HENRY N. JABBOUR
Medical Research Council Human Reproductive Sciences Unit, Centre for Reproductive Biology, The University of
Edinburgh Academic Centre, Chancellor's Building, Edinburgh, Scotland EH16 4SB, United Kingdom
Overexpression of cyclooxygenase (COX)-2 and enhanced syn¬
thesis of prostaglandin E2 (PGE2) have been implicated in
human endometrial pathologies. To investigate the molecular
role ofCOX-2, the Ishikawa human endometrial epithelial cell
line was stably transfected with the pIKES2 vector containing
COX-2 cDNA in either the sense or antisense directions. PGE2
concentrations were significantly elevated in the cells trans¬
fected with the COX-2 sense compared with wild-type cells or
cells transfected with the antisense cDNA (P < 0.01). Elevated
PGE2 synthesis was associated with enhanced expression
and signaling of PGE2 receptors (EP). cDNA array analysis
revealed differential expression of cathepsin D between the
COX-2 sense and antisense cells. Cathepsin D RNA and protein
expression was 6.7- and 2.1-fold lower in the COX-2 sense com¬
pared with COX-2 antisense cells respectively. Cathepsin I) is
known to cleave plasminogen to the potent antiangiogenic
factor angiostatin. To investigate differential angiostatin gen¬
eration, conditioned media from COX-2 sense, COX-2 anti-
sense and wild-type cells were incubated with plasminogen
and subsequently subjected to Western blot analysis. In
comparison to wild-type cells, the cleavage of plasminogen to
angiostatin was abolished when incubated in COX-2 sense
cells conditioned media and elevated when incubated in
COX-2 antisense cells conditioned media. Coincubation of
plasminogen with the cathepsin O inhibitor pepstatin A in¬
hibited the cleavage of plasminogen to angiostatin in the
COX-2 antisense conditioned media. These data demonstrate
that COX-2 exerts a negative feedback on the expression of
cathepsin D. This in turn reduces the generation of the anti¬
angiogenic factor angiostatin, hence promoting a proangio-
genic environment. (Endocrinology 144: 5322-5328, 2003)
TWO PREDOMINANT ISOFORMS of the cyclooxygen¬ase (COX) enzymes have been identified (COX-1 and
COX-2). COX-1 is constitutively expressed in many cell types
and has been shown recently to be inducible in certain can¬
cers (1-4). COX-2 is the readily inducible form of the enzyme
and is commonly associated with several pathological con¬
ditions including tumorigenesis (5, 6). The COX enzymes
catalyze the rate-limiting step in the biosynthetic pathway of
prostanoids. There are five endogenous prostanoids PGD2,
PGE2, PGF2,„ prostacyclin (PGI2) and thromboxane A2 (7).
Arachidonic acid, once released from the membrane phos¬
pholipids is converted to the prostanoid intermediate PGH2
by the COX enzymes. PGH2 acts as a substrate for synthases
specific to each prostanoid such as PGE synthase (PGES) for
PGE2 (8, 9). Once synthesized, PGE2 elicits its effects via its
seven frans-membrane G protein-coupled receptors, of
which four have been identified (EP1, EP2, EP3, and EP4).
These receptors signal via alternate and in some cases op¬
posing signaling pathways (7, 10). EP1 receptor activation
leads to elevated inositol-3-phosphate and Ca21 levels, ac¬
tivation of both EP2 and EP4 results in increased intracellular
cAMP levels and depending on the splice variant, EP3 ac¬
tivation either decreases or increases cAMP levels (7).
Numerous studies have demonstrated that overexpres¬
sion of COX-2 in epithelial cells is associated with enhanced
production of angiogenic factors (11,12). These factors act in
a paracrine manner to promote endothelial cell migration
Abbreviations: COX, Cyclooxygenase; EP, PGE2 receptor; PGE, pros¬
taglandin E; PGR, prostacyclin; PGES, PGE synthesis.
and microvascular tube formation (12). In the female repro¬
ductive tract, a role for COX enzymes and PGE2 in normal
and pathological angiogenesis has been proposed. In the
human endometrium expression/synthesis and signaling of
COX-2, PGE2, and EP receptors colocalize in glandular ep¬
ithelial and endothelial cells of the normal and neoplastic
endometrium (13-19). Moreover, overexpression of COX en¬
zymes in epithelial cells of the reproductive tract has been
shown to promote the expression of various angiogenic fac¬
tors (4).
A role for COX enzymes has also been proposed in benign
pathologies of the endometrium such as endometriosis, dys¬
menorrhea, and heavy menses (20-26). Furthermore, several
studies have associated heavy menses with abnormalities in
vasodilatatory prostanoid production such as PGE2 from the
uterus (20-22). PGE2 synthesis and PGE2 binding sites in
uterine tissues are greater in women diagnosed with heavy
menses compared with women with normal blood loss (18,
21, 27-29). The elevated prostanoids detected in menstrual
flow of patients with heavy menses has lead to the admin¬
istration of COX enzyme inhibitors as a means of therapy
(30). COX enzyme inhibitors such as ibuprofen have been
shown to reduce menstrual blood loss (31). This suggests that
the degree or duration of menstrual bleeding in women
diagnosed with menorrhagia is augmented following eleva¬
tion of vasodilatatory factors by COX enzyme products.
This study was designed to investigate the potential role
of COX-2 in regulating endometrial epithelial cell function.
The specific aims of the study were to examine the effect of
5322
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COX-2 overexpression in an endometrial epithelial cell line
(Ishikawa) on PGE2 secretion, EP receptor expression and
signaling and to identify genes regulated by COX-2 that may
be associated with endometrial function and angiogenesis.
Materials and Methods
Cell culture
Ishikawa wild-type, COX-2 sense, and COX-2 antisense cells were
routinely maintained in DMEM nutrient mixture F-12 with glutamax-1
and pyridoxine, supplemented with 10% fetal bovine serum and 1%
antibiotics (500 U/ml penicillin and 500 /Ag/ml streptomycin) at 37 C
and 5% C02 (vol/vol). In addition, COX-2 sense and COX-2 antisense
cells were maintained in media containing 800 /ag/ml G418 (Calbio-
chem, Nottingham, UK).
Transfectioti of cells
The pBS(SK-)PSHl containing the full-length COX-2 cDNA (kindly
supplied by Dr. Stephen Prescott, University of Utah, Salt LakeCity, UT)
was used as the template plasmid. The COX-2 cDNA was excised from
the template plasmid and ligated at the EcoRl site of the pIRES2 vector
(CLONTECH, Hampshire, UK). The orientation of the COX-2 cDNA
insert was determined by dideoxy DNA sequencing using sequence
specific primers for pIRES2. Wild-type Ishikawa cells were plated in a
12-well plate at a density of 1.2 X 10"" cells per well and left to attach
overnight. The following day, the plRES2 vector containing the COX-2
cDNA in either the sense or antisense directions was transfected into the
Ishikawa endometrial epithelial cell line using pfx-5 (Invitrogen, Paisley,
Scotland, UK) diluted in Optimem (Life Technologies, Inc., Paisley,
Scotland, UK). Following a 4-h incubation at 37C, 5% C02 (vol/vol), the
transfection mixture was replaced with fresh complete media. The trans¬
fected cells were allowed to grow for 24 h and then seeded with wild-
type cells and selected using G418 (Calbiochem; at a concentration of 800
/LAg/ml). A total of 120 colonies with the COX-2 sense cDNA and 60
colonies with the COX-2 antisense cDNA were picked using cloning
rings. The clones were screened for COX-2 protein expression using
Western blot analysis. Initial experiments were performed on four
COX-2 sense and two COX-2 antisense clones. All of the COX-2 sense
clones generated significantly higher PGE2 into the culture media com¬
pared with COX-2 antisense and wild type. The data presented in the
manuscript and all further investigations were performed using the
COX-2 sense 72 clone and COX-2 antisense 15 clone as these generated
the highest and lowest levels of PGE2, respectively.
Protein extraction and Western blot analysis
Ishikawa wild-type, COX-2 sense, and COX-2 antisense cells were
seeded at a density of 7.5 X 105 cells in six-well plates, allowed to attach
for 24 h in complete media and then cultured in serum free media
overnight (n 4 independent experiments). Subsequently, cells were
lysed on the plates for 20 min with the lysis buffer [150 mM NaCl, 50 mM
Tris-HCl (pH 7.4), 10 mM EDTA, 0.6% Nonidet P-40,1 mM Na3V04,10%
glycerol, 10 /Ag/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride].
The lysates were clarified by centrifugation and the supernatants col¬
lected. Protein concentration was determined by the modified Lowry
method (Bio-Rad D2 Protein Assay kit, Bio-Rad Laboratories, Hemel
Hempstead, UK). A total of 20-/Ag protein for cathepsin D expression and
40 /LAg protein for COX-2, COX-1, and /3-actin, expression were denatured
and subjected to SDS-PAGE on 4-12% Tris-glycine gels (Invitrogen). The
proteins were transferred onto polyvinylidene difluoride membrane
and blocked for 1 h in TBS-Tween [50 mM Tris-HCl, 150 mM NaCl, and
0.05% (vol/vol) Tween 20 containing 5% skimmed milk powder]. The
membranes were probed with one of the following antibodies: COX-2
(sc-1745; at dilution of 1:1000), COX-1 (sc-1752; at dilution of 1:500),
/3-actin (sc-1616; at dilution of 1:1000), cathepsin D (sc-6486; at dilution
of 1:2000) or plasminogen (sc-15034; at dilution of 1:500) overnight
followed by rabbit antigoat conjugated to alkaline phosphatase second¬
ary antibody at a dilution of 1:30,000 (Sigma, Poole, UK). The specificity
of some of the antibodies has been confirmed previously in our labo¬
ratory by preadsorbtion of the antibodies to the respective blocking
peptides (4). All the primary antibodies were purchased from Santa Cruz
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Biotechnology (Autogenbioiclear, Whiltshire, UK). The membranes
were developed and revealed by Phosphorlmager analysis using the
ECF chemifluorescence system according to the manufacturer's instruc¬
tions (Amersham Biosciences UK Ltd., Little Chalfont, UK). The mo¬
lecular weights of the proteins were determined by comparing mobility
on the gel with a molecular weight standard (Invitrogen). Protein bands
were semiquantified by densitometry using STORM 860 system (Mo¬
lecular Dynamics, Amersham Biosciences, Buckinghamshire, UK). Rel¬
ative expression of cathepsin D protein was calculated by normalizing
with /3-actin and expressed as mean ± sem.
PGE2 assay
Ishikawa wild-type, GOX-2 sense, and COX-2 antisense cells were
seeded in six-well plates at a cell density of 3.5 X 105 cells per well,
allowed to attach for 24 h in complete media and then cultured in serum
free media overnight (n = 4 independent experiments). The cells were
incubated for a further 48 h in serum-free media containing 5 /Ag/ml
arachidonic acid in the presence or absence of 10 /am NS398 (Calbiochem,
Nottingham, UK). PGE2 secretion in the culture media was assayed
using an EL1SA as described by Denison et al. (32). The data are pre¬
sented as mean ± sem. The intra- and interassay coefficients of variation
were 7.8% and 15.0%, respectively, with an assay detection limit of 10
Pg/ml.
Taqman quantitative RT-PCR
To determine the effect of COX-2 on EP receptor expression, wild-
type, COX-2 sense, and COX-2 antisense cells were seeded at a density
of 5 X 103 in six-well plates, allowed to attach for 24 h in complete media
and then cultured in serum-free media overnight (n = 3 independent
experiments). These experiments were conducted in the absence of
NS398 as recent data suggest that this inhibitor up-regulates the ex¬
pression of EP receptors (33). Thereafter RNA was extracted using Tri
Reagent (Sigma) following the manufacturer's instructions. RNA sam¬
ples were quantified and reverse transcribed using 5.5 mM MgCl2, 0.5
mm each deoxynucleotide triphosphates, 2.5 /am random hexamers, 0.4
U/ml ribonuclease inhibitor, and 1.25 U/ml Multiscribe reverse tran¬
scriptase (all from PE Applied Biosystems, Warrington, UK). A total of
400 ng template RNA was added to RT mix and incubated for 60 min
at 25 C, 45 min at 48 C, and 5 min at 95 C. The PCR mix consisted of 1 X
Universal PCR Mastermix, forward and reverse primers for either EP1,
EP2, EP3, or EP4 (300 nM) and EP1, EP2, EP3, or EP4 probe (200 iim) and
ribosomal 18S forward primer, reverse primer and probe (50 nM; all from
PE Applied Biosystems, Warrington, UK). For PCR, 48 /a1 of PCR mix
was mixed with 2 /a1 cDNA and subsequently a volume of 24 /a1 of this
mixture was placed in duplicate into wells on a PCR plate along with
a no template control. The wells were sealed using optical lids and the
PCR was carried out using an ABI Prism 7700 (PE Applied Biosystems).
The primers for the EP receptors and 18S were designed using PRIMER
express software (PE Applied Biosystems) and the sequences are pre¬
sented in Table 1. 18S rRNA was used as an internal standard to nor¬
malize the samples for RNA loading. Results were expressed relative to
a positive standard (cDNA obtained from a single sample of endometrial
tissue) run in each PCR. Relative EP receptor expression was calculated
by dividing EP receptor expression in the COX-2 sense and COX-2
antisense cells by expression detected in wild type. Data are presented
as mean ± sem.
cAMP turnover
lshiwawa wild-type, COX-2 sense, and COX-2 antisense cells were
seeded in six-well plates at a cell density of 2 x 105 cells per well, allowed
to attach for 24 h in complete media and then cultured in serum free
media overnight (n 4 independent experiments). The media was then
replaced with fresh serum free media containing 1 mm l-methyl-3-
isobutylxanthine (Sigma) for 1.5 h. Cells were stimulated with 0 or 100
nM PGE2 for 10 min. The media was removed and the cells were lysed
using 0.1 m HC1. cAMP generation was quantified using a cAMP ELISA
kit (Biomol, Affiniti, Exeter, UK) according to the manufacturer's in¬
structions and normalized to protein concentrations of the homogenate.
Protein concentrations were determined using protein assay kits (Bio-
Rad Laboratories). The data are presented as the mean (±sem), fold
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TABLE 1. Oligonucleotide sequences for the various EP receptor primers and probes
Gene Primers and probe
EP1 Eorward primer 5' -aga tgg tgg gcc agc ttg t- 3'
Reverse primer 5'-gcc acc aac acc agc att g- 3'
FAM linked probe 5' -cag cag atg cac gac acc acc atg-3'
EP2 Forward primer 5' -gac cgc tta cct gca gct gta- 3'
Reverse primer 5' -tga agt tgc agg cga gca--3'
FAM linked probe 5' - cca ccc tgc tgc tgc ttc tca ttg tct
EP3 Forward primer 5'-gac ggc cat tca gct tat gg- 3'
Reverse primer 5' -ttg aag atc att ttc aac atc att atc
FAM linked probe 5' -ctg tcg gtc tgc tgg tct ccg ctc-3'
EP4 Forward primer 5' -acg ccg cct act cct aca tg- 3'
Reverse primer 5' -aga gga cgg tgg cga gaa t- 3'
FAM linked probe 5'-acg cgg gct tca gct cct tcc t-3'
18S Forward primer 5' -cgg cta cca cat cca agg aa- 3'
Reverse primer 5'-gct gga att acc gcg gct--3'
VIC linked probe 5'-tgc tgg cac cag act tgc cct c-3'
induction of cAMP in COX-2 sense and antisense cells after treatment
with PGE2 where fold induction was calculated relative to the wild-type
samples. The intra- and interassay coefficients of variation were 8.3%
and 11.6%, respectively.
cDNA array analysis
Differential gene expression in the COX-2 sense and antisense cells
was assessed using cDNA array analysis. COX-2 sense and COX-2
antisense cells were grown to approximately 70% confluency in com¬
plete media. The cells were cultured in serum free media overnight and
then harvested by trypsinization for 5 min. The cells were resuspended
in PBS, pelleted by centrifugation, snap frozen on dry ice, and stored at
— 70 C. The cell pellets were sent to CLONTECH Laboratories Inc. (Palo
Alto, CA) for custom cDNA array analysis using the Atlas plastic human
8K gene Microarray service. This array includes a list of 8000 genes that
are involved in diverse molecular and cellular functions (for further
information visit www.clontech.com). The results were analyzed using
Atlaslmage software and expressed as a comparison between the COX-2
sense and COX-2 antisense cells.
Determination of angiostatin generation
Ishikawa wild-type, COX-2 sense, and COX-2 antisense cells were
seeded in six-well plates at a density of 3.5 X 105, allowed to attach for
24 h in complete media and then cultured in serum-free media overnight
(n = 3 independent experiments). Following culture, the media was
collected, spun at 1000 X g for 5 min to pellet cell debris, and the
supernatant was aspirated. To investigate the differential cleavage of
plasminogen to angiostatin by the three cell lines, aliquots of cell media
(100 pi) were incubated with 25 pg /ml plasminogen at 37 C for 0, 4, 8,
or 24 h. To investigate whether cathepsin D mediates the cleavage of
plasminogen to angiostatin, 100 pi of media from COX-2 antisense cells
were incubated in the presence or absence of 1 pM pepstatin A (Sigma)
for 8 h. Subsequently, a total of 20 pi of each reaction was denatured and
subjected to SDS-PAGE on 4-12% Tris-glycine gels (Invitrogen). The
generation of angiostatin from plasminogen was assessed by Western
blot analysis and probed with a plasminogen antibody as described
above
Statistical analyses
The data in this study were analyzed by ANOVA using StatView 5.0
software (Abacus Concepts, Berkeley, CA). Statistical significance was
taken as P < 0.05.
Results
Stable transfection of the Ishikawa human endometrial ep¬
ithelial cells with the pIRES2 vector containing COX-2 cDNA in
the sense direction resulted in the overexpression of COX-2





Fig. 1. Western blot analysis of 40 pg protein from wild-type Ish¬
ikawa cells (WT) and Ishikawa cells stably transfected with COX-2
cDNA in either the sense (S) or antisense (AS) directions. A, Specific
bands for COX-2 and /3-actin proteins were detected at approximately
72 and 46 kDa, respectively. B, COX-1 and 0-actin proteins were
detected by specific bands at 71 and 46 kDa, respectively.
protein. Western blot analysis revealed strong COX-2 protein
expression detected as 72-kDa band in the COX-2 sense cells
compared with the COX-2 antisense and wild-type cells (Fig.
1A). Basal levels of COX-2 were detected in the wild-type Ish¬
ikawa cells that was abolished by transfection with COX-2
antisense cDNA. (Fig. 1A). Stable transfection of the COX-2
cDNA in either the sense or antisense direction had no effect on
COX-1 protein expression (Fig. IB); no differences were de¬
tected in COX-1 protein levels between the wild-type, COX-2
sense, or COX-2 antisense cell lines.
To confirm functionality of the transfected cDNA, PGE2
synthesis was measured by ELISA in COX-2 sense, COX-2
antisense and wild-type cells (Fig. 2). PGE2 secretion was
significantly increased (P < 0.01) in the culture media of the
COX-2 sense cells (2391.25 r 311.09 pg/ml) compared with
wild-type and COX-2 antisense cells (359 ± 71.54 and 78.96 ±
50.9 pg/ml, respectively). Coculture of the cells with the
specific COX-2 enzyme inhibitor NS398 reduced the in-
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Fig. 2. The functionality of the transfected COX-2 was assessed by
ELISA to measure PGE2 secretion by wild-type (WT), COX-2 anti-
sense (AS), and COX-2 sense (S) cells into culture media following
incubation with 5 pg arachidonic acid (AA) for 48 h in the presence
or absence 10 p.u of the COX-2 enzyme inhibitor NS398. The data are
mean ± SEM of n = 4 experiments. Different letters denote statistical
significance iP < 0.05).
creased secretion of PGE2 in the wild-type, COX-2 sense, and
COX-2 antisense cells to almost undetectable levels. To in¬
vestigate the effect of COX-2 overexpression on EP receptors,
real time quantitative RT PCR was performed to quantify the
expression of EP1, EP2, EP3, and EP4 receptors (Fig. 3A).
Relative expression of EP2 and EP3 mRNA (compared with
expression levels detected in wild-type cells) was signifi¬
cantly higher (P < 0.05) in the COX-2 sense cells compared
with COX-2 antisense cells (EP2 receptor: 3.73 ± 0.43 vs.
1.19 ± 0.39 for COX-2 sense and antisense cells, respectively;
EP3 receptor: 2.35 ± 0.3 vs. 1.03 ± 0.105 for COX-2 sense and
antisense cells, respectively). EP1 mRNA was not detectable
in any of the cell lines and EP4 receptor expression showed
no significant differences between the COX-2 sense and an¬
tisense cells. Functionality of the EP receptors was investi¬
gated by measuring the generation of cAMP in COX-2 sense,
COX-2 antisense and wild-type cells in response to treatment
with 100 nM PGE2 for 10 min (Fig. 3B). Fold induction of
cAMP relative to that measured in wild-type cells was sig¬
nificantly higher (P < 0.05) in the COX-2 sense cells com¬
pared with the COX-2 antisense cells (2.57 ± 0.16 us. 0.88 ±
0.33 for COX-2 sense and antisense cells, respectively).
Differential gene expression between COX-2 sense and
COX-2 antisense cells was investigated using RNA extracted
from the two cell lines and the CLONTECH Atlas human 8K
microarrays. A number of genes demonstrated differential ex¬
pression between the two cell lines. Of the genes differentially
expressed, one of the greatest differences observed was cathep-
sin D. Cathepsin D mRNA expression demonstrated a 6.7-fold
difference between the COX-2 sense and the COX-2 antisense
cells; cathepsin D RNA expression was reduced in the COX-2
sense compared with the COX-2 antisense cells (Fig. 4A). West¬
ern blot analysis conducted using proteins extracted from the
wild-type, COX-2 sense, and COX-2 antisense cell lines con¬
firmed lower cathepsin D protein expression in theCOX-2 sense
and elevated expression in the COX-2 antisense cells compared
with the wild-type cells. Cathepsin D protein expression in the
COX-2 sense and COX-2 antisense cell lines was 0.8 ± 0.13 and
B
Fig. 3. A, Relative expression of EP2, EP3, and EP4 receptors in
Ishikawa cells stably overexpressing COX-2 in either the sense (S) or
antisense (AS) directions. Relative expression was determined by
dividing expression detected in COX-2 sense and antisense cells by
expression detected in wild-type cells. The data are mean ± SEM ofn =
3 experiments. Different letters for each of the receptors denote sta¬
tistical significance (P < 0.05). B, ELISA for cAMP generation. Fold
induction of cAMP generation in COX-2 antisense (AS) and COX-2
sense (S) cells following treatment with 100 nM PGE2 for 10 min. Fold
induction is calculated by dividing cAMP generation in COX-2 sense
and antisense cells by cAMP generation in wild-type cells. The data
are mean ± SEM of n = 4 experiments. Different letters denote sta¬
tistical significance (P < 0.05).
1.68 ± 0.39-fold relative to wild-type cells. The difference in
cathepsin Dexpression was 2.16 ± 0.22-fold lower in theCOX-2
sense compared with COX-2 antisense cells P < 0.05 (Fig. 4, B
and C).
We investigated the potential effect of differential cathep¬
sin D expression in the three cell lines, on cleavage of plas¬
minogen to angiostatin. Plasminogen was cultured in the
media collected from COX-2 sense, COX-2 antisense, and
wild-type cells for 0, 4, 8, and 24 h. Using antiplasminogen
antibody and Western blot analysis, angiostatin bands were
detected at 36 and 32 kDa, which are within the reported
range (34, 35). Angiostatin production was elevated follow¬
ing culture of plasminogen in media collected from COX-2
antisense cells compared with wild-type cells. However, an¬
giostatin production was abolished when plasminogen was
incubated in the culture media collected from COX-2 sense
cells (Fig. 5). To confirm that the cleavage of plasminogen to
angiostatin is mediated by cathepsin D, the incubation ex¬
periments were repeated by incubating plasminogen in
COX-2 antisense conditioned media in the presence of the
cathepsin D inhibitor pepstatin A. Coincubation of plasmin¬
ogen and cathepsin D in the conditioned media from COX-2
antisense cells for 8 h resulted in inhibition of angiostatin
production (Fig. 6).
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A Antisense Sense
Wild type Antisense Sense
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Fig. 4. A, Atlas plastic 8K Human cDNA array image following hy-
bridysation with cDNA from untreated COX-2 antisense and COX-2
sense cells. Arrows correspond to cathepsin D position. B, Western
blot analysis of 20 pg protein isolated from untreated Ishikawa wild-
type (WT), COX-2 antisense (AS), and COX-2 sense (S) cells. The blot
was probed with cathepsin D antibody that detected procathepsin D
(1), pseudocathepsin D (2) and cathepsin D (3) protein expression at
52 kDa, 51 kDa, and 32 kDa, respectively. C, Relative expression of
cathepsin D in COX-2 antisense and COX-2 sense cells normalized for
j3-actin and expressed relative to expression detected in wild-type
cells. Bands were semiquantified as outlined in Materials and Meth¬
ods and presented as mean ± SEM relative expression of n = 4 ex¬
periments. Different letters denote statistical significance (P < 0.05).
Discussion
In this study, we describe the establishment of an endo¬
metrial epithelial cell line stably overexpressing COX-2.
COX-2 protein expression was higher in the sense clone
compared with the antisense and wild type. Overexpression
of COX-2 in the Ishikawa endometrial epithelial cells was
Plasminogen
Angiostatin
Fig. 5. Generation of angiostatin following incubation of 25 pg /ml
plasminogen for 0, 4, 8, and 24 h in serum-free conditioned media
collected from Ishikawawild-type, COX-2 antisense, and COX-2 sense
cells. Angiostatin production was detected by Western blot analysis
using 20 pi of media. Plasminogen and angiostatin were detected at
expected molecular masses of 97 and 36/32 kDa, respectively.
0 Vehicle Pepstatin A
Plasminogen
Angiostatin
Fig. 6. Inhibition of angiostatin generation by pepstatin A following
incubation of 25 pg/ml plasminogen in media collected from COX-2
antisense cells in the presence or absence of 1 pM pepstatin A for 8 h.
Angiostatin production was detected by Western blot analysis using
20 pi of media. Plasminogen and angiostatin were detected at ex¬
pected molecular masses of 97 and 36/32 kDa, respectively.
associated with elevated secretion of PGE2 that was abol¬
ished by the COX-2 selective inhibitor NS398. This is in
agreement with previous studies that have demonstrated
increased prostanoid generation in response to the overex¬
pression of COX-2 (12). Similar expression of COX-1 protein
was detected in all three cell lines, suggesting that COX-1
expression is not regulated by COX-2. Treatment of the cells
with NS398 reduced PGE2 secretion in wild-type, COX-2
sense, and COX-2 antisense cells to almost undetectable lev¬
els. This suggests that PGE2 secretion in the wild-type, COX-2
sense, and COX-2 antisense cell lines is predominantly a
result of COX-2 activity. COX-2 overexpression was also
associated with increased EP2/EP3 receptor expression and
signaling with no effect on EP1 and EP4 receptor expression.
The elevation in EP receptor expression in the COX-2 sense
cells suggests that COX enzyme products act in an auto-
Downloaded from endo.endojournals.org on October 3, 2005
Perchick and Jabbour • COX-2 Inhibits Angiostatin Production
crine/paracrine manner to up-regulate EP receptor expres¬
sion. The COX-2 sense cells displayed also significantly
higher fold induction of cAMP relative to the COX-2 anti-
sense cells. The EP2 receptor is associated with Gs coupled
signaling and results in enhanced cAMP generation (7),
whereas a number of splice variants have been described for
the EP3 receptor and these have been shown to be linked to
either the Gs- or Gi-coupled signaling (7). The net increase in
cAMP in response to exogenous PGE2 in the COX-2 sense
cells suggests an overall balance toward Gs coupled signal¬
ing in response to exogenous PGE, is favored. Hence, these
data confirm that prostanoids such as PGE2 secreted in re¬
sponse to COX-2 regulate the expression of their receptors
and regulate gene expression in an autocrine/paracrine
manner.
To identify differential gene expression between the
COX-2 sense and the COX-2 antisense cells, we employed
cDNA array analysis. We demonstrated reduced cathepsin D
mRNA and protein expression in the COX-2 sense cells com¬
pared with wild-type and antisense cells. In the human en¬
dometrium, cathepsin D expression has been localized to
glandular and stromal cells, and glandular expression has
been shown to be highest during the secretory phase of the
menstrual cycle (36). The elevated expression of cathepsin D
is thought to be positively regulated by progesterone. How¬
ever, cathepsin D expression remains elevated in the mid to
late secretory phase despite a reduction in progesterone re¬
ceptor activity. This has prompted the suggestion that ca¬
thepsin D expression is also under the control of other factors
(37). Our data demonstrating that cathepsin D expression is
inhibited via a COX-2 mediated action suggests COX-2 may
be one of those factors. COX-2 expression in the human
endometrium is highest during the late secretory and pro¬
liferative phases of the menstrual cycle (14) when cathepsin
D levels have been reported to be at their lowest. Interest¬
ingly, elevated COX-2 and reduced cathepsin D have inde¬
pendently been associated with a poor prognosis in repro¬
ductive tract carcinoma (38-40). Moreover, COX-2 has been
shown to be induced in endometrial adenocarcinomas (15-
17). Hence it is plausible to suggest that increased COX-2
may be an indicator of low cathepsin D expression.
Angiostatin is a potent antiangiogenic factor that is pro-
teolytically derived from plasminogen (41). Angiostatin in¬
hibits vasodilation, proliferation, and migration of endothe¬
lial cells and endothelial tube formation possibly via the
induction of apoptosis in endothelial cells (41-45). Condi¬
tioned medium of human prostate carcinoma cells has been
demonstrated to cleave plasminogen to angiostatin by the
action of procathepsin D. Furthermore, purified mature ca¬
thepsin D can cleave plasminogen to angiostatin (46). We
initially investigated the generation of angiostatin from plas¬
minogen in conditioned media collected from COX-2 sense,
COX-2 antisense, and wild-type cells. Angiostatin accumu¬
lation was abolished in the media from COX-2 sense cells and
elevated in the media from the COX-2 antisense cells com¬
pared with the wild-type cells supporting a role for cathepsin
D in the generation of angiostatin in endometrial epithelial
cells. The differential cleavage of plasminogen to angiostatin
in the three cell lines is reflective of the varying degrees of
COX-2 expression. Coincubation of plasminogen in condi-
Endocrinology, December 2003, 144( 12):5322-5328 5327
tioned media from antisense cells with the cathepsin D in¬
hibitor, pepstatin A, reduced angiostatin formation. This
suggests that the cleavage of plasminogen to angiostatin is
mediated in part by cathepsin D. Other proteolytic enzymes
are known to cleave plasminogen to angiostatin. These in¬
clude matrix metalloproteinases, plasminogen activators,
pepsin, and cathepsin E (35, 46-50). Hence, it is plausible to
suggest that, in addition to cathepsin D, other enzymes may
be involved in the regulation of angiostatin production that
may be inhibited by pepstatin A.
Overexpression of COX-2 and prostanoid receptors such
as EP2 play a role in angiogenesis by promoting the forma¬
tion of proangiogenic factors (51). Once synthesized the an¬
giogenic factors act in a paracrine manner on endothelial cells
to promote enhanced cell migration and tubular formation
(12). However, it is now well accepted that the promotion of
an angiogenic environment is the result of a balance in the
production of angiogenic and anti angiogenic factors (52).
Recently, inhibition of COX-2 has been demonstrated to up-
regulate the generation and expression of the antiangiogenic
factors endostatin and thrombospondin-1 (53, 54). The data
presented herein demonstrate an alternative pathway by
which COX-2 can regulate angiogenesis in endometrial ep¬
ithelial cells through inhibition of production of antiangio¬
genic factors such as angiostatin. Hence it is hypothesized
that, in endometrial pathologies that are associated with
elevated COX-2 enzyme expression, vascular function may
be promoted through overexpression of angiogenic factors
and reduced production of antiangiogenic factors such as
angiostatin. However, the underlying cellular and molecular
mechanisms by which COX-2 down-regulates cathepsin D
expression resulting in reduced angiostatin generation re¬
mains to be elucidated.
In conclusion, the data outlined here demonstrate over-
expression of COX-2 results in a concomitant induction of
PGE2 secretion and EP2/EP3 receptor expression. COX-2
inhibits cathepsin D expression in endometrial epithelial
cells via an unknown mechanism, which contributes to an
inhibition of the formation of angiostatin. These data outline
a novel function of COX-2 in promoting a proangiogenic
environment through suppression of production of
angiostatin.
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